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Abstract
The osteocyte is a load-sensing bone cell, which plays a pivotal role in the bone modeling process.
This process is highly regulated by feedback control and poorly described by isolated in vivo or in vitro
experiments. In silico systems models present a way by which experimental and clinical data can be
integrated in a mathematical framework so that physiology, pharmacology and disease progression as
it relates to bone health, at the level of cell signaling networks up to the tissue level, can can be better
understood. The Multiscale Systems Pharmacology Model presented here began as an endeavor to link
biological markers and clinical endpoints in a mathematical framework. The goal is to be able to make
quantitative inferences around bone physiology, disease progression, and therapeutic modulation of
biological targets. This underlying framework has now been extended to include the osteocyte as a
source of sclerostin protein, signaling effects of this protein on the Wnt pathway and downstream ef-
fects on osteoblasts and osteoclasts. A model of sclerostin inhibition by monoclonal antibodies (mAbs)
was developed using data from recent clinical trials, describing the unique mechanism of Wnt path-
way modulation for a new treatment for osteoporosis. Techniques for parameter identifiability and
optimization were compared and contrasted. Parameters describing mAbs exhibiting target-mediated
drug disposition (TMDD) pose identifiability problems, and techniques for establishing identifiability
of TMDDs were analyzed. A predictive framework for regional changes in bone mineral density (BMD)
was further developed for sclerostin mAbs, and marketed therapies teriparatide and denosumab. Fi-
nally, a hazard model of fracture was implemented using lumbar spine BMD, patient baseline char-
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acteristics and an additional drug effects as covariates in order to compare efficacy of therapies, their
dosing regimens and possible combinations that would elicit the best outcome for patients with osteo-
porosis. This novel framework is a powerful predictive tool for furthering knowledge of new therapeutic
mechanisms in the context of a data-driven, integrated physiological platform.
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Preface
“The average Ph.D. thesis is nothing but the transference of bones from one graveyard to another.”
- Frank J. Dobie.
I like this quote because not only does my PhD dissertation happen to be about bones, but also
when thinking about what the author meant by this statement, a lot of ideas come to mind. Some are
deeply personal. Some are theological. And yet this quote has a melancholy and sarcastic tone that
makes one think that her entire body of work that she’s slaved over for years is just another part of the
endless life cycle and that there’s really ‘nothing new under the sun.’
I never would’ve imagined how personal the graveyard would become to me during the time I was
working on my PhD. A year into my schooling, I lost my husband of 2 and half years to the disease of
colon cancer, suddenly and unexpectedly. The graveyard was no longer a place where someone who
has fulfilled their days lies to rest and where the rest of us remember him as our grandfather or uncle
who might have served in a world war or immigrated from Europe so that we could live in a great land.
No, it is the thing that stole him I loved the most in the world, far before his time.
Still the phrase ‘transference of bones’ speaks to me about legacy and to the one still living, the
concept of legacy evokes hope and vitality. Joseph, in the bible, was attributed great faith because he
gave instructions to his children before he died about the transference of his bones from Egypt to the
promised land of Israel. You see, Joseph had a legacy of being a dreamer and through many trials he
maintained that God would bring his dreams to pass. Joseph wanted his descendants to see the place
where his bones lay and remember that God is the one who brings dreams to pass.
There was a time when receiving a PhD was only a dream- one very far off. I hope that instead of
“the average PhD thesis [that] is nothing but" this thesis summarizes an idea of substance and forward-
thinking. It encompasses what I have learned during times of success and times of defeat. What I
ultimately surmise from this quote is that PhD work is about putting some theories to death (even those
you have grown attached to). But it is also about raising other theories and concepts to life (that is, if
the data support them!). Both lead to advances for a ‘next generation’ of dreamers and thesis-writers
to use and build upon.
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Chapter 1
Introduction
1.1 Clinical Relevance
Today, an unprecedented number of the general population is living longer and the demand for
the health care industry to support a good quality of life is increased proportionally. Because of this
longevity, osteoporosis is a large and growing problem because more and more people worldwide are
faced with risks of bone fracture. An estimated 34 million Americans have low bone mass, which indi-
cates they are at a high risk for developing osteoporosis [1]. The estimated cost of the disease in the US
ranges from $10 to $22 billion in addition to indirect cost associated with reductions of quality of life
and productivity.
The gold standard for treatment of osteoporosis is alendronate, part of a class of therapies called
bisphosphonates. While effective in significantly increasing bone mineral density (BMD) through an
anti-resorptive mechanism, bisphosphonates are not without controversy. Recent studies have shown
an increase risk of abnormal fracture in patients on bisphosphonate therapy [2, 3], which has lead to
discourse on length of maintenance of these therapies. Because osteoporosis is a chronic metabolic
disease this presents quite a problem.
Newer lines of therapy include teriparatide, a parathyroid hormone (PTH) analog with an anabolic
mechanism. In contrast to bisphosphonates, anabolic agents increase bone growth by stimulating os-
teoblast activity, rather than limiting resorption by decreasing osteoclast activity. Unfortunately, teri-
paratide is limited in its use because it requires a once-per-day subcutaneous injection [4], and func-
1
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tions by replacing areas of older, mineralized bone with new bone of lower mineral content [5]. There
remains an unmet clinical need for new therapies for osteoporosis which will improve patient compli-
ance, are more effective in preventing loss of bone density, and will improve fracture rate after several
years of active therapy [6].
1.1.1 Sclerostin in Targeted Bone Remodeling
Sclerosteosis and Van Buechem are both rare bone diseases that were discovered over 40 years
ago [7], characterized by thickening of the skull, facial and jaw bone enlargement and overall increased
BMD above age-matched non-affected individuals [8]. While these diseases were identified long ago, it
was recently discovered that they were caused by autosomal-recessive loss of function and hypomor-
phic mutations, respectively, on the SOST gene. The complete loss of SOST expression causes nerve
entrapment as a result of bone deformities, and some patients report hearing and vision loss and/or
intracranial pressure [9]. Heterozygote carriers of SOST, however, have low circulating sclerostin levels,
do not have these symptoms, but do have higher-than-normal bone mass. This finding led to the line of
thinking about the potential benefits of dose-dependent sclerostin inhibition for individuals suffering
with osteoporosis or other diseases contributing to bone loss. Wnt is implicated in many differentia-
tion pathways in the body, but sclerostin is mainly produced by the osteocyte, so the modulation of
sclerostin on Wnt is, for the most part, targeting Wnt signaling in the bone limiting the off-target for
non-bone cells. Furthermore, because of it’s role in differentiation, Wnt modulation is associated with
tumor formation [10], but because osteocytes do not divide, the potential for uncontrolled cell growth
leading to tumor formation associated with modified Wnt signaling may be assuaged [11]. The absence
of osteosarcoma in patients with van Beuchem disease and sclerosteosis [12, 13] further supports this
notion, however oncogenic effects of long term of pharmacological modulation of sclerostin are un-
known.
Sclerostin functions by binding to the coreceptor, low-density lipoprotein receptor-related pro-
tein (LRP)5/6, competitively inhibiting the binding of Wnt ligands. By preventing Wnt signaling, scle-
rostin inhibits actions of the canonical Wnt pathway, which includes the formation of the “destruction
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complex”: Axin, adenomatous polyposis coli -1 (APC-1), and glycogen synthase kinase 3 beta (GSK3b)
which phosphorylatesβ-catenin labeling for ubiquination and destruction [14,15]. The canonical Wnt
pathway is involved in various developmental processes, including osteogenic differentiation of mes-
enchymal stem cells (MSC). Specifically,β-catenin suppresses MSC differentiation into adipogenic and
chondrogenic lineages and promotes an osteoblastic lineage [16]. Sclerostin completes the negative
feedback loop at the end of a remodeling event, inhibiting further bone formation. It does this by in-
hibiting accumulation of β-catenin by acting as a competitive inhibitor of Wnt.
Sclerostin expression is regulated in part by hormones which affect bone metabolism, such as
PTH, calcitonin, and glucocorticoids [17]. Patients with primary hyperparathyroidism have signifi-
cantly lower circulating sclerostin levels and this is consistant with in vitro studies demonstrating that
PTH inhibits SOST expression [9]. Serum estrogen is inversely associated with serum sclerostin [18],
thus estrogens inhibit sclerostin production [19] and estrogen replacement therapy inhibits increases
in circulating sclerostin. Conversely, glucocorticoids increase sclerostin expression in vivo, and calci-
tonin up-regulates osteocyte-derived sclerostin expression.
In studies of SOST knockout (KO) animals, increased BMD is seen in trabecular and cortical bone
at the peri- and endosteal surfaces [20]. Osteocalcin, a marker of osteoblast growth, is increased in KO
mice while the marker of osteoclast growth, tartrate-resistant acid phosphatase (TRACP 5b), was un-
changed. This seems to indicate an uncoupling of bone formation and resorption that is atypical of
bone growth pathways and osteoporosis-targeting therapies. This KO model has a similar phenotype
to that elicited by LRP5 receptor mutations, which also resulted in a increase in osteoblasts without
an increase in osteoclast population [21], further supporting the decoupling phenomenon associated
with this mechanism.
Consistent with SOST KO models, monoclonal antibodies inhibiting sclerostin administered in
vivo resulted in increases in BMD of cortical and trabecular bone and vertebral and femoral bone
strength [22, 23]. In one study, serum osteocalcin at the trabecular and periosteal surfaces was in-
creased with increasing doses of the inhibitor. Another study showed bone formation markers serum
osteocalcin and N-terminal propeptide of type 1 collagen (P1NP) were significantly elevated for the du-
ration of 12-week-long treatment, while the bone resorption marker TRACP 5b remained unchanged
A Multiscale Systems Model for Advancement of a New Line of Therapy for Osteoporosis 3
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[23].
In healthy post-menopausal (PM) women, a single dose of the sclerostin inhibitor romozozumab
Table 1.1: Sclerostin Inhibitors Currently in Clinical Development
Company Therapy Development Stage
Amgen & UCB monoclonal antibody Phase 3 clinical trial
Eli Lilly monoclonal antibody Phase 2 clinical trial
Novartis monoclonal antibody Phase 2 clinical trial
OsteoGeneX small molecule Preclinical
Ossify, Inc.
(spinoff of OsteoGenex) Bone graft Unknown
resulted in dose-dependent increases in lumbar spine and total hip BMD. The largest increases were
5.3% and 2.8%, respectively, above the baseline value in the 10 mg/kg dose cohort after 12 weeks [24].
Consistent with in vivo studies, P1NP and osteocalcin increased over 1.5-fold over their baseline val-
ues, while serum C-telopeptide (CTx), the bone resorption marker, decreased. In a comparison study
of post-menopausal women with low BMD, 210 mg of this mAb dosed once monthly increased BMD
at the lumbar spine by 11.3% [25]. Two phase-2 studies were also conducted in wherein blosozumab
was dosed in post-menopausal women every 2 weeks or every 4 weeks for a total of 16 weeks [26]. In
this study, consistent with the anabolic mechanism, P1NP and osteocalcin were dose-dependently in-
creased, while serum CTx decreased. At the highest dose of 270mg, BMD increased 17.7% at the spine
and 6.2% at the total hip. These first in human studies seem to support a mechanism resulting in im-
proved performance compared to existing bone therapies, as increasing formation and sustained or
decreased resorption results in a larger anabolic window. The result is a much faster increase in BMD
compared to the gold standard therapy for osteoporosis, alendronate. It also surpasses effects seen with
teriparatide, the only other anabolic therapy on the market. Table 1.1 lists the sclerostin inhibitors cur-
rently being developed by various pharmaceutical companies and table 1.2 describes the development
status of leading compounds, romozosumab and blosozumab.
Questions remain about the sustained anabolic effect of this target mechanism, as changes in
bone formation markers did not persist and returned to baseline in patients still on active therapy, and
A Multiscale Systems Model for Advancement of a New Line of Therapy for Osteoporosis 4
CHAPTER 1. INTRODUCTION Rena Eudy
studies longer than a year in duration are not yet reported. The optimal treatment duration for the
greatest efficacy with these therapies is unknown. While there were no significant adverse events re-
ported in these relatively short studies, and off-target effects are limited with this mechanism, there is
still some concern about cardiovascular safety with longer-term treatment, particularly because Wnt
signaling is known to be involved in vascular pathophysiology [27]. These “unknowns” associated
with this mechanism of action are opportunities for model development and exploration. Duration
of treatment and washout, intermittent treatment, switching between therapies and possible thera-
peutic combinations are all areas that can be exploration within a modeling platform.
In order to develop a good understanding of what impacts expression of SOST and functions of
Table 1.2: Ongoing Clinical Trials with Romosozumab
Therapy Trial Duration Endpoints Estimated
Completion
Romozosumab
and Teriparatide
Phase 3
(STRUCTURE)
12 months
Changes in BMD by DXA and QCT
and strength by FEA at total hip
June 2015
Romosozumab 12 mo. followed by
denosumab for 24 months
Phase 3
(FRAME)
24 months
Primary: Vertebral fracture incidence
Secondary: BMD changes
February 2017
Romosozumab vs Placebo
in men with osteoporosis
Phase 3
(BRIDGE)
12 months
Changes in BMD by
DXA at LS, FN, and TH
December 2016
the sclerostin protein, it is essential to grasp the function of the cell the produces it. Recently the osteo-
cyte has received more attention from experimental researchers in the area of bone, because it is the
longest living bone cell and therefore constitutes more than 90% of all bone cells [28]. The ability of the
osteocyte to propagate mechanical signals of loading into chemical signals, make it an important part
of the remodeling and repair [29]mechanism. Osteocytes are terminally differentiated osteoblasts, and
function to synthesize mineralized matrix and remain trapped therein. They communicate through an
system of canaliculi which extend through the matrix and are proximal to circulatory systems, and thus
may function as an endocrine organ, directly releasing proteins into the circulation [30].
Through the production of sclerostin, osteocytes control bone formation by two mechanisms: 1.)
directly by antagonizing bone morphogenentic protein (BMP) and 2.) indirectly through prevention of
Wnt signaling [31], by binding to LRP5 and LRP6. While it is not fully understood cellular signaling in-
volved in resorption activities, the apoptosis of osteocytes is a cue which signals osteoclast recruitment
A Multiscale Systems Model for Advancement of a New Line of Therapy for Osteoporosis 5
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and increased bone resorption [30]. This is consistent with anti-remodeling properties of estrogens and
bisphosphonates, which prevent osteocyte apoptosis. Furthermore, it is known that osteocytes are a
major source of receptor activator of nuclear factor kappa-B ligand (RANKL), which also increases re-
sorption activity [32]. Wnt pathway activation in osteocytes has been shown to increase expression
levels of osteoprotegerin (OPG) [33]. Taken together, it is clear that osteocyte regulation of cytokines
involved in feedback signaling is integral to regulation of remodeling, and therefore understanding how
these signals are impacted by therapeutic modulation is imperative.
1.2 Systems Models in the Development of New Therapies
The bone remodeling process is a difficult system to describe at a cellular or molecular level be-
cause the cell populations and turnover markers involved are constantly in flux and regulated through
multiple control mechanisms. An in silico model-based approach is an efficient way to promote un-
derstanding of this highly dynamic behavior. Scientists, academic researchers, regulatory and industry
representatives desire to understand how new therapies impact biological systems, in order to maxi-
mize efficacy and minimize adverse events in patients.
Quantitative Systems Pharmacology (QSP) is somewhat new, or at least newly defined, discipline
using physiological modeling to understand how drugs function to affect the system and influence
pathophysiology and disease progression. This discipline has targeted the need to make the transi-
tion for drugs from discovery to market more efficient and widen the bottleneck caused by late-stage
failure in drug development. The goal of this discipline is to use mathematical models to define the
input-output relationship between disease and drug activity. Three steps are used in this process: 1.)
gather knowledge from literature or preliminary experiments 2.) construct the model, 3.) simulate the
outcomes [34]. Not only can this method be used to promote understanding of the underlying biology
and improve pathway targeting, it can also be used to impact clinical design via dose and patient se-
lection.
Benefits of applications of QSP to the development of new therapies for osteoporosis are numer-
ous. Mechanistic models promote understanding of how short-term clinical endpoints, like regional
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changes in BMD, impact fracture outcomes. Dosing regimens and combination therapies can be in-
vestigated in these models to mitigate risks of failure during the long-term clinical trials required for
demonstration of efficacy of new therapies on fracture incidence. Recently, a QSP model of bone was
used in a clinical pharmacology assessment reviewed by the FDA and influenced a decision to recom-
mend a post-marketing study to test additional dosing regimens in order to avoid hypercalcuria [35].
Investigation of factors (covariates) on relevant outcomes such as turnover markers, BMD changes,
and fracture also point to the physiological pathways that have greater impact on these outcomes and
may reveal new therapeutic targets.
1.3 Other in Silico Models of Bone Physiology and Related Pathways
Pivonka and Komarova [36] issued a thorough review of in silico models of bone in 2010, and cat-
egorized them into four groups according to the physiological aspects that were the primary focus of
each model: 1.) Receptor-ligand interactions and intracellular signaling 2.) Cell dynamics 3.) Tissue-
function and 4.) Whole-body calcium homeostasis. Models that fall into these categories are discussed
here to highlight the strengths and weaknesses of different modeling approaches, as specifically ap-
plied to models of osteocyte function or Wnt signaling.
1.3.1 Receptor-Ligand Interactions and Intracellular Signaling
In an attempt to more fully elucidate the roles of different Wnt signal inhibitors Kogan et al. [37]
built upon the work of Lee and Mirams [15,38]. This model describes ligand binding (secreted frizzled-
related protein-1 (sFPR1) and Wnt inhibitory factor 1 (WIF) binding to Wnt, and dickkopf (dkk-1) bind-
ing to LRP, a Wnt co-receptor) and events leading to β-catenin accumulation. This model was val-
idated by two independent published experiments, and provides quantitative measures for the pre-
dicted synergistic effects of sFPR1 and dkk-1 on β-catenin accumulation. The aim of this model de-
velopment project was to suggest potential targets for treatment of cancer, which also involves the
Wnt pathway, therefore examining sclerostin-specific targets, like LRP5/6 or other implications of β-
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catenin accumulation on bone metabolism was unfortunately not in the scope of this work. The au-
thors also acknowledge that many underlying mechanisms of Wnt pathway have not been elucidated
by experimentation; still this work illustrates how mathematical models can generate new hypotheses
and be used in generation of new targets, related to Wnt pathway modulation.
1.3.2 Cell Dynamics
A cell dynamics model created by Graham and colleagues, defines interactions between discrete
bone cell populations and predicts qualitative effects of sclerostin inhibition on bone mass [39]. De-
scriptive parameters in the model represent effectiveness of paracrine, autocrine and other regulative
signaling of bone cells, and the authors used the model to demonstrate how changing expression levels
of key proteins, like RANKL, may impact the bone remodeling cycle. A simulation of relative changes
in BMD after an increase in osteocyte apoptosis and corresponding inhibition of sclerostin inhibition
was demonstrated. Some generalized relationships are defined and sensitivity of parameters due to
system perturbation are demonstrated by this model. However, without using experimental data to fit
model parameters, it is difficult to make meaningful inferences about parameter estimates and related
cellular mechanisms, or to quantify effects of modulation of sclerostin in this qualitative framework.
A semi-empirical cell dynamics model developed by Carew [40] describes the effects of a strain
stimuli on bone turnover. The novel aspect of this model is the inclusion of the effect of a physical
stimulus on osteocyte response and the modified bone mass and calcium flux that results. The model
suggests relative lengths of formation vs. resorption phases under different strain stimuli and possible
mechanisms for loss of bone during “strain-free" conditions. One shortcoming of this model is that
the structure is mathematically uncoupled; that is, the amount of resorption is fixed for all simulations
while formation rate is estimated. In reality, increased strain inhibits osteoclastogenesis and this re-
sponse is coupled to an increase in osteoblast activity resulting in increased turnover. Also, while there
are parameters in the model for key protein binding kinetics, such as receptor activator of nuclear fac-
tor kappa-B (RANK), RANKL, OPG and PTH, there is no representation of sclerostin or other proteins
and factors important to the osteocyte contribution to the remodeling process. Finally, the model sim-
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ulations are unidirectional and do not describe cellular concentrations returning to equilibrium after
a remodeling event. Each of these shortcomings were addressed by the authors. Although the model
is still semi-empirical, the rate functions were derived from known relationships and the model simu-
lated absolute concentrations consistent with the underlying biology of strain effects on turnover rate.
1.3.3 Tissue-function
Another application of systems models of bone addresses the coupled biochemical and biome-
chanical processes that govern bone remodeling. This is a very important aspect, as bone quality as
the combination of geometry, material properties and microstructure [36], is ultimately what influ-
ences fracture risk in osteoporosis patients and disease severity. Van Oers et al. (2007) [41] constructed
a model examining the mechanosensory role of osteocytes and their influence on osteon size changes
during mechanical load. The model describes the relationship between strain magnitude and osteo-
cyte signaling to osteoblasts and -clasts. Signals indicate specific spatial resorbtion and formation of
bone. Their model re-enforces the inverse relationship between osteon diameter and strain magni-
tude, where osteoclasts ultimately determine the size of the osteon and osteoblasts govern the rate
and extent of filling of the osteon volume. This model is speculative and qualitative in nature, describ-
ing volume/strain components of the biochemical-mechanical relationship of bone remodeling and
does not provide any link to specific binding interactions or cellular feedback between osteoclasts and
osteoblasts.
Colloca, et al (2014) [42] also constructed a similar model relating the mechanical sensing function
of the osteocyte to osteoblast and osteoclast activity in a 3-D finite element model describing longitudi-
nal and transverse stiffness in trabecular bone. The model predictions were compared to stiffness ten-
sors of healthy tissues spanning different ages and states of use. The model predictions were consistent
with experimental data. A limitation to this model is that the authors greatly simplified the represen-
tation of bone matrix in structure and shape in order to find an analytical solution to the model. There
was also no signaling between osteocytes and osteoclasts included in the model, nor any other kind of
biochemical messenger pathways or feedback signaling. Finally this model assumed constant lacunar
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porosity per volume element of bone matrix in the finite element analysis, when in reality, porosity per
volume is dependent on the extent of load-bearing activity specific to a region.
Buenzli (2015) [43] also created a mathematical model describing the embedding process of os-
teoblasts becoming osteocytes. The model estimates burial rate of osteoblasts based on experimen-
tally derived osteocyte densities and matrix secretory rates are scaled up from in vivo data. The model
shows that, rather than the density of osteocytes being determined by osteoblast density, there is in-
stead a greater dependency on burial rate of osteoblasts and secretory rate of bone matrix. The model
suggests that a large signal derived from multiple osteocytes, likely nonlocal to the embedding site, is
required for a negative correlation between burial rate and number of osteocytes in the zone of influ-
ence. While several of the model parameters were estimated based on experimental data, the model
in its entirety is empirical in nature, while assumptions of the bone mulitcellular unit (BMU) geometry
were made and while mechanisms of osteocyte formation remain poorly understood.
1.3.4 Whole-body CalciumHomeostasis
Hydroxyapatite of bone serves as a depo for calcium which is released into the blood stream
through resorption signals under the control of PTH, calcitonin, sex steroids and thyroid hormones
[44]. Kidneys and the intestine also regulate calcium for whole-body processes. Disregulation of whole-
body calcium homeostasis is implicated in diseases, such as hyper or hypo-parathyroidism, chronic
kidney disease, or other physiological states such as pregnancy or lactation. Therefore, mathematical
modeling of calcium homeostasis promotes understanding of how multiple levels of regulation of cal-
cium are affected by disease or physiological state.
Kaiser, et al. (2011) [45] extended a model of interstitial fluid flow through the canaliculus to in-
clude movement of calcium to and from the bone tissue and examine how the movement of calcium
may affect sheer stress at the osteocyte membrane. This model takes into account fluid flow being
governed by electro-osmotic, osmotic and hydraulic effects. The model indicated that for most of the
canalicular fluid, the hydraulic gradient governs the flow velocity, but at the boundary layers near a
canalicular wall or osteocyte membrane, electro-osmotic and osmotic effects are significant. Shear
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stress experienced by the osteocyte is actually affected by a range of chemical gradients relevant to
those maintaining calcium homeostasis. These findings provide further explanation for the osteo-
cyte function in sensing mechanical change and translating these to chemical signals. This model as-
sumes simplifications of canalicular geometry and the authors acknowledge lack of understanding of
the complex in vivo environment of osteocytes, as these model parameter estimates were analytically
derived and were not based on experimental data.
In a research area where model applications and scopes vary widely, it is important to identify
model qualifications in advance of model selection. Many of these qualities are outlined in Agoram et
al. (2014), are used to validate the model discussed in chapter 8. These include:
1. Fit-for-purpose: In the presentation of the model do the authors clearly state model objects and
does the model contain all the elements needed to investigate the relevant questions? In efforts
to make a model well-representative of the physiology, are there also considerations of model
parsimony?
2. Quantitative in nature: Does the model accurately predict directional changes in state variables,
as well as magnitude of system dynamics with some level of precision, relative to experimental
data?
3. Validation by accepted methods: Were the criteria for choosing the best model established by the
authors, and was the model fully validated, preferably by an untested experimental dataset?
While there is a spectrum of mathematical models describing the mechanical role of osteocytes
and effects of stress/ strain on chemical signaling [36, 41, 42, 45], these models do not link these sig-
nals to full signaling networks which include the RANK/RANKL/OPG axis, transforming growth factor
beta (TGF-b) and other sources of feedback. The models lack quantitative descriptions of the system
as a whole. Across the spectrum of physiological bone models, there is a missing link between the role
of the osteocyte and Wnt pathway modulation required to predict clinical outcomes of new therapies
implicated in this pathway. The lack of experimental data linking the Wnt pathway intermediates like
β-catenin, axin, APC-1, and other intermediates involved in differentiation pathways, to the feedback
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pathways involved in the regulation of bone remodeling, is likely the main reason for the lack of mod-
els describing osteocyte function. Much progress has been made in the recent years examining the
contribution of the osteocyte to the mechanical and chemical signaling pathways that direct remod-
eling. The novel aspect of this QSP model is the integration of information gained from experimental
data, (information contained in KO mice experiments, in vitro data generated from isolated osteocyte
cultures) and clinical data to explore hypotheses and help elucidate osteocyte function in the context
of therapeutic modulation of sclerostin. This quantitative modeling approach may help to link the
biochemical processes to cellular activity to help more clearly define the role of the osteocyte in re-
modeling.
1.3.5 The Basis of aMultiscale Systems PharmacologyModel Extension
In addition to the Pivonoka review, Webster and Muller issued a thorough review of published
physiological bone models in 2011 [46]. One of the featured cell populations models was development
by Peterson and Riggs in 2010 [47]. The goal of this model was to provide a platform for evaluating lon-
gitudinal effects of therapies and disease states on whole body calcium homeostasis by building upon
cellular dynamic models of Lemaire, et al. [48], a quantitative model of calcium handling by Raposo,
et al. [49] and a model describing relative activities of PTH by Bellido, et al. [50]. While this multiscale
model is comprehensive in descriptions of cell dynamics, signaling and calcium homeostasis, it was
published at a time when not as much was known about osteocyte biology. In their evaluation of sev-
eral bone models, Webster and Muller stated, “A major deficiency of the aforementioned mathemat-
ical models is that they exclude the role of the osteocyte and neglect the effect of mechanical stimuli
on bone formation.” The field is in agreement that a quantitative framework describing the osteocyte
role in bone remodeling has immediate relevance to the development of these therapies. The addition
of the osteocyte to the cell population-type models will be a more complete picture of physiological
response to proteins involved in modeling that was previously lacking.
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1.4 Project Aims
The goal of this work was to extend the Peterson and Riggs [47] model of whole body calcium
homeostasis (henceforth named the multi-scale systems pharmacology model (MSPM)) to create a
quantitative framework for simulation of clinical endpoints such as turnover markers, BMD and frac-
ture rate after administration of sclerostin monoclonal antibodies. In doing so the aim is to address the
criteria previously outlined for evaluation of the extended systems model.
The relevant questions are:
• Are TMDD models a priori identifiable, and if not, which approximations to the model can be
used which are identifiable? If so, what are the conditions that lead to a posteriori identifiable?
• Does the model accurately describe changes in P1NP and CTx and regional changes in bone min-
eral density (BMD) seen after sclerostin monoclonal antibody (mAb) administration?
• What is the quantitative role of the osteocyte as it relates to feedback regulation during modeling
and remodeling?
• Which dosing regimen with sclerostin inhibitors elicits the greatest increase in BMD in patients
with osteoporosis?
• Which model involving changes in lumbar spine (LS) BMD best describes changes in fracture
rate from an aggregate dataset?
• In a head-to-head comparison with teriparatide, does the model predict that sclerostin mAb
treatment will result in greater increases in BMD and protection from fracture?
Specific aims desgined to answer these questions were:
1. Establish a priori identifiability of target mediated drug disposition (TMDD) models and model
approximations; estimate pharmacokinetic (PK)/pharmacodynamic (PD) parameters describ-
ing sclerostin mAbs and circulating sclerostin using a TMDD model approximation.
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• To provide discussion around structural vs. practical identifiability and how lack of identi-
fiability can affect the interpretation of parameter values.
• To discuss methods for establishing model identifiability, namely compare and contrast dif-
ferential algebra identifiability of systems (DAISY), exact arithmetic rank (EAR) algorithms
and likelihood profiling as methods for establishing model identifiability.
• Create and validate a PK/PD model to describe sclerostin mAbs and circulating sclerostin,
using data from published Phase1/Phase2 clinical trials with romosozumab and blosozumab.
2. Integrate the PK/PD model into the MSPM and create structural framework for osteocyte and
compartments and regional BMD changes after sclerostin mAb administration.
• Structure osteocyte and estimate parameters linking changes in sclerostin to cellular func-
tion.
• Link osteocyte population to changes in osteoblasts/-clasts by defining effect parameters
on the RANK/RANKL/OPG axis.
• Define structure for total hip, femoral neck, and lumbar spine BMD and estimate parame-
ters describing sclerostin mAbs effects on BMD.
• Validate the model with an external dataset (reference [51]).
• Estimate parameters for combination arm (denosumab+ teriparatide) to use as a compara-
tor. This also served as another layer of validation for the model.
3. Further develop a time-to-event (TTE) / hazard model of fracture to describe a complete meta-
data set; use this hazard model of fracture to compare therapies for osteoporosis and investigate
parameter modulation effects in the context of sclerostin mAb administration.
• To systematically construct a metadata set with clinical studies reporting fracture and lon-
gitudinal changes in lumbar spine BMD.
• Develop a TTE / hazard model by testing candidate models with different BMD represen-
tations.
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• Perform model simulations and sensitivity analyses to investigate drug effects on BMD and
probability of fracture.
For this project, the term “multi-scale” refers both to time scales ranging from minutes (e.g. half-
life of PTH) to years (BMD changes and fracture risk assessment), and size scales encompassing changes
in protein concentrations, cell populations, organ (e.g. parathyroid gland, kidney, bone) functions to
clinical measures and outcomes (e.g. BMD and fracture). As a part of future work, linking mechanical
stimulation described as the stress/strain dynamics to sclerostin expression and activity (as in [52]), as
well as characterizing the role of osteocyte in varying bone architecture would provide a more complete
picture of the entire bone remodeling process.
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Methods
2.1 AIM I. Establishing Identifiability of Target-Mediated Drug Disposition
Models and Their Approximations (PAPER I, Chapter 7)
Often, unlike small molecules, monoclonal antibodies (mAbs) exhibit non-linear pharmacoki-
netic behavior. This target mediated drug disposition (TMDD) is caused by high affinity binding of a
drug to its target enzyme, receptor or transporter, relative to drug dose and limited number of targets
within the drug distribution space [53]. Sclerostin mAbs exhibit this property of non-linearity during
the elimination phase, which can be seen in the dose range used in a phase 1 study (fig. 2.1).
Therapeutics exhibiting TMDD can be difficult to model because often the drug’s target concen-
tration is not available, and the biological processes described by the full model occur on different time
scales [54], making it difficult to identify all parameters in the system. Establishing the a priori iden-
tifiability of the TMDD model and TMDD model approximations is a novel contribution to the field
of pharmacokinetics, in which TMDD models are frequently being used to analyze clinical population
data. Identifiability analyses aid in interpretation of model parameters and indicate which parameters
may be more or less informed by the experimental data. In the context of MSPM development, TMDD
model approximations were also used to develop a PK/PD model linking sclerostin mAb concentration
to serum sclerostin.
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Figure 2.1: Serum concentration-time profiles of romozosumab from a phase 1 study. Note the non-linear decline in exposure, typical of
mAb elimination kinetics. Used with permission from [24]
Chapter 7 outlines identifiability analyses processes and summarizes results using the exact arith-
metic rank (EAR) approach. The differential identifiability of systems (DAISY) approach was also im-
plemented, but limitations to the algorithm prevented analysis of all input/output scenarios impli-
cated in TMDD models, so the EAR approach was relied upon for the final manuscript. DAISY was
developed by Saccomani and colleagues [55] and, unlike EAR, which can only establish local identifi-
ability, DAISY can be used to establish global a priori identifiability of a system. This algorithm is run
as a package within the REDUCE (v3.8) Algebra freeware [56]. It iteratively divides of the set of differ-
ential equations by ranked variable sets until a reduced set of minimum rank is reached. A test set of
pseudorandom parameter values chosen by the algorithm is evaluated within the reduced system to
determine if a unique solution exists.
The following was supplied in the input file:
• a vector, B, of inputs, outputs and state variables.
• a vector, B1, of unknown parameters. The parameters used in each test case are listed in table 1
(chapter 7).
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• a set, C, of differential and output equations.
• a seed value, which determines the range of pseudorandom values used for each variable in the
reduced system.
• a vector, IC, of initial conditions.
Results are stored in a separate text file.
Initial conditions are not needed in DAISY if global identifiability can be determined without them. If
the system is locally identifiable or nonidentifiable without initial conditions, the algorithm re-starts
after the reduction step, with this information included. See appendix A for example input/output
files for the case of a single-target TMDD when only free drug concentration is available as an input.
Because DAISY can only deal directly with pure polynomial forms for the differential equations, the al-
gorithm did not accept the quadratic solution form for free drug concentration, C, that is used in quasi-
equilibrium (QE) and quasi-steady state (QSS) approximations of TMDD models. However it was used
to establish global identifiability of single target, 2-target, and antibody-drug conjugate (ADC) TMDD
models.
The profile likelihood (PL) approach, as discussed briefly in chapter 7, can also be used to investi-
gate parameter identifiability of a system, but in a design-dependent way. Because it relies heavily on
experimental design, PL alone is not useful to determine whether a system is structurally identifiable,
but it can be used to assess impact of study design on a posteriori identifiability, once a priori identifia-
bility has been determined. Compared with EAR and DAISY, this approach requires the most extensive
set-up time and thus was used for comparative purposes, but not to test identifiability of every sce-
nario. NONMEM (v7.3, Icon Development Solutions, Elicott City, MD, USA) was used to implement
this approach as maximum likelihood estimation (MLE) is a commonly used algorithm for parameter
estimation in this software and is the basis for likelihood profiling. The likelihood describes the prob-
ability of the data given the model and parameter values. The maximum likelihood is the highest joint
probability of the provided data in a multivariate system. A marginal likelihood profile can be con-
structed for each parameter by fixing each parameter at a different value above and below the MLE,
while reoptimizing all other parameter estimates.
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To test for identifiability using this method for a single target TMDD, each variable was fixed at
10 different values within +/- 3 standard errors of the ML estimate. These values are plotted against
the minimum objective function value (MOFV) generated in NONMEM, which is approximately pro-
portional to -2log(Likelihood) for each fixed value of the parameter. A perfectly flat profile indicates a
structurally non-identifiable parameter. Profiles that identify a unique minimum but exhibit a broad
profile within the range of parameter values indicate parameters that are not well supported by the
data generated from that experimental design.
Because the PL method requires posing a parameter estimation problem, a real-world example
of a TMDD model of the endothelin-receptor antagonist bosentan was analyzed. In the model de-
veloped by Mager and Jusko [53], the free target was treated as a time-independent variable and km
was used instead of ksyn and kdeg parameters. In order to analyze a full TMDD system, a simulated
dataset was generated with parameter estimates and the sampling times from the bosentan study [57]
(see appendix A for setup code and example control stream). An exponential inter-individual variance
model was applied to Vc and Km (10% coefficient of variation [CV], each) and a proportional residual
error model (15% CV) was also applied to simulate a more realistic study population. A full TMDD pa-
rameter set was then re-estimated from this simulated dataset of 16 subjects in each dosing arm. The
intravenous (iv) doses simulated were 10, 50, 250, 500 and 950 milligrams (mg).
2.1.1 PK/PDModel of SclerostinmAbs (PAPER II)
As previously described, the plasma concentration profiles of sclerostin mAb exhibit nonlinear
clearance and with information about the binding protein (sclerostin) it would theoretically be possi-
ble to fit an approximation of a TMDD model. Unfortunately there are no published reports of scle-
rostin mAb concentration and resulting serum sclerostin levels for the same antibody at the same dose
levels. Currently there are published mAb concentration levels in a phase 1 study after single doses of
romozosumab and circulating sclerostin profiles from phase1/phase2 studies with single and multiple
doses of blosozumab. As a result, the PK and PD models used to describe these profiles were fit se-
quentially, as described in chapter 8 and concentration profiles from romozosumab were fixed while
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estimating the PD parameters, with the exception of km, which was re-estimated for blosozumab un-
der the premise that the two antibodies have different binding affinities (see the chapter 8 appendix
for additional assumptions).
2.2 AIM II. Implementing PK/PD Model in Bone Model and Determining
Model Structure and Parameter Values to Describe Changes in Turnover
Markers and BMD (PAPER II, Chapter 8)
The process of implementing osteocytes (OCY) into the MSPM is described in chapter 8. The
osteoblast-related compartments were developed initially, followed by the osteoclast-related compart-
ments. The compartments and parameters describing changes in BMD were implemented and esti-
mated last. Other additions to the model included BMD compartments for combination therapy of
teriparatide and denosumab, in order to be able to simulate effects seen in the DATA trial, in which
the combination arm elicited significantly greater increases in LS BMD, FN BMD and TH BMD after 24
months of active therapy [58]. These additions were built using data from from 27 documented clinical
trials with teriparatide [58–75] , denosumab (these are cited in chapter 8) and/or combination therapy.
Parameters were optimized using the R package minqa [76] and changes in BMD were simulated
using R package mrgsolve. To avoid problems with parameter identifiability, only the rate constant for
the BMD compartment and the power term on the OC within the BMD equation, were estimated for the
combination. The other parameters were fixed to the values of the denosumab BMD compartments.
The rationale for this is that the turnover marker profiles for the combination arm resembled those of
denosumab, so the assumption is that the same mechanisms of action are at work in the combination
arm. The final model was evaluated by sensitivity analysis (shown in appendix A, Figure A.1).
2.2.1 Optimization Routines
For a parsimonious model, it is ideal to be able to optimize parameters simultaneously to the end-
points of interest. Although this is not a requirement of a fit-for-purpose systems model, multivariate
optimization is highly desired for parameters describing processes that are tightly regulated by feed-
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back control, in which there is a high level of dependency between parameters for a given outcome.
After the model structure and initial parameter estimates were in place, the parameters EMAXSCLER,
γD r , γO C Y , γO P G ,γOB, k o u tT , SMAX, and k o u tT O L were optimized simultaneously to the turnover
markers P1NP and CTx.
Multiple optimization routines were explored for this task. Global optimization for large systems
models is difficult and this was especially true in this system where P1NP and CTx are highly variable
endpoints regulated by feedback control and the available dataset was somewhat sparse. The opti-
mization routes that were explored are summarized in table 2.1. Criteria for optimization method se-
lection were that the method allowed all parameters to move (i.e. avoided falling into local minima
over the multivariate parameter space), the method resulted in a lower objective function value than
the initial parameter estimates, and that the resulting optimized parameter values resulted in predic-
tions that resembled the clinical data by visual inspection.
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Table 2.1: Optimization methods in R
Function Description Benefits Drawbacks
Gradient-based methods
optim::Nelder [77] Default optimization method; uses simplex
method that does not require gradients
• gives hessian
• derivative free
• cannot specify bounds so
for difficult problem it can
slip into unsolvable variable
space
optim::SANN [78] Stochastic method; searches neighboring re-
gions and calculates acceptance probability us-
ing metropolis function.
• derivative free • very slow
optim::LBFGSB [79] Quasi-newton method with box-constraints; re-
lies on approximation of inverse hessian and ex-
ecutes a backtracking line search until an accept-
able point is found and then it updates the hes-
sian
• allows bounds to be speci-
fied
very slow
Rvmmin [80, 81] Same method as BFGS-B, but updated for effi-
ciency by using masks ie. temporarily fixing pa-
rameters
• allows bounds to be
specified
Quadratic Approximation Methods
minqa::newuoa [76] Forms a trust-region by models of interpolation
and searches within this space for minimum
function value
• fast
• derivative free
• can set trust region radius
• easily falls into local
minimum
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Continued from previous page
Function Description Benefits Drawbacks
RsolnP:: solnp [82] Solves a linearly constrained optimization prob-
lem. In the first step, the optimization prob-
lem tests a vector of Lagrange multipliers chang-
ing with each major iteration and this is sub-
ject to a function containing the numerical ap-
proximation to the jacobian. In the second step,
minor iterations approximate a solution to a
quadratic function is found, subject to the same
constraints
• takes boundary conditions
• gives hessian
• highly constrained by
boundary conditions
Sampling Methods
MCMCpack::
MCMCmetrop1R
[83]
Calls optim first to generate a hessian (the
variance-covariance matrix for the Gaussian pro-
posal distribution) as a starting point from which
to sample. Then pulls samples from a continu-
ous distribution using a random walk Metropolis
algorithm
• user can supply a hessian
matrix from a previous opti-
mization step to help speed
up algorithm
• robust method for difficult
problems
• slow
DEoptim [84] A genetic algorithm which creates a starting pop-
ulation of several vectors of parameter values,
based on draws from a uniform distribution de-
fined by specified bounds. This population is
transformed based on the strategy selected and
the vector most likely to minimize the function is
carried forward to the next iteration. New popu-
lations are generated and process is repeated un-
til the maximum number of evaluations (speci-
fied by the user) is reached
• can be easily parallelized
• good for stochastic, noisy
functions, or those difficult
to differentiate
• takes boundary conditions
• can specify a starting pop-
ulation, in addition to initial
estimates
• does not give hessian
• slow
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2.3 AIM III. Fracture Model and Simulations (PAPER III, Chapter 9)
A time to event (TTE) / hazard model of fracture was also developed, to be implemented into the
bone model and used to explore how therapeutic modulation affects fracture outcome. The primary
objective of this part of the project was extend a previously-developed model of fracture to determine
the best covariate structure for lumber spine BMD and differentiate the effects of therapy on the the
probability of fracture in patients with osteoporosis. The methods for development, results and valida-
tion are shown in chapter 9. The final model simulations were performed within the MSPM by linking
continuous changes in LS BMD simulated by the systems model, to the TTE model of fracture. The
other model covariates required by the TTE model were supplied via an external dataset.
Simulations of regional changes in LS, total hip (TH), and femoral neck (FN) BMD were guided
by the STRUCTURE clinical trial that recently completed [85] . To populate baseline characteristics
of patients in these studies, patients were resampled from a normal distribution from a subset of the
NHANES dataset. Only patients with an osteoporosis diagnosis, age greater than or equal to 55, and
with a screening LS BMD of less than 0.83 g/cm2 were included in the sampling pool. Parameters for
the hazard model were sampled from the posterior distribution generated by the model described in
chapter 9. 1000 samples were drawn from this posterior and inter-trial random variability was gen-
erated for the h0, and BMD parameters by sampling from a multi-variate normal distribution of the
estimated random effects for these parameters. These simulations were performed using mrgsolve [86].
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Chapter 3
Results
3.1 AIM I. Results of Identifiability Analysis for Target-Mediated Drug Dis-
position (TMDD) Model (PAPER I, Chapter 7) and PK/PD Model for
Sclerostin mAbs (PAPER II, Chapter 8)
In the case of a full single-target TMDD, the system was fully globally identifiable under any out-
put scenario, with the exception of the complex only output under iv infusion, and single outputs drug
only, target only, or complex only after a subcutaneous dose. The Ritt algorithm performing these steps
required unreasonable run times and could not be resolved using this method. All input/output sce-
narios under the MM approximation were found to be globally identifiable using DAISY, as were all
of the TMDD2-target scenarios with the exception of free-drug only input, which was limited by time
constraints of the reduction steps, as described. The antibody-drug-conjugate TMDD model is at least
locally identifiable if either drug and toxins or target and toxins can be measured and it is globally
identifiable only if all species in the model are measurable. Results for this analysis are shown in ta-
ble 3.1.The results of the likelihood profile analysis of the bosentan study are shown in fig. 3.1 and the
code for the analysis is in appendix A.
The final PK/PD model structure and parameter estimates are shown in PAPER II (chapter 8). The
visual predictive checks with these parameter estimates are shown in the supplement to PAPER II, fig-
ures 4 and 5. The PK and PD dynamics are well-described by the data, within the therapeutic dosing
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range (1-5 mg/kg with romosozumab and 150-540 mg blosozumab, single and multiple doses).
Table 3.1: Analysis Results for Antibody-Drug Conjugate TMDD (See Appendix 2 for equations)
Inputs Outputs Parameters Result
iv inf Drugs & complexes only kdeg, kon, koff, kel1, Non-identifiable:
kel2, kelT, kpt, ktp,
Vc, ksyn, kint, k2dec kelT
iv inf Drugs & target or complexes &target Same as above Non-identifiable:
kelT
iv inf Drugs & toxins or complexes & toxins Same as above Locally identifiable1
iv inf Drugs, targets, complexes & toxins Same as above Globally identifiable
1 The system was too complex for the Ritt algorithm within DAISY; the algorithm which performs the reduction steps. The EAR approach
was used here, limiting results to nonidentifiable or locally identifiable
3.2 AIM II. Sclerostin-Related Modifications to the Multiscale Systems Phar-
macology Model (PAPER II, Chapter 8)
Development and selection of the final model structure for all sclerostin-related components are
presented in chapter 8. The step-wise process used to determine the compartmental structure of these
effects is outlined in this section.
3.2.1 SystemsModel Equations Describing Compartmental Structure
Sclerostin Effect on Osteoblast Compartment
1. Increase formation rate of responding osteoblasts (ROB, γD r ) and formation rate of osteoblasts
(OB) (kb), by applying a sclerostin effect, normalized to baseline.
D r = k b · OB0
P i c0
·

SCLER
SCLER0
γD r
(3.1)
b i g D b = kb ·OB0 ·Pic0/ROB ·

SCLER
SCLER0
γD b
(3.2)
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Figure 3.1: Likelihood profiles for single-target TMDD model, showing all parameters to be identifiable
both apply to the equations:
d
dt
ROB = D r ·PicROB · 1
E ST
r o b G AM −kp t ·R O B (3.3)
d
dt
OB =
b i g D b
P i c O B
·D ·FracOBfast ·Frackb2−k b fast ·OBfast (3.4)
Result: Rapid and large increases in P1NP.
2. Apply an EMAX effect on a precursor pool in order to supply the responding osteoblasts (os-
teoblast precursor pool) (ROB) compartment with additional substrate and avoid ROB depletion:
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d
dt
PREROB = PREROBin ·

1− EMAX ·
SCLER
SCLER0
EC50 +
SCLER
SCLER0

−k o u tPREROB ·PREROB (3.5)
d
dt
ROB = D r ·PicROB · 1
E ST
r o b G AM ·

1
PREROB
PREROB0

−kp t ·ROB1 (3.6)
Result: Tmax (time at maximum P1NP concentration) and the slope of the decline in P1NP af-
ter the peak was now closer to the concentration curve in the clinical data, but the accumulation
phase of the simulations were still not as rapid as in the clinical data.
3. Apply a direct effect on OBfast compartment, using change from baseline (CFB) in sclerostin as
a signal.
d
dt
OBfast =
b i g D b
PicOB
·D ·FracOBfast ·Frackb2 ·

1+
EMAX ·CFBSCLER
EC50 +CFBSCLER

−kbfast ·OBfast (3.7)
Result: Rapid accumulation phase still not achieved.
4. Apply a direct effect on OBfast compartment, using sclerostin normalized to baseline as a signal.
d
dt
OBfast =
b i g D b
PicOB
·D ·FracOBfast ·Frackb2 ·

1+
EMAX · SCLERSCLER0
EC50 +
SCLER
SCLER0

−kbfast ·OBfast (3.8)
Result: Again, the magnitude of the response can be adjusted by adjusting EMAX, but the accumu-
lation phase was still not as rapid as in the clinical data.
5. Apply a direct effect on OBfast compartment, using a power model of sclerostin normalized to
baseline.
d
dt
OBfast =
b i g D b
PicOB
·D ·FracOBfast ·Frackb2 ·

SCLER
SCLER0
γD r −kbfast ·OBfast (3.9)
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Result: This had a similar effect as the previous step.
6. Apply pre-cursor pool effect to in-rate and out-rate of ROB; power effect on in-rate precursor
pool effect to remove substrate from ROB pool more rapidly.
d
dt
ROB = D r ·PicROB · 1
E ST
r o b G AM ·

1
PREROB
PREROB0
γD r
− PREROB
PREROB0
· Kp t ·R O B 1 (3.10)
Result: Accumulation slope of P1NP is closer to clinical data, but as soon as the ROB pool is de-
pleted, P1NP declines (see fig. 3.2 and fig. 3.3, panels 3 and 4).
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7. Finally, an EMAX model was applied directly onto the OB compartment. This resulted in a supe-
rior fit than all other mechanisms that were tried. The structure of the final model was a sigmoid
EMAX model propagated through a "translation compartment" to allow for a lag time between
peak sclerostin response and peak P1NP response.
d
dt
trans = k i ntrans ·

1+
EMAX SCLER ·SCLERγOB
EC
γOB
50,SCLER +SCLER
γOB

−k o u ttrans · trans, (3.11)
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where
OB = OBfast · trans+OBslow & k i ntrans = k o u ttrans (3.12)
P1NP simulations using this model are shown in the appendix of chapter 8.
Sclerostin Effect on Osteoclast Compartment
Next, OC effects were implemented in the model and several modifications were also attempted
before arriving at a final model structure.
1. Change “OB effect” applied to the kin parameter on the RANKL compartment to an OCY effect:
OBeffect =
OCY
OCY 0
γOCYeffect
(3.13)
Result: OC activity declined between γOCYeffect values of 0.1-1, but either did not decline quickly
enough or failed to return to baseline.
2. Keep an OB effect (as in the original model) and add an OCY effect on RANKL.
Result: This seemed to have the desired effect if the OB effect was very low (γOBeffect <0.01) and the
OCY effect was relatively high (γOCYeffect between 0.2-0.3), but still did not have the initial decline
in CTx described by the data (see fig. 3.4).
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Figure 3.4: Simulations of CTx from a single arm in the clinical dataset show OB and OCY effects on RANKL with a range of test values for
the γ parameters. Clinical data from a single treatment arm is shown in red
3. Finally, a sclerostin effect was implemented, in the form of a power model on OPG, as described
in chapter 8.
Result: This had the desired effect of rapidly decreasing OC in the early phase of treatment, but still
allowed for recovery at the later phase.
4. EMAX models for the sclerostin effect on OCY and the sclerostin effect on OPG were also tried,
but resulted in poor prediction profiles, specifically a 2-phase decline in CTx.
The CTx profiles simulated with the final model structure are shown in the appendix for chapter 8.
Final global optimization of parameters was performed after final model structure describing P1NP
and CTx profiles was in place. After optimization the parameters related to turnover markers, regional
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BMD compartments and parameters were implemented. The optimization methods and BMD portion
of the model development for sclerostin-related effects is also described at length in chapter 8.
Model Development for Simulation of Combination Therapy
Further adjustments had to be made to the model so that the OCY effects on RANKL would not
interfere with simulations of PTH or teriparatide administration. The steps taken which lead to the
final model structure in which sclerostin mAb or teriparatide could be correctly simulated are outlined
below.
1. Coupling the anabolic effects together on OCY
TERIeffect = 1− TERICENTγTERISCLER (3.14)
d
dt
OCY = OB ·FRACTIONOCY −OBbaseline ·FRACTIONOCY ·SCLERγOCY · TERIeffect ·OCY (3.15)
Under the premise that PTH signals to stimulate OCY. There is evidence that increased PTH re-
sults in increased expression of OPG and RANKL; perhaps this is signaled through the osteo-
cytes [31, 87].
Result: Magnitude of P1NP and CTx response was still blunted and CTx effect did not decline ini-
tially to the extent of the clinical data.
2. Apply PTH effects to areas in the model where sclerostin has an effect, but to varying degrees by
supplying different values for γP T HD r ,γP T HO C Y and γP T HO P G .
d
dt
ROB = D r ·PicROB · 1
E ST
r o b G AM −SCLEReffectγD r ·

P T H
P T H0
γP T HD r · Kp t ·ROB1 (3.16)
d
dt
OCY = OB ·FRACTIONOCY −

P T H
P T H0
γP T HO C Y ·OBbaseline ·FRACTIONOCY ·OCY (3.17)
d
dt
OPG = OPG ·SCLEReffectγO P G ·

P T H0
P T H
γP T HO P G −k 1 ·OPG ·RANK +k 2 ·COMPLEX −k 0 ·OPG
(3.18)
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Result: Profiles not improved from previous modification.
3. Apply PTH signal only to the in-rate on OCY compartment.
d
dt
OCY = OB ·FRACTIONOCY ·

P T H
P T H0
γP T HO C Y −OBbaseline ·FRACTIONOCY ·OCY (3.19)
Result: Marked improvement in P1NP response, but no improvement on CTx.
4. Apply a direct PTH effect on OB compartment, either via the trans compartment or OBfast.
d
dt
trans = k i ntrans ·

1+
EMAX SCLER ·SCLERγOB
EC
γOB
50,SCLER +SCLER
γOB

·

P T H
P T H0
γP T HO B −k o u ttrans · trans, (3.20)
d
dt
OBfast =
bigDb
PicOB
·D ·FracOBfast ·Frackb2 ·

P T H
P T H0
γP T HO B −kbfast ·OBfast (3.21)
Result: Again, there is a marked improvement in P1NP response, but this is artificially elevated
and no feedback response is elicited to improve the CTx profile.
5. Apply a fractional contributions from OB and OCY to RANKL, so that when there is no sclerostin
effect present, the OB effect on RANKL takes the value from the original model.
OSTEOEFFECT =

OCY
OCY baseline
δ
· TOTOsteoEffect ·

1− 1
FRACTIONOBeffect

(3.22)
where TOTOsteoEffect = 0.173833 and FRACTIONOBeffect = 20 (fixed values)
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Result: Again there is a marked improvement in P1NP response, but this is artificially elevated and
no feedback response is elicited to improve the CTx profile (see fig. 3.5).
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Figure 3.5: Results of fractionating RANKL signal between the OB and OCY: OB contribution is 120 th the OCY contribution. Magnitude of
P1NP response (left) is slightly over-predicted, and initial decline in CTx (right) is still slightly under-predicted, for a subset of the clinical
data (shown in red)
6. Apply an EMAX “tolerance” model, whereby the OCY contribution to RANKL pool phases out
with the sclerostin effect.
TOLSCLER =

1+
SMAX ·SCLEREFFECT
SC50+SCLEREFFECT

(3.23)
k o u tOCY = OBbaseline ·FRACTIONOCY · TOLSCLER (3.24)
Result: P1NP drops too quickly after repeated doses; CTx drops abruptly after initial dose and re-
bounds after therapy is removed.
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7. Structure tolerance as an independent compartment, as in an indirect response model; apply
this TOL effect on OCY compartment, in addition to sclerostin effect.
d
dt
TOL= k i nT O L ·exp (−5 · TOL)−k o u tT O L · TOL (3.25)
where k i nT O L = k o u tT O L
k o u tOCY = OBbaseline ·FRACTIONOCY ·SCLERγOCY · TOL (3.26)
Result: Tolerance effect a little too strong. P1NP / CTx responses look like the clinical data during
initial dose phase, but then increase as sclerostin-driven tolerance effect declines.
8. Use sclerostin effect as a signal to decrease TOL; Implement tolerance compartment like a pre-
cursor pool, tied into the osteocyte compartment.
Use the EMAX effect for TOLSCLER:
TOLSCLER =

1− SMAX ·SCLEREFFECT
SC50+SCLEREFFECT

(3.27)
k 0TOL = OB ·FRACTIONOCY ·baseline (3.28)
k i nTOL = OBbaseline ·OCY baselineFRACTIONOCY TOLbaseline (3.29)
k o u tOCY = OBbaseline ·FRACTIONOCY · TOLSCLER (3.30)
d
dt
TOL= k 0T O L −k i nT O L · TOLSCLER −k o u tT O L · TOL (3.31)
A Multiscale Systems Model for Advancement of a New Line of Therapy for Osteoporosis 35
CHAPTER 3. RESULTS Rena Eudy
d
dt
OCY = OB ·FRACTIONOCY −k o u tOCY ·OCY (3.32)
Result: P1NP profiles resemble the clinical data but CTx responses do not decline during the initial
dose phase.
9. Final model: combine tolerance effect with portioned osteoeffect from #5: at full tolerance (TOL=1),
the OBeffect is 1/20 of the OCYeffect:
FRACTIONOBeffect = 20/TOL (3.33)
Use the same equation for TOLSCLER
TOLSCLER =

SMAX ·SCLEREFFECT
SC50+SCLEREFFECT

(3.34)
where k i nTOL = k o u tTOL and the OCY compartment structure returned to what it was before:
d
dt
OCY = OB ·FRACTIONOCY −OBbaseline ·FRACTIONOCY ·SCLERγOCY ·OCY (3.35)
Result: Both P1NP and CTxprofiles are better described with tolerance compartment and propor-
tioned osteoeffect (see fig. 3.6).
Additional modifications were made to the model in efforts to stabilize the model and allow an-
abolic mechanisms of PTH stimulations to persist along with anabolic effects of sclerostin modulation.
In the final model, the osteocyte effect on RANKL was modified.
Model Stability
In order to address the problem of model stability (ie. obtaining a complete simulation with the
same results every time without premature termination by the ODE solver), the steady-state principle
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from the original bone model [47]was applied to the sclerostin effect, and the EC50 was solved in terms
of EMAX:
EC50SCLER = exp

l o g (EMAXSCLER −1)
γSCLEROB

(3.36)
The final, globally-optimized parameter values are shown in table 3.2. The final estimated BMD
parameters for teriparatide, denosumab, sclerostin mAbs and the combination of teriparatide and
denosumab is shown in table 3.3. The parameter estimates for the BMD compartments represent-
ing combination treatment were expressed as fractions of monotherapy-related parameters, in order
to make inferences about temporal aspects of modulation of two pathways at work in the combination
arm, ie. anti-resorptive activity and anabolic activity. Simulated teriparatide and denosumab studies
are shown in fig. 3.9 and fig. 3.10. Simulations for changes in LS BMD with the study design from the
DATA trial are shown in fig. 3.8.
3.2.2 Optimization Routines
A visual demonstration of the results of simulation using different algorithms to fit a subset of
parameters to a sclerostin P1NP dataset is shown in fig. 3.7. In addition to the methods displayed,
Rsolnp was also tried but was unsuccessful after only a couple of iterations. The parameters were not
permitted to change very much and resulted in poor fits, but a hessian matrix was generated from the
parameter estimates. Gradient-based methods proved to be unreliable because it was difficult for the
solver to resolve at all possible values of the parameters, which the algorithm prompted it to explore.
The derivative-free method, minqa::newua was used for local parameter estimates and for estimates of
BMD parameters because the parameter sets were small and more manageable. The final parameter
optimization step, in which all parameters describing the turnover makers were optimized simultane-
ously was performed using DEoptim, which terminated at a pre-specified number of maximum itera-
tions (300), yielded a lower objective function than the initial estimates, which had been determined by
tuning and prior optimization, and resulted in good predictions of P1NP and CTx by visual inspection.
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Figure 3.7: A comparison of optimization methods using the blosozumab P1NP dataset and optimizing E C 50SC L E R , E M AXSC L E R and
γSC L E R . Max interactions for DEoptim fits was 200
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Table 3.2: Final Estimated Values for Parameters Involved in Estimation of Turnover Markers
Variable Value
EMAX SCLER (nM) 4.67
FRACTIONOBeffect (unitless) 20.0 fixed
FRACTIONOCY (1/hrs) 0.50 fixed
γD r (unitless) 0.0446
γO C Y (unitless) 0.276
γO P G (unitless) 1.60
γOB (unitless) 0.163
k o u tT (1/hrs) 0.00607
k o u tT O L (1/hrs) 0.00190
SMAX (unitless) 8.69
TOTOsteoEffect (unitless) 0.174 fixed
Table 3.3: Estimated BMD Parameters
LUMBAR SPINE
kout (1/hrs) gamOC (unitless) gamOB (unitless) del (1/hrs)
SCLER 0.000145 0.0653 0.758 0.00246
DENO 0.0000740 0.0791 0.0793 -
TERI 0.000554 0.0169 0.271 0.00100
COMBO 1.86 ·D E N O 1.28 ·D E N O 1 ·D E N O -
TOTAL HIP
kout (1/hrs) gamOC (unitless) gamOB (unitless) del (1/hrs)
SCLER 0.000145 0.0653 0.225 0.00246
DENO 0.000108 0.0552 0.0793 -
TERI 0.000139 0.131 0.298 0.00100
COMBO 0.971 ·D E N O 1.28 ·D E N O 1.00 ·D E N O -
FEMORAL NECK
kout (1/hrs) gamOC (unitless) gamOB (unitless) del (1/hrs)
SCLER 0.000145 0.0653 0.131 0.00246
DENO 0.000119 0.0515 0.0793 -
TERI 6.63E-05 0.212 0.496 0.00100
COMBO 1.08 ·D E N O 1.30 ·D E N O 1.00 ·D E N O -
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Figure 3.8: Simulated changes in LS BMD in DATA trial. Points and bars indicate mean and 95%CIs from the clinical trial [58]. Lines and
ribbons are simulated means and 90%CI
3.3 AIM III. Development of a Hazard Model of Fracture (PAPER III, Chap-
ter 9)
The results for the hazard model simulations are discussed in chapter 9. Section 3.3 shows the
relative hazard ratio for the additional drug effect for each class of drug represented in the metadataset.
DATA trial simulations for fracture rate are shown in fig. 3.12. This is the simulated survival (probability
of no fracture) if the DATA trial had been extended for 10 years.
The STRUCTURE study is an ongoing Ph3 study comparing head-head treatment of romosozumab
and teriparatide in women with osteoporosis with a high risk of fracture. The primary endpoint in this
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study is longitudinal changes in TH BMD over one year. STRUCTURE trial simulations are shown in
figs. 3.13 and 3.14. These are hypothetical three-year trial simulations, as the STRUCTURE trial is only
one year in duration. 3-year probability of fracture is shown in fig. 3.15.
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Figure 3.6: Results of using a tolerance model structure to describe OCY signaling on RANKL and effects on P1NP, OCY, CTx and TOL com-
partments. A subset of the sclerostin mAb dataset is simulated here; yellow and orange lines represent the simulations from the model
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Figure 3.9: Trials with teriparatide. Graphs show simulated (blue) overlaying data (red) and 95%CIs
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Figure 3.10: Trials with denosumab. Graphs show simulated (blue) overlaying data (red) and 95%CIs
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Figure 3.11: Hazard ratios and posterior distributions for the additional drug effect covariates. Hazard ratios were calculated relative to
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Figure 3.12: Survival curves simulated with the hazard model using predicted changes in BMD generated by the MSPM. Shading represents
90% prediction intervals
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Figure 3.14: Simulated changes in P1NP (A) and CTx (B) during 3 years of treatment
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Figure 3.15: Simulated predicted 3-year fracture rate for teriparatide and sclerostin mAb. The shading represents the 90% prediction interval
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Chapter 4
Discussion
4.1 AIM I. A Priori Analysis: A Comparison of Methods
In almost all cases, the results generated in DAISY and EAR were in agreement, except for in-
stances when DAISY could not resolve the model structure, took an unreasonably long time to compile,
or when the initial conditions influenced the EAR analysis. Software specific limitations were encoun-
tered in some cases that impacted identifiability results, specifically when DAISY was unable to gen-
erate a characteristic set from state variables represented by rational expressions. Differential algebra-
based algorithms like DAISY are one of the few types of algorithms that can systematically distinguish
global and local identifiability without a user-supplied domain of definition of the parameters or the
initial conditions [88]. However, DAISY can accept only some polynomial forms of state variables and
cannot analyze QE and QSS approximations which include quadratic expressions. Also in most cases
the DAISY program is very fast, but when the model system had a limited number of outputs relative
to the number of parameters, the program failed to converge within a reasonable timeframe.
In contrast, EAR can support large and complex systems and is easier to implement because it
operates within the Mathematica software package. A limitation of EAR is that the algorithm relies on
initial conditions. The inability to perform rank testing independent of initial conditions limits the abil-
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ity to establish unique solutions for some TMDD systems with initial conditions equal to zero. DAISY
was able to establish identifiability for these systems. Of the three approaches, the profile likelihood
(PL) approach requires more in-depth knowledge of the required software and it took the most time to
implement. It is also the only approach tested that is sensitive to both a priori and a posteriori identifi-
ability of model parameters. The PL analysis performed on simulated TMDD data with low variability
confirms that all parameters are both a priori and a posteriori identifiable (see fig. 3.1).
Cheung, et al. [89] illustrated how the issue of nonidentifiablity of PK/PD models can be formally
solved by reparameterization or by analysis of parallel experiments [90]. A prerequisite of the repa-
rameterization process is that all system parameters need to be at least locally identifiable, and glob-
ally identifiable parameters can be grouped in order to render the entire system globally identifiable.
However the nonlinear similarity transformation approach used is highly complex if the system can-
not be made into a polynomial form with a linear observation, which was also what prevented global
identifiability of the QE system in DAISY. The parallel experiments analysis is a way of achieving global
identifiability by formally constraining the system. Neither of these processes can be applied to the
antibody-drug conjugate (ADC) system in such a way that the elimination rate of the toxin can be ren-
dered identifiable without explicitly measuring free toxin in the experiment, or by making the assump-
tion that kelT is somehow a function of the other parameters in the system (see table 3.1).
Often achieving TMDD model convergence and well-defined minima under real world experi-
mental conditions is impossible without fixing some parameters or making assumptions to simplify
the model [54]. Given the findings of this work, a likely explanation is that it is impractical to achieve
an adequate experimental design at the time scales necessary for a posteriori identifiability of all pa-
rameters and appropriate model approximations should be used to estimate parameters. Following a
priori identifiability analyses for other complex systems, deoptimization and simulation can be used
to explore and explain sources of a posteriori nonidentifiability due to experimental noise or sampling
conditions.
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4.2 AIM II. Implementing PK/PD Model in Bone Model and Determining
Model Structure and Parameter Values to Describe Changes in Turnover
Markers and BMD
Discussion around the results of parameter estimation and the sclerostin-related changes made
to the model is included in chapter 8. An interesting finding of this work is that the BMD compart-
mental structure describing anabolics and anti-resorbtives is similar, however, an additional compart-
ment added to describe the delay for anabolic therapies to lay down new bone matrix and become
mineralized. Within the compartmental structure for each mechanism, parameters were shared be-
tween regions. For romosozumab and blosozumab, only the power term on the OB effect was re-
estimated for each region. This description supports a dose-dependent response of the mAb according
to sclerostin expression in the region tied to the degree of loading in that region [91]. For denosumab
and teriparatide, there were different time constants (kin, kout) estimated for each region. This sup-
ports site-specific remodeling/modeling activity characteristic of each mechanism. Denosumab has
demonstrated differential effects of site-specific remodeling and modeling [92]. It has been suggested
that teriparatide response is synergistic with loading and depends heavily on mechanical environment
at each site [93].
To truly understand site-specific activity of each drug mechanism an understanding of the under-
lying factors involved in bone microarchitecture is required, but is very complex. It is also important
to note not only the difficulties involved in acquisition and analysis of images of bone composition,
but the high degree of variability in these process between studies [94]. Some examples of mis-guided
interpretations can be 1.) interpreting cortical fragmentation measured as trabeculae [94], 2.) mis-
interpretation of incomplete coalescence of adjacent trabeculae as higher cortical “porosity” in a tran-
sitional zone, or 3.) mis-interpreting increased cortical thickness as secondary mineralization [72].
These types of analyses should be interpreted with discretion.
However, these analyses are very important, as discussed in chapter 9, changes in turnover mark-
ers and aBMD do not automatically correlate with bone strength which is dictated by cortical and tra-
becular geometry [95, 96]. In fact, Burghardt, et al (2010) found that only volumetric BMD measures
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and cortical porosity at the tibia correlated with changes in turnover marker BSAP (not areal BMD or
trabecular microarchitecture) [95]. Findings like these have large implications on development of new
therapies or combination treatment strategies, especially when only turnover markers and aBMD are
measured in early clinical trials.
A few patterns emerge when examining the relationship between changes in microarchitecture,
areal bone mineral density (aBMD), and turnover markers between therapies. Anabolic therapies with
a strong renewing bone resorption mechanism, as indicated by a decline in CTx, tend to have no change
or a decrease in distal 1/3 radius BMD, a site usually associated with changes in cortical bone. How-
ever, an analysis by Poole [97] found that teriparatide increased cortical thickness in the femoral neck,
an area which sustains habitual mechanical loading. The authors suggest that PTH augments the me-
chanical load signal to osteocytes to reduce sclerostin secretion and increase formation in these re-
gions, similar to the mechanism of sclerostin inhibition by sclerostin mAbs. Teriparatide is known
to increase cortical porosity, which is correlated with bone-specific alkaline phosphatatse (BSAP) [95]
and cancellous bone volume [5] owing again to its metabolically active mechanism of high turnover. In
essence, teriparatide over-replaces areas of older mineralized bone with new bone with lower mineral
content in some areas.
Anti-resorptives, alendronate and denosumab, also elicit greater trabecular and cortical responses
in regions of loading, although denosumab has demonstrated improvement over alendronate in total
and cortical volumetric bone mineral density (vBMD) and cortical thickness [96]. In the DIRECT study,
3 years of denosumab treatment also resulted in significant increases in BMD from placebo in the 1/3
distal radius, unlike anabolic therapies [98]. It is possible that anti-resorptives are somewhat less dis-
criminating of regions of loading because they have no direct effects on osteocytes (only indirectly
through RANKL) and this, combined with increased vBMD at cortical sites, is why the mechanism is
able to elicit increased BMD at the distal radius, unlike teriparatide and romosozumab.
The combination of teriparatide and denosumab resulted in a decline in osteoclasts (OC) num-
ber, and OB but to a lesser degree [58]. In this arm, trabecular and cortical vBMD increased, cortical
thickness increased, consistent with mechanism of denosumab, and cortical porosity was unchanged.
It is difficult to say what is the source of the significant improvement of BMD in the regions of loading
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in the combination arm. The combination therapy resulted in a slight further reduction in resorbtion
activity over the monotherapies, but formation activity was also reduced in this arm. It could be that,
in accordance to Poole, et al. theory that PTH, by the same mechanism which causes a reduction in
sclerostin, that is, by signaling a remodeling event in the osteocytes, causes more RANKL to be secreted,
which in turn amplifies the denosumab effect as more target ligand is sequestered. Sugiyama et al. [93]
suggest the significant reduction in OC activity results from the combination of modeling-based for-
mation at specific sites and a non-site specific decline in remodeling-based bone formation. This is
consistent with findings of anti-resorptives increasing periosteal bone formation in the hip but not the
lumbar spine.
It is known that sclerostin inhibition, unlike teriparatide is not subject to coupled bone forma-
tion and resorbtion, dictated by bone remodeling processes, but is instead governed by uncoupled
model-based formation and resorption [91, 99], as markers of formation increases while resorbtion
markers simultaneously decrease. Sclerostin ablation results in increased cortical bone volume [100],
although increases in distal 1/3 radius BMD have not been seen at the doses of sclerostin mAb tested
in clinical trials to date. Sugiyama, et al. suggest that perhaps sclerostin levels are reduced in non-
weight bearing sites like this and may require much higher doses to see dose-dependent increases
in these regions. The attenuation of the modeling response after a year of continuous dosing sug-
gests that there are other mechanostat-related mechanisms at play that cannot be overcome only by
blocking sclerostin. The increase in bone mass after mechanical loading in the absence of sclerostin
has been demonstrated in mice [100], indicating mechanisms other than sclerostin signaling are im-
plicated in load response. Dkk-1 could increase Wnt/b-catenin in response to loading, independent
of sclerostin. Other factors involved in mechanotransduction may include estrogen-receptor alpha
(ER-a), insulin-like grown factor 1(IGF-1), leptin, prostanoids, prostaglandin E2 (PGE2), connexin 43,
interleukin-11, or BMPs. For this reason, administering sclerostin mAbs in sequence, or in combina-
tion with, a remodeling-modifying therapy may be the best approach for achieving sustained increases
in BMD.
As microarchitecture analyses become more robust and streamlined this information can be har-
nessed to inform parameters in the model-based framework developed here. Currently, the model links
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aBMD to underlying metabolic processes in the bone, as described by the markers routinely measured
in clinical studies. As discussed previously, time constants and implementations for lag-time may indi-
cate translation and signal transduction processes that inform drug mechanism and may help optimize
therapeutic combination strategies.
4.3 AIM III. Hazard Model Development to Predict Probability of Fracture
The discussion around the developed hazard model of fracture is included in chapter 9. The haz-
ard model was also used to simulate possible fracture outcomes after combination therapy, similar to
the regimen in the Leder study [58]. Both denosumab and teriparatide independently to improve frac-
ture rate, likewise the combination arm showed improved reduction in 10-year probability of fracture
(see fig. 3.12). Denosumab also showed improved reduction of fracture rate over teriparatide. This is
because the model also predicts that LS BMD continues to rise with repeated dosing while teriparatide
rapidly increases LS BMD returns to steady state (fig. 4.1). It is not completely understood why this is
the case, but likely the model predicts anabolic effects (increased P1NP) to return to the range of nor-
mal even after persistent treatment (see fig. 3.14). CTx activity with denosumab remains significantly
below baseline levels, indicating resorption activity is significantly curtailed throughout the duration
of treatment with this mechanism.
One of the significant findings of the hazard model development was the necessity of a model
parameter representing an additional drug effect, beyond the effects elicited by therapy on BMD. Be-
cause this cannot be estimated specifically for sclerostin mAb or combination treatment arms because
there are no fracture data available for this new therapy, it is difficult to determine with certainty if these
treatments will have an improved effect on fracture beyond denosumab or teriparatide. Simulations
with these arms were performed using the same version of the model but without the drug effect. Haz-
ard ratios for the additional drug effect, relative to placebo, are shown in section 3.3. The additional
drug effect elicited by bisphosphonates, teriparatide/PTH and denosumab have high probabilities of
significantly reducing the hazard of fracture, as compared to placebo, beyond the BMD effects elicited
by each therapy. The additional drug effect of calcitonin, the growth secretagogue MK-677 and stron-
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Figure 4.1: 10-year simulations of denosumab (yellow) and teriparatide (black), demonstrating denosumab causes continuous increase in
BMD after repeated doses
tium ranelate are not statistically significantly different than the placebo but the sparse data for these
treatments arms contribute to the long right tails of the respective posterior distributions.
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Limitations and Future Work
5.1 Limitations and Future Work
Many assumptions are made in the building of this systems model and are discussed at length in
papers II and III (chapter 8, chapter 9). Acknowledging these assumptions, making full use of model
diagnostic tools and fulfilling “good model criteria”, as described in Agoram et al. [101], help to build an
objective case for use of this systems model to generate hypotheses, explore optimal dosing regimens
and combination therapies, and evaluate different classes of therapies for prevention of fracture.
A major contribution of this work is the ability to link clinical outcomes to underlying biology
and microarchitecture in a more mechanistic way. More experimental data is needed to guide this ef-
fort. Specifically, there is also a lack of conclusive data linking Wnt-pathway intermediates to sclerostin.
This makes it difficult to mechanistically describe the relationship between osteoblasts and osteocytes.
β-catenin builds up in the presence of a Wnt signal, which is one of the mechanisms by which block-
ing sclerostin leads to increased osteoblast activity. Osteocytes also directly produce RANKL [102] but
presentation of RANKL at the cell surface is also tightly regulated by OPG in osteocytes [103]. There
is evidence to suggest membrane-bound RANKL on osteocytes plays a more significant physiological
role on osteoclastogenesis, contributing to localized bone remodeling [104]. There is also a temporal
element to Wnt signaling effects on osteoblast differentiation. For example, knocking out β-catenin in
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osteoblasts did not change RunX2 levels, which suggests that early signals of osteoblast differentiation
do not depend on β-catenin but β-catenin is essential for mature osteoblasts’ performance through
osteocalcin expression [33]. Because much is still unknown about the differentiation process of os-
teoblasts, osteocytes and osteoclasts and how the signaling pathways influence these processes, it is
difficult to fully characterize the pathway intermediates in the model.
As discussed previously, there are also sclerostin-independent mechanisms which govern mod-
eling [100]. BMP works upstream of sclerostin in osteoblasts to inhibit Wnt signaling [105]. However,
sclerostin can, in turn, antagonize BMP [31]. Dkk-1, like sclerostin is also a Wnt-pathway inhibitor and
is also regulated by BMP. In an in vivo study, sclerostin mAb administration resulted in an increase
of dkk-1 [106]. The authors of this study suggest the osteocytes themselves may regulate modeling
through the “mechanostat” mechanism by increasing expression of SOST and dkk-1. In a clinical study
with denosumab circulating levels of sclerostin increased, while dkk-1 decreased [107], which may also
indicate feedback signaling in response to treatment, at the level of the osteocyte. IL-6 has also been
shown to increase during osteocyte apoptosis [31], but mRNA expression decreases during exercise in
a rat model of osteoporosis [108], thereby reducing resorption during loading. These all represent ad-
ditional layers of regulation by which osteocytes can direct modeling activity. These are mechanisms
not currently represented in the bone model but should be implemented in future work.
In the fracture model, outlined in chapter 9, LS BMD is the major driver of changes in fracture rate
contributed by most of the drug classes represented in the dataset. This assumes that the integrated
effects on LS BMD resulting from the action of different drug mechanisms contribute to changes in
fracture rate in the same way. This assumption does not account for differences in patient response to
therapy and does not acknowledge that measures of LS BMD may not be fully representative of changes
in bone quality attributed by each drug mechanism individually. In the latter case, including the ad-
ditional drug effect covariate accounts for the contribution of each mechanism to the probability of
fracture independent of LS BMD. The interpretation of this covariate is rather vague but is discussed
at length in the discussion section of paper III (chapter 9). In future work the model maybe improved
upon by including more data at the level of the individual patient and incorporate some measure of
bone quality (volumetric BMD, trabecular or cortical thickness, ect) into the calculation of fracture
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probability.
As described in Aim I (section 1.4), there are many mechanistic models in the literature which
describe the effects of loading and shear stress on osteocyte activity and sclerostin production. An-
other future application of the model is leveraging finite element analysis data to describe localized
remodeling in bone occurring during loading. This would allow model application to extend beyond
osteoporosis with BMD outcomes to bone healing during traumatic events or implant placement [36].
Several efforts have been made to link the function of mechanoreceptors to biochemical signals in
the loading process [41]. Still, all of the osteocytic signaling molecules involved in inhibition of bone
resorption during loading and the extent of their involvement in this process have not been fully iden-
tified. Current models are limited to aspects of loading in narrower terms, such as osteon diameter
in response to an osteocyte signal [41] or mechanical bone adaptation only at the bone surface [109].
Propagation of chemical signaling after mechanical stimuli to bone cell populations is an aspect of
osteocyte function within the remodeling process that is still needed in the current model of calcium
homeostasis.
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Conclusion
6.1 Conclusion
This work demonstrates:
• A priori identifiability of PK/PD models typically used to describe mAbs using differential algebra
identifiability of systems (DAISY), exact arithmetic rank (EAR) and likelihood profiling (LP) and
drawing a comparison of these methods.
• PK/PD model development of sclerostin mAb and circulating serum sclerostin using a TMDD
approximation of Michaelis-Menten (MM) kinetics.
• Implementation of this PK/PD model into the MSPM in order to investigate the role of osteocytes
in the remodeling process and link OCY activity to changes in OB and OC.
• Development of model structure and estimation of parameters for regional changes in BMD after
sclerostin, teriparatide, denosumab, or combination therapy.
• Development of a hazard model for fracture using a systematically-derived metadata set
• Linking MSPM-simulated LS BMD to the fracture model in order to compare effects of therapy
on fracture risk.
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Quantitative model building can inform both experimental research and drug development. In the
context of bone remodeling, models are used to understand signaling pathways and feedback pro-
cesses that are highly regulated and often misunderstood. Models can also be used as powerful simu-
lation tools to investigate dosing regimens or combinations of therapies in patients, when perhaps little
information about a new therapy is available. As computational models increasingly become an inte-
gral part of experimental research, both bodies of work inform one another to quickly bring new ther-
apies to market as well as promote a greater understanding of the underlying physiology. This original
work is only a small representative piece of continuing advancements in mathematical modeling and
points towards a future of stronger collaborative efforts between experimental and theoretical groups
to advance bone biology research.
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A Priori Identifiability of Target-Mediated Drug Disposition Models
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Abstract. A priori identifiability of mathematical models assures that for a given input/output experiment,
the parameter set has one unique solution within a defined space, independent of the experimental
design. Many biologic therapeutics exhibit target-mediated drug disposition (TMDD), and use of the full
compartmental model describing this system is well documented. In practice, estimation of the full
parameter set for TMDD models, given real-world clinical data, is characterized by convergence
difficulties and unstable solutions. Still, the formal assessment of the a priori identifiability of these
systems has yet to be reported. The exact arithmetic rank (EAR) approach was used to test the a priori
identifiability of a TMDD model as well as model approximations. The full TMDD and quasi-
equilibrium/rapid binding (QE/RB), quasi-steady state (QSS), and Michaelis-Menten (MM) approx-
imations were fully identifiable, a priori, regardless of whether observations were taken from a single or
multiple compartments. The results of these identifiability analyses indicated that the difficulty with
TMDD model convergence, a posteriori, lies in the experimental design, not in the mathematical
identifiability in the lack of samples from several compartments. Experiments can be tailored to resolve
these structurally non-identifiable parameters, notwithstanding practical implementation challenges. This
work highlights the importance of identifiability analyses, specifically how they can influence
experimental design and selection of the appropriate model structure to describe a dynamic biological
system.
KEY WORDS: approximation; a posteriori; a priori; identifiability; target-mediated.
INTRODUCTION
A priori global identifiability analysis is the process of
determining if different combinations of parameter values
lead to indistinguishable model output in terms of inherent
model structure (1). A system is a priori globally identifiable
(also known as structurally or mathematically identifiable) if
all parameters have a unique solution within the full domain
of the parameter space, given specific observation points
within the system. A system is locally identifiable if a unique
solution to a parameter is found within some neighborhood of
that parameter (2). In contrast, a posteriori, also known as
practical identifiability, is the quality of a system that
determines whether or not parameters can be estimated
based on informativeness of an experimental design and
resulting data. A priori identifiability is a requirement for a
well-posed mathematical system and a prerequisite for
parameter estimation because if identifiability is not achieved
independent of experimental design conditions, the system
will not be identifiable in practice. Determining which
parameters in the system are not identifiable before running
an experiment may save resources by informing experimental
design. Unfortunately, this practice is underutilized because
of the computational complexity involved in these analyses.
Establishing a priori, identifiability for the highly non-
linear models common in systems biology is especially non-
trivial in cases when there are many more parameters than
observables. A comparison of three approaches for evaluat-
ing identifiability for complex systems (two of these were
focused on a priori) was recently published by Raue and
colleagues (3) and forms the basis for the approaches
considered in this analysis. Of these methods, the exact
arithmetic rank (EAR) approach was the most robust and
most easily implemented. The a priori identifiability of the
widely used target-mediated drug disposition (TMDD) mod-
el, describing the dynamic system of antibodies binding to the
target molecule (4), and approximations to this model has
never been established. Gibiansky and Gibiansky also
formulated extension of this model to include two-target
TMDD (5). The model equations for the TMDD model
represent amounts of free drug, target, the drug-target
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complex, and the transfer rates between these states (Fig. 1),
and the extension includes dual targets and complexes
(Fig. 2). Model approximations include quasi-equilibrium or
rapid binding (QE/RB), quasi-steady state (QSS), and
Michaelis-Menten (MM) (6). While approximations to the
model make it possible for one to mathematically describe
experimental data, the interpretation of these model param-
eter values can be vague or even inaccurate (6). Identifying
system parameters that are not unique, a priori, indicates the
need for re-parameterization or model simplification in
advance of the parameter estimation step. A priori analyses
may also assist in understanding which modifications of the
experimental design are necessary to achieve meaningful
parameter estimates.
METHODS
Of the three different approaches discussed by Raue and
colleagues (3), the exact arithmetic rank (EAR) approach
was chosen to evaluate parameter identifiability for TMDD
models and their approximations. The EAR approach was
developed by Karlsson and colleagues (7) and is designed to
handle larger systems with more generally parameterized
initial conditions. This algorithm constructs a symbolic form
of the Jacobian matrix by way of generating a truncated
power series expansion of partial derivatives of the output
with respect to state variable x(0) (the value of each
compartment at its initial condition) and parameter θ and
performs rank testing, the process of relating higher order
derivatives to lower order derivatives and using the
inverse function theorem, to determine local identifiability.
Single-target TMDD (Fig. 1) and QE/RB, QSS, and MM
approximation models were tested first, followed by a TMDD
model with two targets (Fig. 2). The input of each model was
an intravenous (i.v.) infusion or subcutaneous (s.c.) dose.
Whether or not the output scenario was plausible, all were
included in the analysis for completeness and for use as a
reference. To use EAR, the package BIdentifiabilityAnalysis^
was loaded in Mathematica (v9.0). The differential equation
set and initial conditions were assigned to variable deq. In this
approach, the initial conditions must be supplied by the user,
even if they are unknown and set to zero, as they are required
to construct the Jacobian. The arguments to the Identifiabi-
lityAnalysis function are simply deq, the system outputs, a
vector of variables, the independent variable (t), and the
input variable (u). The vector of variables represents the
parameters in the model but are supplied symbolically and
assigned no values or bounds. If the results of the analysis are
Bfalse,^ the system is unidentifiable and the parameters without
unique solutions can be identified with the call
BNonIdentifiableParameters.^ Example code for a full TMDD
model analysis is included in the Supplementary Materials.
RESULTS
Results for all model structures and output scenarios
are shown in Tables I and II. The full single-target
TMDD model was identifiable with any system output. It
follows that the QE/RB, QSS, and MM are also identifi-
able with any output. Like the single-target TMDD, the 2-
target TMDD model structure was found to be identifi-
able under any output scenario.
DISCUSSION
The EAR application has been used to demonstrate a
priori identifiability of TMDD models and model approx-
imations within scenarios when different outputs are avail-
able. The full TMDD model is a priori identifiable, even
when only information about the drug (free or total) is
available. This was not an obvious finding because a posteriori
parameter estimates are often imprecise at best, and usually
at least one parameter must be fixed in order for the model to
converge. Gibiansky et al. show many examples of this in
their 2009 publication (8). Often, it is the time scale of the
drug measurements being much greater than that of the
Fig. 1. TMDD model schematic. C, R, RC, and At represent the drug
concentration, target, drug-target complex, and peripheral compart-
ments, respectively. Ks indicate time constants
Fig. 2. Extension of the TMDD model to the two-target case. C, R1,
R2, R1C, R2C and At represent the drug concentration, targets 1 and
2, drug-target complexes 1 and 2, and peripheral compartments,
respectively. Kss indicate time constants
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Table I. Identifiability Results for Full TMDD and Approximations (Supplemental 1 Eqs 1–20)
Model Full TMDD, iv inf
System parameters kon, koff, kel, kpt, ktp, Vc, ksyn, kdeg, kint
Possible outputs Free drug Target Complex Free drug and target Free drug and complex Target and complex Free drug, target, and complex
Result Model is locally identifiable with any output
Model Full TMDD, sc dose
System parameters ka, koff, kel, kpt, ktp, Vc, ksyn, kdeg, kint
Possible outputs Free drug Target Complex Free drug and target Free drug and complex Target and complex Free drug, target, and complex
Result Model is locally identifiable with any output
Model Quasi-equilibrium (QE) approximation, iv inf
System parameters kd, kel, kpt, ktp, Vc, ksyn, kdeg
Possible outputs Free drug Target Total target Free drug andtotal drug Free drug and total target Total drugand total target Free drug, total drug, and total target
Result Model is locally identifiable with any output
Model Quasi-steady-state (QSS) approximation, iv inf
System parameters Kss, kel, kpt, ktp, Vc, ksyn, kdeg
Possible outputs Free drug Target Total target Free drug and total drug Free drug and total target Total drug and total target Free drug, total drug, and total target
Result Model is locally identifiable with any output
Model Michaelis-Menton (MM), iv inf
System parameters Km, kint, kel, kpt, ktp, Vc, ksyn, kdeg
Possible outputs Free drug Total target Free drug and total target
Result Model is locally identifiable with any output
TMDD target-mediated drug disposition, QSS quasi-steady-state, QE quasi-equilibrium, MM Michaelis-Menten, iv inf intravenous infusion, sc subcutaneous
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binding process that limits practical identifiability of kon and
koff. The QE or QSS approximations are often used to avoid
overparameterization. Selection between these approxima-
tions involves availability of target dynamics or pharmacody-
namic data (9). Peletier and Gabrielson determined that
specific regions of the drug concentration curve inform
specific model parameters and parameter identifiability
largely depends on the richness of data in each of these
regions (10). These identifiability results confirm that all
parameters in a full TMDD model can be uniquely estimated
using a dataset with ideal sampling and no experimental
noise. The full two-target TMDD system is also structurally
identifiable under the same conditions.
cannot perform rank testing independent of initial conditions,
and this limits the ability to establish unique solutions for
some systems with initial conditions equal to zero. The
differential identifiability of systems (DAISY) approach (11)
was used as a first-pass attempt at establishing global a priori
identifiability. Unfortunately, DAISY can only deal directly
with pure polynomial forms for the differential equations, and
the program did not accept the quadratic solution form for
free drug concentration, C, that is used in the QE and QSS
approximations. This shortcoming of DAISY is well docu-
mented (3, 12). Finally, the profile likelihood (PL) approach
was also considered, but it is a data-based approach and not a
specific analysis of a priori identifiability.
CONCLUSION
In the case of single-target TMDD models and approx-
imations, all parameters are a priori identifiable, as is the full
two-target TMDD model. These findings indicate that
sampling times relative to the widely varying time scale of
binding kinetics vs. distribution and elimination kinetics are
the most likely culprit limiting a posteriori identifiability of
TMDD model parameters. The principle of a priori identifi-
ability is that a unique solution can be found under ideal
sampling times and error-free experimental conditions. While
noise-free systems do not exist, identifiability analyses are an
important first step in model design. If parameters are found
not to be structurally identifiable, they will never be a
posteriori identifiable when experimental noise and design
limitations abound. As shown in Gibiansky and Gibiansky
(13), it is possible to achieve good model fits without
establishing identifiability of model parameters. In this same
work, however, it was noted that resulting parameter
estimates were not always accurate or reliable reflections of
the proposed drug disposition mechanisms. Identifiability
analyses, on the other hand, allow for meaningful interpreta-
tion of parameters under Breal-world^ conditions if model
assumptions hold. Non-identifiability in these types of anal-
yses can indicate the necessity for model simplification and
show when more information is needed within a given
experimental design to achieve a posteriori identifiability of
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contains rational expressions that cannot easily be converted
to polynomial. A limitation of EAR is that the algorithm
Of the available approaches used for establishing
structural identifiability of a system, the EAR algorithm was
relied upon as the more robust of the approaches, specifically
for approximations to the TMDD model when the model
all parameters. Recent advances of computational algorithms
allow for easy and fast determination of structural identifi-
ability of a biological system.
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Supplemental 1: Model Equations
Full Target-Mediated Drug Disposition (TMDD) Model
In(t) refers to a continuous i.v. infusion
dAd
dt
=  kaAd (1)
dC
dt
=
ln(t) + kaAd
V c
  (kel + kpt)C   konC · R + koffRC + ktpAT
V c
(2)
dAT
dt
= kptC · V c  ktpAT (3)
dR
dt
= ksyn   kdegR  konC · R + koffRC (4)
dRC
dt
= konC · R  (kint + koff )RC (5)
Ad = Dose; C(0) = 0; AT (0) = 0; RC(0) = 0; R(0) =
ksyn
kdeg
(6)
Equations from: D. E. Mager and W. J. Jusko. General pharmacokinetic model for drugs exhibiting
target-mediated drug disposition. J Pharmacokinet Pharmacodyn, 28(6):507-532, Dec 2001.
1
Quasi-Equilibrum/Rapid Binding (QE/RB) Approximation
In(t) refers to a continuous i.v. infusion
C =
1
2

(Ctot  Rtot  KD) +
p
(Ctot  Rtot  KD)2 + 4KDCtot
 
(7)
dCtot
dt
=
ln(t)
V c
  kintCtot   (kel + kpt   kint)C + ktpAT
V c
(8)
dAT
dt
= kptC · V c  ktpAT (9)
dRtot
dt
= ksyn   kdegRtot   (kint   kdeg)(Ctot   C) (10)
Ctot(0) = 0; AT (0) = 0; Rtot(0) =
ksyn
kdeg
(11)
Equations from: L. Gibiansky, E. Gibiansky, T. Kakkar, and P. Ma. Approximations of the target-
mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharma-
codyn, 35(5):573-591, Oct 2008.
2
Quasi-Steady-State (QSS) Approximation
In(t) refers to a continuous i.v. infusion
C =
1
2

(Ctot  Rtot  KSS) +
p
(Ctot  Rtot  KSS)2 + 4KSSCtot
 
(12)
dCtot
dt
=
ln(t)
V c
  (kel + kpt)C   RtotkintC
KSS + C
+
KtpAT
V c
(13)
dAT
dt
= kptC · V c  ktpAT (14)
dRtot
dt
= ksyn   kdegRtot   (kint   kdeg) RtotC
KSS + C
(15)
Ctot(0) = 0; AT (0) = 0; Rtot(0) =
ksyn
kdeg
(16)
Equations from: L. Gibiansky, E. Gibiansky, T. Kakkar, and P. Ma. Approximations of the target-
mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharma-
codyn, 35(5):573-591, Oct 2008.
3
Michaelis Menten (MM) Approximation
In(t) refers to a continuous i.v. infusion
dC
dt
=
ln(t)
V c
  (kel + kpt)C   Rtotkint
Km + C
+
ktpAT
V c
(17)
dAT
dt
= kptC · V c  ktpAT (18)
dRtot
dt
= Rsyn   kdegRtot   (kint   kdeg) RtotC
Km + C
(19)
C(0) = 0; AT (0) = 0; Rtot(0) =
ksyn
kdeg
(20)
Equations from: L. Gibiansky, E. Gibiansky, T. Kakkar, and P. Ma. Approximations of the target-
mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharma-
codyn, 35(5):573-591, Oct 2008.
4
TMDD Extended to Two Targets
In(t) refers to a continuous i.v. infusion
dC
dt
=
ktpAT + In(t)
V c
  (kel + kpt)C   (kon1C · R1+
kon2C · R2) + (koff1R1C + koff2R2C) (21)
dAT
dt
= kptCV c  ktpAT (22)
dR1
dt
= ksyn1   kdeg1R1   kon1C · R1 + koff1R1C (23)
dR2
dt
= ksyn2   kdeg2R2   kon2C · R2 + koff2R2C (24)
dR1C
dt
= kon1C · R1   (kint1 + koff1)R1C (25)
dR2C
dt
= kon2C · R2   (kint2 + koff2)R2C (26)
C(0) = 0; AT (0) = 0; R1(0) =
ksyn1
kdeg1
; R2(0) =
ksyn2
kdeg2
; R1C(0) = 0; R2C(0) = 0
(27)
Equations from: L. Gibiansky and E. Gibiansky. Target-mediated drug disposition model for drugs
that bind to more than one target. J Pharmacokinet Pharmacodyn, 37(4):323-46, Aug 2010.
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Connecting the Dots: Linking Osteocyte Activity
and Therapeutic Modulation of Sclerostin by Extending
a Multiscale Systems Model
RJ Eudy1,2, MR Gastonguay1,2,3, KT Baron3 and MM Riggs3
The goal of this work was to extend a mathematical, multiscale systems model of bone function, remodeling, and health in
order to explore hypotheses related to therapeutic modulation of sclerostin and quantitatively describe purported osteocyte
activity within bone remodeling events. A pharmacokinetic model with first-order absorption and dual elimination pathways
was used to describe the kinetics of romosozumab, a monoclonal antibody (mAb) against sclerostin. To describe total
circulating sclerostin, an extended indirect response model of inhibition of offset was developed. These models were
subsequently linked to the systems model, with sclerostin signaling changes in resorption and formation through established
osteocyte-mediated mechanisms. The model proposes relative contributions of the osteocyte to the RANKL pool, a major
player in feedback signaling, and is used to explore hypotheses surrounding attenuation of anabolic activity after multiple
doses of sclerostin mAbs, a phenomenon whose mechanism is poorly understood.
CPT Pharmacometrics Syst. Pharmacol. (2015) 00, 00; doi:10.1002/psp4.12013; published online on 0 Month 2015.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? ! The current systems pharmacology models that include
osteocyte activity or sclerostin mAb intervention are not designed to predict quantitative clinical outcomes. • WHAT
QUESTIONS DID THIS STUDY ADDRESS? ! Is it possible to leverage the clinical study data available with sclerostin
mAbs to extend a systems model to predict responses to therapeutic modulation of sclerostin and describe osteocyte
activity within bone remodeling events? • WHAT THIS STUDY ADDS TO OUR KNOWLEDGE ! The extended systems
model can be used to examine hypotheses surrounding the mechanism for attenuation of anabolic activity after multiple
doses of sclerostin mAbs. This has not been fully explored by laboratory experimentation. It is also used to investigate
the relative contribution of osteocytes to feedback regulation within the bone. • HOW THIS MIGHT CHANGE CLINICAL
PHARMACOLOGY AND THERAPEUTICS ! The extended model can be used to explore therapeutic target modulation
in order to maximize and maintain increased BMD in osteoporosis patients.
Sclerostin has been identified as a target for osteoporosis
treatment because preventing sclerostin inhibition of Wnt
has been shown to both increase markers of bone forma-
tion and decrease markers of resorption, expanding net
gain of bone calcification and increasing bone mineral den-
sity (BMD).1 This mechanism, which “decouples” bone for-
mation and resorption, is differentiated from other
osteoporosis treatment mechanisms that are either purely
anabolic (both formation and resorption increase, e.g.,
intermittent parathyroid hormone (PTH)) or catabolic (both
formation and resorption decrease, e.g., bisphosphonates,
RANKL-inhibition). Furthermore, sclerostin is mainly
expressed in the osteocyte, limiting off-target effects of inhi-
bition in other tissues.
Questions remain about the mechanism of sclerostin inhi-
bition and how this is linked to osteocyte activity and feed-
back regulation in bone remodeling.2 One clinical question
is whether or not efficacy can be maintained after multiple
doses of an anti-sclerostin monoclonal antibody (mAb).
Identification of appropriate dosing regimens of sclerostin
mAb and/or its combination with an antiresorptive to pro-
mote greater formation and prolonged maintenance of
strong bone is a critical step in the advancement of this
therapy. Potential for a model that is aimed at elucidating
the mechanisms of sclerostin modulation includes explora-
tion of dosing regimen and trial design considerations.
Such inputs, although not meant at this stage to generate
statistical probabilities, could generate hypotheses (learn-
ings) for further experimental confirmation, e.g., through
clinical investigation.
A multiscale bone model has been published3 that com-
bines important aspects of three previous models of bone
in order to combine quantitative aspects of bone physiol-
ogy: all major organ systems involved in calcium handling,4
feedback control between osteoblasts (OB) and osteoclasts
(OC) through the Receptor Activator of Nuclear Factor j#/
RANK-ligand/Osteoprogerin (RANK/RANKL/OPG) axis,5
and dynamics of intermittent PTH administration.6 In its cur-
rent construct, the model lacks the osteocyte and
sclerostin-related components necessary to predict effects
of sclerostin mAb treatment on clinical outcomes like BMD.
Other published models of sclerostin, osteocytes (OCY),
1Department of Biomedical Engineering, University of Connecticut, Storrs, Connecticut, USA; 2Metrum Institute, Tariffville, Connecticut, USA; 3Metrum Research Group,
Tariffville, Connecticut, USA. Correspondence: RJ Eudy (renae@metrumrg.com)
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and Wnt signaling are either qualitative in nature, with
model variables lacking physiological meaning,7 or they are
focused on mechanical strain analysis.8,9 The “strain” mod-
els depict quantitative changes in a single bone unit during
loading, but they do not account for feedback signaling
between bone cells, which largely contribute to signal trans-
duction and remodeling. In contrast with other models, the
multiscale bone model provides an evaluated platform to
predict changes in BMD based on clinical markers of for-
mation and resorption. It has already been used to predict
changes in BMD after treatment with denosumab.10 The
new model components were developed by incorporating
knowledge of the Wnt/b-catenin signaling and its role in
bone formation by leveraging data from recent clinical stud-
ies.1,11,12 The updated model promotes understanding of
how OCY signals contribute to remodeling within the bone
and how sclerostin mAbs can be used to harness these
signals to maximize bone formation in patients with
osteoporosis.
MATERIALS AND METHODS
Data
A phase I study reporting time–concentration profiles of
romosozumab after a single dose1 was used to build the
pharmacokinetic (PK) model. Total sclerostin concentrations
measured in two phase I studies over a range of single and
multiple doses of blosozumab12 were used to estimate
parameters in the pharmacodynamics (PD) model. C-terminal
telopeptide (CTx) and procollagen type 1 N propeptide
(P1NP) data from these three studies and two additional stud-
ies11,13 were used to build the sclerostin-related components
and BMD changes into the model. A sixth was used as a qual-
ification dataset.14
The bone formation marker, serum P1NP, as a marker of
bone formation, has replaced serum bone-specific-alkaline-
phosphatase (BSAP) in newer clinical trials. Since the exist-
ing model only described changes in BSAP, a regression
model was developed to calculate P1NP as a function of
BSAP. Data collected from 21 different studies (Supporting
Information refs. 4-22) identified by a PubMed search con-
ducted on or around March 6, 2014, using keywords
“osteoporosis” or “postmenopausal,” and “alkaline phos-
phatase,” or “ALP,” “amino-terminal propeptide,” or “P1NP,”
and “clinical trials,” and “humans.” Graphical presented
data from these publications were digitized using Graph-
Click (v. 3.0 Arizona Software).
PK/PD model
A PK model was used to describe nonlinear kinetics of
sclerostin mAbs and this was linked to a PD model describ-
ing changes in levels of circulating sclerostin. Typical values
for PK parameters were estimated using a maximum likeli-
hood (MLE) approach, based on the reported treatment
arm-level data. Unexplained residual variation was
described with a proportional residual variance model, with
residual random effect assumed to be normally distributed
with mean zero and variance, r.2 Four subcutaneous dose
levels of 1, 3, 5, and 10 mg/kg and two intravenous (i.v.)
dose levels of 1 mg/kg and 5 mg/kg were used to fit a two-
compartment model with first-order absorption and parallel
linear and nonlinear clearance pathways. An indirect
response PD model was used to describe changes in total
circulating sclerostin. The PK/PD parameters were esti-
mated using nonlinear-mixed effects models (NONMEM
software, v. 7.2, ICON Development Solutions, Hanover,
MD).
Translational relationship between formation markers
Regression models were used to explore the relationship
between time-matched BSAP and P1NP, both normalized
to baseline. Model development considered linear and non-
linear relationships between P1NP and BSAP. Inter-arm
variance for BSAP was weighted by the inverse of the sam-
ple size for each arm15:
BSAPTV5BSAPi ! eð!=!ni Þ; (1)
where e represents the random effect and n5 the number
of subjects contributing to the data point for the ith arm.
A random effect was applied to the slope term in linear
and nonlinear models to account for longitudinal differences
between arms. Model selection was based on successful
model minimization and the Akaike Information Criteria
(AIC).16
Multiscale model expansion to include osteocyte
function and sclerostin modulation
Code to represent the multiscale bone model has been
developed in R.17 Simulations were performed using the
DLSODA differential equation solver provided through
ODEPACK within C11 interfaced to R (“Rcpp” package18).
Parameters were coarsely estimated by tuning individual
parameters involved in indirect changes in OB and OC over
physiological ranges, solvable by the ODEsolver. Model
performance was evaluated by visual inspection, compared
to the clinical data. After model structure and initial parame-
ter estimates were in place, the parameters were optimized,
individually or in groups, using the R package “minqa.”19
This is a derivative-free optimization algorithm by quadratic
approximation, used to minimize an ordinary least-squares
objective function. BMD-related parameters were tuned and
optimized last. The order in which parameters were opti-
mized and the data used to optimize each parameter is
summarized in Table 3.
Qualification of expanded multiscale model
To evaluate model structure, simulated data were plotted
against the model-building dataset.1,11–13 After the final
model structure was in place and the univariate parameter
optimization step was performed, a local sensitivity analysis
was conducted on all of the 23 estimated sclerostin-related
parameters (Tables 2, 3; Supplementary Figure 1). This
analysis determined the influence of each parameter esti-
mate on clinical endpoints, since simultaneous optimization
in this context was not possible. Monte Carlo simulations
over a range of parameter estimates spanning 60.8 * the
value of the final parameter estimate were plotted against
time-matched changes in P1NP and CTX from a new clini-
cal study,14 which had not been used for the initial parame-
ter estimation. This same analysis was also performed for
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each of the lumbar spine (LS) and total hip (TH) BMD
parameters (femoral neck (FN) BMD was not reported in
the new study).
Simulations were performed to verify that changes made
in the model did not negatively impact the denosumab ther-
apy simulations from previous works.10 The simulated
denosumab dataset contained nine treatment arms with
doses taken from several clinical trials of denosumab: pla-
cebo, 6, 60, 140, 100, and 210 mg at dosing intervals of 3
and 6 months.20–24 Simulated P1NP and CTx concentra-
tions for each of these arms were overlaid with time-
matched observations and validated by visual inspection
(Supplementary Figure 2). Dose-matched simulations
were performed to explore the impact of dosing interval on
clinical outcomes. The final model was evaluated according
to the criteria outlined by Agoram25 for large systems phar-
macology models.
RESULTS
PK/PD model
The PK of rosozumab and blosozumab were used to drive
the PD response in sclerostin (Figure 1). Identifiability of
PK and PD parameter estimates for each drug was dictated
by data availability. Currently, public-source data included
only PK data for romosozumab, but not blosozumab, and
only sclerostin data for blosozumab, but not romosozumab.
Therefore, the PK parameters were estimated from the
antibody concentration–time profiles of romosozumab1 and
the PD parameters were estimated from blosozumab12
(Table 1).
For the PD estimates, the PK parameters, including the
Vmax parameter describing binding kinetics, were assumed
to be the same for both mAbs and the PD parameters were
subsequently estimated. In this sequence, the Km
Figure 1 (a) The PK model describes circulating sclerostin mAb concentrations that drive changes in circulating total sclerostin protein
(SCLER) in the PD model. C represents drug concentration; At is the peripheral compartment; sc5 subcutaneous; iv5 intravenous;
Vc, Vp, CL, Kin, Kout, Vmax, Km are model parameters defined in Table 1. (b) Parameter estimates for the PK model were generated
by fitting the model to romosozumab data, and parameter estimates for the PD model were generated by fitting the model to blosozu-
mab data.
Table 1 Estimated PK/PD parameters for antibodies against sclerostin
Parameter Value (95% CI)
Absorption rate constant ka 0.187 (0.142, 0.233) day
21
Linear clearance, CL 0.254 (0.228, 0.281) L/day
Maximum elimination rate constant, Vmax 5.87 (2.49, 9.26) L/day
21
Michaelis-Menten constant, km 0.423 (021.64) nM for
blosozumab and 9.93
(0.77721.03) nM for
romosozumab
Volume of the central compartment, Vc 2.9 (2.31, 3.48) L
Volume of peripheral compartment, Vp 3.29 (2.43, 4.16) L
Intercompartmental clearance, Q 0.467 (0.326, 0.609) L/day
Bioavailability, F 0.904 unitless
Synthesis rate constant, kin 3.68 (0215.3) nM/day
Degradation rate constant, kout 26.0 (0–95.9) day
21
Internalization rate constant, k0 0.195 (0.0349–0.356) day
21
CIs were calculated as the estimate6 1.96* asymptotic standard error of the
estimate; symmetric CIs were truncated at 0 for rate constants km, kin, and kout.
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parameter in the nonlinear clearance component of the
PK model was estimated based on romosozumab concen-
tration and was estimated separately for blosozumab
using the sclerostin response. Therefore, all the PK
parameters derived for romosozumab were fixed and used
to simulate mAb concentration in the PD model, with the
exception of km, which was reestimated for blosozumab.
The rationale for this is discussed further in the Support-
ing Information.
Translational relationship between formation markers
Various linear and nonlinear relationships were explored to
describe the BSAP-P1NP translation (Table 2). The lowest
calculated AIC value resulted from the sigmoid Emax model
(AIC5 4707.93), and this model structure was carried for-
ward. An intercept parameter of int5 20.4181 was also
added to this model within the multiscale bone model, so
that at the initial conditions, percentage of baseline
BSAP5P1NP5 100%.
The estimated parameters for this model were Emax5
2,050, 95% CI: (295, 3,800), c5 1.8, 95% CI: (1.52, 2.08),
and EC505467, 95% CI: (128,805). XA5 2.27, 95% CI:
(0.376–4.16), %CV538.2, r50.515, 95% CI: (0.0756–
0.955), %CV5 18.0, for n5 50 subjects.
Developing model structure to describe changes in
turnover markers and BMD
Based on supporting literature, six points of intersection
were identified within the multiscale bone model where
changes in sclerostin have a known effect. These are
(i) the depletion rate of pre-osteoblasts (ROB); (ii) the for-
mation rate of OB; (iii) the rate of OCY apoptosis; (iv) the
level of OCY effect applied to RANKL; (v) the accumulation
of OPG; and (vi) the differential effects of sclerostin on
regional changes in BMD. See Figure 2 to see schemati-
cally how these pieces fit into the model structure. Because
identifiability of new model parameters is problematic if all
are estimated simultaneously, P1NP-associated parameters
were estimated first, followed by those parameters affecting
CTx. This follows our understanding of the mechanism of
Wnt pathway upregulation; b-catenin accumulates and
causes changes in transcription factors regulating differen-
tiation of pre-OB to OB. This effect is upstream, or takes
place ahead, of modification of bone resorption through this
pathway, which is largely controlled by signaling through
RANK/RANKL/OPG in OB26 and OCY.27
To apply a sclerostin signal to the OB, two methods were
tried. First, a “precursor pool” compartment was applied
upstream of the ROB. This physiologically represents cells
earlier in the OB lineage being recruited for differentiation
which cause an increase in formation activity, as the flux of
substrate moving through the OB differentiation pathway
increases.28 The precursor-pool approach resulted in
a very rapid depletion of the ROB pool and a peak P1NP
concentration–time profile that was right-shifted relative to
the true response. An alternative way to signal the flux of
substrate through the OB pathway was to use a direct
approach whereby a sclerostin effect was applied to the
depletion rate of ROB and a separate effect was applied
directly to the OB accumulation rate. Together, these
increased OB activity, but caused an attenuation of OB activ-
ity over time as the ROB became depleted, which is consist-
ent with the pattern of anabolic turnover markers seen after
multiple doses of sclerostin mAb.12 A “translation” compart-
ment was also added in the direct approach to delay the
effect of sclerostin on the increase in OB activity only slightly,
relative to the delay that was elicited by the precursor-pool
approach. Together, these additions represent the first two
points of interaction in the modified model.
OCY are the major source of sclerostin,2 and the cell
type responsible for sclerostin modulation in response to
mechanical stimulation.29 Studies have also shown that
OCY are a major contributor to RANKL trafficking and regu-
lation of osteoblast- and osteoclast-ogenesis at the level of
the RANK/RANKL/OPG axis.30 Membrane-bound RANKL
is provided by dendritic processes on the osteocyte to sig-
nal to osteoclast precursors and upregulate osteoclastogen-
esis. Conversely, upregulating the Wnt pathway can
suppress osteoclast-mediated bone resorption through
reduced expression of RANKL.26,31 For the third and fourth
points of intersection, a sclerostin effect was applied to the
depletion rate (or rate of apoptosis) of OCY and an osteo-
cyte effect was applied to the RANKL production rate. The
combined result is that when sclerostin mAb is dosed, OCY
activity is purportedly decreased, concurrent with dimin-
ished SOST expression29 and RANKL production falls as
well, gradually inhibiting osteoclastogenesis.
For the fifth point of intersection, a direct sclerostin effect,
was applied to the production rate of OPG to simulate the
effect of Wnt-pathway regulation of OPG secretion. In the
literature, this level of regulation was demonstrated by
knocking out osteocytic b-catenin in mice. These mice
became osteoporotic due to increased numbers of OC and
increased bone resorption27 and had diminished expression
of osteocytic OPG, demonstrating that signaling through b-
catenin in the osteocytes is required for regulation of
resorption activity. Modeling a direct sclerostin signal on
OPG production rate had the desired effect of rapidly
decreasing the simulated CTx levels, immediately following
a dose of sclerostin mAb.
To model sclerostin antibody effects on FN, TH, and LS
BMD, the same model structure as was used to describe
denosumab effects on BMD10 was adapted, by reestimating
the power term reflecting the impact of OB activity on BMD.
Table 2 Six candidate models describing the relationship between time-
matched BSAP and P1NP
Model
Model
equation
Random
effects AIC
Linear y5Ax1b On A 5,035.57
Exponential y5Aex1b On A 4,904.99
Emax y5 Emax ! xEC501x On EC50 5,036.15
Sigmoid Emax y5 Emax ! x
c
EC50
c1x c
On EC50 4,707.93
Sigmoid Emax1 Intercept y5 Emax ! x
c
EC50
c1x c1int On EC50 4,710.38
Quadratic y5Axb1Cx On A 4,721.53
Data from 21 clinical trials were evaluated. Random effects were added on
the “slope” parameters in each model to account for variability between
arms.
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Figure 2 Schematic of the bone-remodeling systems model. Intersection points of sclerostin signaling effects within the model are
identified with numbers corresponding to description in the text. New model compartments are indicated with white text and shading
and corresponding equation numbers.
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The predictions resulting from this model yielded a peak
increase in BMD that occurred earlier than it did in clinical
reports. In order to correct for this, a delay compartment
was used to adjust the rate of anabolic bone formation
under the premise that it takes more time for OB to become
embedded in the bone matrix, calcify, and contribute to an
increase in overall BMD than it does for catabolic (OC-
driven) impact on BMD.
Model equations and parameter estimates describing
turnover markers and BMD
For all of the intersection points added to the model, the scle-
rostin effect was applied as a power model in the form of:
SCLEREFF5
SCLER
SCLERBASELINE
! "c
(2)
where c5 a parameter modulating the sclerostin effect.
In general, the steady state assumption used in the origi-
nal publication3 was used and compartmental equations
were solved at initial conditions to minimize identifiability
problems for estimated rate constants. The OB effect took
the form:
d trans
dx
5kinT! 11 EMAXSCLER ! SCLEREFF
cSCLEROB
EC50SCLERcSCLEROB1SCLEREFF cSCLEROB
! "
2 koutT
(3)
kinT 5 koutT (4)
OB5ðOBfast ! trans1OBslowÞ (5)
OBfast and OBslow represent the two pathways of active
OB elimination described in the original model publication.3
The osteocyte compartment was represented as:
d OCY
dx
5OB ! FracOCY 2 koutOCY !OCY (6)
where FracOCY represents the rate of conversion of OB to
OCY and
koutOCY5OB0 ! FracOCY ! SCLEREFF cOCY (7)
The osteocyte effect took the same form as the sclerostin
effect:
OSTEOCYEFFECT5
OCY
OCYBASELINE
! "d
(8)
where d5 a parameter modulating the osteocyte effect.
The final BMD model for sclerostin has separate com-
partments for TH, FN, and LS BMD, where the koutDELAY
and cOB were estimated separately for each region and
each region’s set of compartmental equations took the
form:
kin5kout ! BMDbaseline (9)
kinDELAY5koutDELAY (10)
d DELAY
dx
5kinDELAY ! OBOBBASELINE
cOB
2koutDELAY !DELAY (11)
d BMD
dx
5kin !DELAY2 OC
OCBASELINE
cOC
! kout ! BMD (12)
Because simultaneous parameter optimization was not
possible, considerations with regards to the parameters
describing the turnover markers and BMD included the
order in which they were implemented and optimized, and
the data used to fit each parameter (Table 3).
Qualification
In the model qualification step, simulated P1NP and CTX
were consistent with changes in the turnover markers from
three clinical trials with romosozumab and two clinical trials
with blosozumab (Supplementary Figure 3). TH, FN, and
LS BMD profiles from these same studies were also well
described by the model (Supplementary Figure 4). A qual-
ification dataset from a phase II clinical trial with blosozu-
mab in postmenopausal women was simulated using the
final model and changes in turnover markers and LS and
TH BMD were plotted (Figure 3). The predicted mean
change from baseline for the 180 mg dosed Q2W arm at 4
and 52 weeks were 229% (observed median; 95% CI: 231;
199–262%); for P1NP and 73.5% (83.9; 73.7; 94.2); for
CTX and 152% (90.2; 81.4–99.0%); for P1NP, and 79.2
(84.6; 69.7–99.6%); for CTX, respectively. The predicted
mean change from baseline at 52 weeks (180 mg dosed
Q2W) for LS BMD was 16.5% (observed; 95% CI: 14.9;
12.6–17.1%) and 6.8% (4.5; 3.2–5.8%) for TH BMD.
Despite the small dataset, for most data points the model
predicted the change in the clinical endpoint that fell within
the 95% CI reported in the literature.
In order to demonstrate how the model can be used to
investigate the role of dosing protocol on clinical outcomes,
dose-matched administrations of sclerostin mAb were simu-
lated at several dosing intervals (Figure 4). Simulations of
larger dosing intervals promote greater increases in P1NP
(Figure 4a), due to precursors also achieving higher levels
(Figure 4b). Maximum simulated resorption activity, how-
ever, is also increased with a larger dosing interval
(Figure 4c), resulting in lower increases in total hip BMD
when compared to smaller dosing intervals (Figure 4d).
DISCUSSION
Despite having a limited availability of clinical data, the
updated model was able to capture the central tendency of
the changes in turnover markers and BMD after single and
multiple doses of sclerostin mAb, over a large dose range.
The model, however, greatly underpredicted the peak per-
centage change of P1NP in the highest dosing groups with
blosozumab (Supplementary Figure 1, arms 16 and 23).
This was a consequence of the blosozumab data showing
that a single 750 mg dose did not greatly increase sclerostin
change from baseline over a single dose of 225 mg. The
270 mg dose elicited much greater changes than the
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750 mg dose with the same dosing interval (see ref. 12,
fig 4). Because the model relies on the change in sclerostin
as the signal for increase in P1NP, this apparent discrepancy
can be seen in the model predictions at the 750 mg dose
level, and to some degree in the 540 mg dosing arms.
There are many regulating elements of cellular feedback
that are not explicitly defined in the model. This may
explain why the model failed to recapitulate some of the
dynamics of the CTX-time profile, which was also highly
variable between arms. Recent data has shown that OCY
and OB can also control bone remodeling directly through
bone morphogenetic protein (BMP), which can affect
endogenous sclerostin, independent of Wnt signaling,32 but
sclerostin is also a potent antagonist of some BMPs.33 This
feedback mechanism needs to be fully elucidated by experi-
mental data before implementation into the model. OCY
undergoing apoptosis also secrete interleukin (IL)21 and
IL-6, which promote osteoclastogenesis34 and provide
another layer of feedback control that is not yet represented
in the model. OB are also a source of IL-6, as well as
macrophage-colony-stimulating factor (M-CSF), which also
contributes to osteoclastogenesis.34 Supporting data are
needed to fully characterize effects of sclerostin mAb on
changes in CTx, as even the PBO arms show relatively
large fluctuations in CTx over several months.1,11,12
It was hypothesized that diminishing the pre-OB pool with
sclerostin inhibition contributes to attenuation in bone-
formation activity after multiple doses. A consequence of
this from a treatment perspective is that if a sclerostin mAb is
dosed with a small dosing interval, and the mesenchymal-
derived pre-OB do not have sufficient time to be replenished,
the anabolic effect of the mAb will be diminished with
repeated doses. Indeed, simulations of sclerostin mAb
administration at equivalent dose levels, but at different dos-
ing intervals, demonstrate that higher P1NP levels can be
achieved by dosing in longer intervals (Figure 4a), because
levels of pre-osteoblasts have time to recover between doses
(Figure 4b). However, achieving the greatest magnitude of
anabolic activity does not necessarily translate into larger
gains in BMD, due to feedback signaling to OC. Simulations
also show that at longer dosing intervals peak levels of
resorption activity are also higher than at smaller dosing
intervals, blunting the net gain in total BMD that can be
achieved within the dosing interval (Figure 4c,d). This find-
ing suggests that osteocyte-controlled feedback involved in
sclerostin modulation has a considerable impact on turnover
markers and that dosing protocol of sclerostin mAbs impacts
these markers as well as changes in BMD. This model there-
fore offers a potential platform for simulating different regi-
mens in order to explore the effect of dose strength, interval,
and/or combination with other treatment combinations. The
multiscale functionality enables consideration of feedback
effects, for example, and how these mechanisms relate to
BMD changes over a prolonged treatment period.
The model underpredicts BMD changes at the lumbar
spine and total hip after multiple doses in the low dosing
arm (Supplementary Figure 2A,B, arms 32, 33). This is
likely due to the simulated peak P1NP responses, which
reflect OB activity, at these later timepoints falling below
baseline values (see Supplementary Figure 1A). Although
it is difficult to assess what the true peak P1NP values are
under this dosing regimen, it appears that P1NP response
is attenuated after multiple doses in this arm, for reasons
discussed previously. It is unclear what is responsible for
maintaining the increase in BMD seen in the clinic at these
later timepoints. It is possible that the decreased rates of
resorption play more of a role at these later timepoints and
account for a greater amount of the increase in BMD than
the model currently predicts.
Another interesting finding of this work is the interaction
of sclerostin modification with the RANK/RANKL/OPG axis
and resulting dynamic changes in resorption/OC activity.
The model suggests the immediate and significant
decrease in CTx results from osteocytic Wnt signaling,
which is known to increase OPG directly.33 This effect is
coupled with a more gradual decline in CTx due to a drop
in osteocytic contribution to RANKL. Finally, a mechanism
in the model was needed to delay the anabolic effects of
Table 3 Parameters describing changes in turnover makers and BMD associated with sclerostin mAbs
Order Parameter Definition Value (units)
Data used to
estimate
1 cROB Exponent on sclerostin effect on differentiation rate of OB 0.0703 (unitless) P1NP
2 EMAXSCLER Max sclerostin effect on OB 5.22 (hours) P1NP
2 cSCLEROB Hill coefficient for sclerostin effect on OB 1.15 (unitless) P1NP
2 EC50SCLER Half-max effect of sclerostin on OB 667 (hr21) P1NP
3 kout_T Depletion rate on translation compartment 0.00692 (hr21) P1NP
Fixed* FracOCY Fraction of OB becoming OCY 0.50 (unitless) –
Fixed* q Exponent on osteoblast effect on RANKL 0.0100 (unitless) –
4 d Exponent on osteocyte effect on RANKL; scales PTH effect on RANKL 0.0592 (unitless) P1NP, CTx
4 cOCY Exponent on sclerostin effect on OCY apoptosis rate 0.405 (unitless) P1NP, CTx
5 cOPG Exponent on sclerostin effect on OPG 1.61 (unitless) CTx
Fixed* kout_BMDdel Delay parameter on anabolic effects on BMD 0.001 (unitless) Lumbar spine BMD
6 cOB LS Exponent on anabolic contribution to overall lumbar spine BMD 0.711 (unitless) Lumbar spine BMD
6 cOB FN Exponent on anabolic contribution to overall femoral neck BMD 0.0934 (unitless) Femoral neck BMD
6 cOB TH Exponent on anabolic contribution to overall total hip BMD 0.686 (unitless) Total hip BMD
*These parameters were shown to be relatively insensitive within the tested range so these values were fixed prior to optimization.
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sclerostin inhibition on overall BMD. We conjecture that it
takes more time for OB to embed themselves in the matrix
and form new bone than it does for a decrease in resorp-
tion to produce an increase in BMD. This finding may help
efforts to characterize the effects of other anabolic thera-
pies like PTH and teriparatide on regional changes in BMD
within the modeling framework.
Although simultaneous parameter fitting and full parameter
identifiability could not be accomplished in this context, the
updated model fulfilled the Agoram25 criteria: (i) Fit for pur-
pose: only compartments and parameters that were neces-
sary to improve predictions of specific measurable clinical
endpoints were added to the model. (ii) Justification of model
structure: every point of intersection for a sclerostin effect has
an experimental or clinical basis in the published literature. (iii)
Evaluation of component submodels: models were evaluated
by goodness-of-fit and individual parameter sensitivity analyses
were conducted. (iv) Qualification of the emergent properties of
the system: the final model was cross-validated with denosu-
mab therapy simulations to ensure the changes in turnover
(a) (b)
(c) (d)
Figure 3 Simulated P1NP (a), CTx (b), lumbar spine BMD (c), and total hip BMD (d) (blue line) overlaying data from a clinical trial
with blosozumab (red points). This qualification dataset was not used in constructing the model (n5 29, 31, 30, 30 for arms PBO,
180 mg Q2W, 180 mg Q4W, and 270 mg Q2W, respectively).
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markers were consistent with what was reported in previous
work.10 The model also predicts a significant increase in circu-
lating PTH, after sclerostin mAb administration, which is con-
sistent with clinical reports.12,14
CONCLUSION
A previously published multiscale model of bone function,
control, and health was extended to include OCY, sclerostin,
and effects of the upregulated Wnt signaling pathway elicited
by sclerostin mAb administration. The model was used to
simulate P1NP, CTX, and BMD profiles that resembled those
in clinical studies with sclerostin mAb treatment. The utility of
the model to explore biological implications of Wnt pathway
modification and the role of the OCY in bone remodeling
was demonstrated. Model simulations point to differential
effects of osteocyte-driven feedback-driven increases in
resorption activity and suggest possible benefits of shorter
dosing intervals in future clinical trials with sclerostin mAbs.
The model also suggests osteoporosis patients may benefit
from combination therapy to mitigate these feedback effects.
(a) (b)
(c) (d)
Figure 4 Simulations of dose-equivalent sclerostin mAb administered at different dosing intervals demonstrate that changing the dosing
interval may alter clinical outcomes. P1NP (a), osteoblast precursors (b), CTx (c), total hip BMD (d). Colored marks indicate the final
dose in each arm.
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The extended model offers a broader in silico model-based
platform to explore therapeutic target modification towards
the goal of more efficiently addressing clinical development
considerations and improving long-term outcomes.
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Supplementary Figures 
 
 
Supplementary Figure 1. Sensitivity analysis showing the impact of perturbing each individual parameter by +/- 
0.8*estimated parameter value, on P1NP, CTX, LSBMD, and THBMD 
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Supplementary Figure 2. For model qualification, several doses of denosumab were simulated along with data from 7 
clinical studies. Simulations show good agreement with clinical data   
 
 
Supplementary Figure 3. Simulated turnover markers plotted overlaying actual data from 5 clinical studies with 
romosozumab and blosozumab 
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Supplementary Figure 4. Simulated regional changes in BMD plotted overlaying available BMD data from 5 clinical 
studies with romosozumab and blosozumab. Numbered labels correspond to the same arms from Supplementary Figure 3 
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Supplementary Figure 5: PK predictive checks for romosozumab data, grouped by 1, 3, 5, and 10 mg/kg sc (IDs 3-6), and 
1 and 5 mg/kg iv (IDs 7,8) dosing arms. Clinical data is show in blue, simulations in red 
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Supplementary Figure 6: PD predictive checks from clinical trial with blosozumab, grouped by dosing arm and route. 
Clinical data for sclerostin is show in blue, simulations of sclerostin in green (left axis); simulations for sclerostin mAb 
concentration are shown in red (right axis) 
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Appendix 
 
 
Model Assumptions: 
1.)  An average 70kg individual body weight was assumed so that a 1 mg/kg dose is equivalent to a 
70 mg dose of the same drug. 
 
2.)  The PK profiles of sclerostin antibodies and resulting effects on sclerostin are the same in healthy 
women and those with osteoporosis. This assumption was made because only phase 1 data of 
Romosozumab exposure was available in healthy women and all other data used to build the model 
was taken from studies in women with osteoporosis. 
 
3.)  The pharmacokinetics are very similar between the two mAbs (romosozumab and blosozumab), 
so that the PK parameters estimated for romosozumab can be carried into the PD model for 
blosozumab. Romosozumab and blosozumab are both igG iosotypes and mAbs of this isotype have 
been shown to have very similar PK properties, but have variable binding properties, defined by 
parameters Km and Vmax 1. The number of receptors available to bind with the target molecule is 
described by the Vmax parameter. In the case of sclerostin antibodies, the number of receptors 
available for binding is common between the two therapies, thus this is a shared parameter in the 
model, and only the Km was re-estimated for blosozumab in the PD model. Having mAb-matched 
free drug and total target profiles would improve model predictions, as the model could then be 
adjusted for relative potencies of the different mAbs, but in the absence of these data, these 
assumptions are required. We know that OCY are terminally-differentiated bone cells derived from 
mesenchymal osteoblast lineage, but there is much uncertainty around the fraction of OB that 
become OCY, or the rate at which they become embedded in the matrix. Bellido (2013) states that 
anywhere from 5-20% of mature osteoblasts become OCY and that OCY make up more than 90% of 
bone cells within the matrix. In our model, we fixed the rate of osteocyte production at 0.5 * OB 
population, and set the initial condition of osteocyte compartment equal to approximately 90% of 
starting population of total bone cells. We assume apoptosis rate of OCY is dependent on sclerostin 
antibody concentration, so that when circulating sclerostin is increased, as a result of sclerostin mAb 
administration, osteocyte activity decreases accordingly. 
 
5.)  Changes in BMD in this model are functions of changes in OB and OC activity, which are 
derived from changes in biomarkers P1NP and CTx. In reality there is more complexing around the 
dynamics occurring at localized sites in the bone that govern changes in BMD. For example, it is said 
that PTH treatment, which increases P1NP and CTx, simulates intracortical bone remodeling and can 
increase porosity at the endocortical surface, but could be offset by increasing cortical thickness 2. 
The result is in an increase in hip BMD but not necessarily bone strength, because it is not certain if 
anabolic or catabolic activity prevails in the optimal endocortical and periosteal proportions.  The 
assumption is that a larger anabolic window is desirable for increased bone strength and fracture 
prevention but the bone modeling and remodeling activity must also occur in the correct regional 
proportions to properly strengthen bone. This model cannot yet be used to predict changes in 
endocortical or periosteal composition. 
6.) A zero-placebo response was assumed, which is consistent with the placebo arms in the clinical 
data not deviating significantly from baseline for either marker or BMD. The model does include 
disease progression in the context of menopause transition which has been used to model effects of 
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estrogen loss3 but in the context of sclerostin, disease progression or modification was not 
considered, given the lack of a discernable signal in the available placebo data. 4–22 
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Abstract  
 
A hazard model of fracture was developed using individual-level data from the NHANES 
(2005-2008) database and summary-level data from an aggregate dataset. The aggregate dataset 
was build by performing a comprehensive and systematic literature search of clinical studies 
published from 1995-2015, recording fracture rate and bone mineral density (BMD) during and 
after various treatments. Eight candidate models were evaluated by deviance information criteria 
(DIC) and posterior predictive check (PPC). The model with covariates for change from baseline 
(CFB) lumbar spine (LS) BMD, baseline LS BMD, and patient body mass index (BMI), years 
post-menopause, fracture measure method (clinical or radiological) and additional drug effects 
outperformed other models with different representations of BMD and those without additional 
drug effects. The approximated hazard ratio relative to placebo for fracture for each drug class 
was 0.544 for bisphosphonates, 0.412 for PTH/teriparatide, 0.485 for denosumab, 0.180 for 
calicitonin, 0.511 for growth hormone secretogogue MK-677, and 0.760 for strontium ranelate.  
Similar to the FRAX® tool [1], this model is useful for predicting the 10-year probability of 
fracture for a patient with osteoporosis but represents an expandable and open-source framework 
for generating these predictions.  
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1. Introduction 
The aging global population has lead to significant increases in osteoporosis diagnoses. 
Patients with progressed form of this disease suffer significant loss of quality of life due to bone 
fragility leading to fracture. Various classes of therapies have demonstrated efficacy in terms of 
increasing bone mineral density (BMD) at various skeletal sites as well as long-term reduction in 
the rate of fracture. As newer therapies are developed, it is important to establish the relationship 
between changes in BMD, which can be measured in early-phase clinical trials, and fracture 
outcomes that develop over longer periods of time. It is also essential to identify those patient 
characteristics that are most significantly implicated in the occurrence of fracture.  
Much work has already been done to establish risk factors associated with fracture.  The 
FRAX® [1] online calculator was developed by the World Health Organization (WHO) and is 
used to calculate the 10-year probability of fracture using information about individual-level 
patient demographics, physical traits, family history, glucocorticoid use, whether or not the 
patient has experienced a previous fracture, smoking habits and alcohol consumption. 
Unfortunately the algorithm is not published and there is no published method detailing how 
these patient characteristics are used to calculate fracture risk.  
The work outlined here involves the development of a time-to-event (TTE)/hazard model 
using a compilation of historic clinical data recording fracture incidence in osteoporosis patients. 
This model-based meta-analysis (MBMA) approach is an attempt to make inferences about 
fracture based on a large body of evidence available from published works. MBMAs are well-
suited for inferences regarding comparative effects of interventions. The objectives of this work 
were to leverage this large body of data to compare marketed therapies and to better understand 
how BMD enters the model, along with the patient covariates that have already been established 
as influential, in order to link short-term clinical outcomes like BMD with fracture outcomes. It 
also specifies a measure of sensitivity of fracture probability to specific patient characteristics.  
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2. Material and Methods 
2.1 Data 
2.1.1 Data Collection 
A subset of individual-level data from the NHANES database was used to build the first 
portion of the model. These observational data were collected from 2005-2008 and the selected 
patients fulfilled the following criteria:  
• Post-menopausal women above 20 years of age 
• Patients who had BMD measurements taken at the time of the interview 
• Patients who were at least 2 years post-menopause at screening 
Only fracture data that were recorded either 2 years post-menopause or 10 years prior to 
screening (whichever was less) were recorded. The fracture incidence was assessed 
retrospectively and reported as the year in which it occurred. Fractures that occurred in the same 
year as screening were not recorded. After filtering, there were 1925 total patients in the 
NHANES dataset.  
To the extent possible, PRISMA guidelines [2] were used to construct an aggregate 
dataset for the fracture model. Data were compiled from a Pubmed search conducted on or around 
June 1, 2015 using keywords “fracture”,“prevent”,“risk”,“occur”,“humans“,“clinical 
trial”,“randomized controlled trial”, “osteoporosis”, “zoledronic acid”, “teriparatide”, 
“alendronate”, risedronate”, denosumab”, “HRT”, MK-677”, “intransal salmon calcitonin”, 
“strontium ranelate” published from 1995 to 2015. 42 Studies were selected from 172 screened 
studies in Pubmed. Trials included were randomized, blinded and open-label, prospective and 
retrospective. Patient inclusion criteria were men with osteoporosis or post-menopausal women 
with osteoporosis greater than 50 years of age. Interventions included in the final dataset included 
denosumab, any bisphosphonate, teriparatide, PTH, calcitonin, MK-677 or strontium ranelate. 
Graphical presented data from these publications were digitized using GraphClick (v3.0 Arizona 
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Software). These data are summarized in Supplementary Table 1. Because vertebral fractures 
were the dominant type of measured fracture in most of the clinical trials, studies that did not 
include vertebral fractures were excluded from the dataset. If non-vertebral and vertebral 
fractures were reported as separate measures, these were combined and recorded as total fracture 
events. Fracture events were reported as percentage of patients experiencing fracture or number 
of categorical fracture (vertebral, nonvertebral, clinical or morphological, for example). Time-
dependent changes in lumbar spine (LS) BMD were reported as change from baseline, percentage 
change from baseline (PCFB), g/cm^2 or t-score and converted to PCFB. Baseline mean or 
median LS BMD were reported in units of g/cm^2 or t-score and were converted to g/cm^2. 
Studies that did not include at least one post-baseline measurement of LS BMD were excluded 
from the dataset. Patient baseline characteristics including age, race, body mass index (BMI), 
years post-menopause, height, weight, prior fracture, and current smoking status were also 
recorded. Whether or not vertebral fractures were routinely evaluated via radiograph or classified 
as ‘clinical vertebral fractures’ was indicated in the dataset.  Study extensions were recorded as 
independent trials, because the extension population typically had its own set of baseline 
characteristics. Supplementary Figure 1 shows longitudinal changes in LS BMD for each study 
included in the aggregate dataset (A), and the corresponding rate of fracture for each study arm 
(B).  
2.1.2 Data Standardization and Missing Data Imputation 
In the NHANES dataset, BMD measurements were taken at screening and thus had to be 
imputed at the time of a fracture event.  The following equation was used to impute BMD, 
stratified by baseline quartiles, wherein coefficients were estimated by linear multiple regression:   
 𝐵𝑀𝐷 =   𝛽! +   𝛽!   𝑝𝑜𝑠𝑡  𝑚𝑒𝑛𝑜𝑝𝑎𝑢𝑠𝑎𝑙  𝑎𝑔𝑒 − 20+     𝛽!   𝑎𝑔𝑒  𝑎𝑡  𝑙𝑎𝑠𝑡  𝑚𝑒𝑛𝑠𝑡𝑟𝑢𝑎𝑙  𝑝𝑒𝑟𝑖𝑜𝑑 − 51.7 +     𝛽! 𝐵𝑀𝐼 − 27.1+ 𝛽!𝐼  !"#$!!"#$%&!' 
[1] 
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For both NHANES and aggregate datasets, missing BMI (kg/m^2) was computed from 
weight and height. If neither BMI nor height and weight were reported, BMI was imputed with a 
multiple linear regression model where the coefficients were estimated separately for each 
dataset:  𝐵𝑀𝐼! = 𝛽! + 𝛽! ∗ (𝑎𝑔𝑒  ! − 𝑎𝑔𝑒) [2] 
for the ith individual (NHANES) or ith treatment arm (aggregate dataset)  
 
In the NHANES dataset, all BMD measures were reported as T-scores. These, and the values of 
BMD in the aggregate data reported as a T scores were converted to units of g/cm^2 using the 
reference BMD and standard deviation (SD) parameters for a white female [47].  𝐵𝑀𝐷!/!"^! =   0.106 ∗ 𝐵𝑀𝐷!!!"#$% + 1.064 [3] 
  
If post-menopausal age was not reported in the aggregate dataset, it was computed by subtracting 
a weighted average of post-menopausal ages of the treatment arms from the average age of the 
reported treatment arm.  
 
2.3 Development of Hazard Model of Fracture 
While the MBMA approach is useful for distinguishing effects of assigned intervention 
across summary-level treatment arms, it is less useful for quantifying the effects of patient 
characteristics on outcome. To address this, separate hazard model structures were used to fit the 
NHANES data and the published aggregate data, respectively. A Bayesian approach as 
implemented in OpenBUGS v. 3.2.2 was used to fit both models simultaneously and the majority 
of parameters were shared between the models. The NHANES dataset represented a single trial, 
as did each of the studies in the aggregate dataset. The covariates included in both models were 
preselected based upon the those examined in the FRAX project [1] and those available in the 
literature. It was determined from a previous analysis that LS BMD was more predictive of 
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fracture outcomes than either total hip or femoral neck BMD (data not shown). No formal 
covariate selection process was conducted. Inter-trial variation for both models was applied to the 
baseline hazard and BMD –related parameter(s) in the respective hazard model. For the 
population-level simulations, values for these parameters were randomly selected from a 
multivariate normal distribution with mean, θ and variance, Ω. 
Markov Chain Monte Carlo (MCMC) simulations generated vectors of parameters from 
the approximate distribution. Four chains of 100,000 iterations are generated, with the first 
50,000 being discarded and every 50th sample retained, resulting in 4000 samples for statistical 
inference. Weakly informative prior distributions for covariate parameters and variance 
parameters were used in all versions of the model to allow the data to influence parameter 
estimation. Model selection was based on values of mean deviance, DIC (deviance information 
criteria), and posterior predictive checks (PPCs). Under the assumption the BMD and drug effect 
parameters in the model are independent, an approximate hazard ratio for each class of drug in 
the model was calculated using the mean area under the curve (AUC) for BMD, calculated by 
trapezoidal rule (eq 14) for each drug class and the estimated drug effect:  𝐻𝑎𝑧𝑎𝑟𝑑  𝑟𝑎𝑡𝑖𝑜 = exp  (𝐵𝑀𝐷!"#$!!"# + 𝐸!"#$   )/exp  (𝐵𝑀𝐷!"#$!!"#!!"#) 
 
 
 
 
[4] 
Where 𝐵𝑀𝐷!"#$!!"# = 0.5 ∗ Σ((𝐵𝑀𝐷!+𝐵𝑀𝐷!!!) ∗ (𝑡 − (𝑡 − 1)),  
 
where 𝑡 is the elapsed time since previous BMD measurement and (t - 1) is the time 
of the previous BMD measurement for each treatment arm.  
 [5] 
 
 
3. Results 
 
3.1. Final Hazard Model Structure 
3.1.1 Time-to-Event Model for NHANES dataset 
The likelihood for the time to first fracture in the ith patient (tfrac,i) took the form:  
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𝐿 𝜃 𝑡!"#$,!,𝑐𝑒𝑛𝑠𝑜𝑟! ,𝑋! =    ℎ! 𝑡!"#$,!   𝜃,𝑋! 𝑒! !! ! !,!! !"
!!"#$,!,! ,𝑎𝑒! !! ! !,!! !"!!"#$,!,!
 
Fracture 
observed 
 
Fracture 
right-
censored 
 
 
[6] 
where censori =1 indicates fracture is right censored (no fracture occurred during the duration of the 
trial) and 0 otherwise. Xi corresponds to the covariate to be estimated. If fracture is right censored, 
tfrac corresponds to the time of last observation during the observation period. hi  represents the hazard 
equation. Observation period was defined as beginning 10 years before the interview or 2 years post-
menopause, whichever occurred last 
 
The hazard equation (hi) for the NHANES model took the form:  
 ℎ!   = ℎ!!   exp  (𝛽!"#,! ∗ log  (BMD!"#$,!/𝐵𝑀𝐷) +𝛽!"#$%&'"()&  (𝑡𝑖𝑚𝑒  ! + 𝑝𝑜𝑠𝑡𝑀𝑒𝑛𝑜𝑎𝑔𝑒  !,! + 𝑝𝑜𝑠𝑡𝑀𝑒𝑛𝑜𝐴𝑔𝑒  )  +   𝛽!"# 𝐵𝑀𝐼! − 𝐵𝑀𝐼  
[7] 
in the ith treatment arm of the jth trial and time is the duration of observation in trial 
 
The BMD portion of the hazard is log-transformed to ensure only BMD predictions that are 
positive enter the model for hazard. The effect of BMD on hazard is also more interpretable in 
this context; as long as the percentage increase in BMD from baseline is fixed, one would expect 
the same amount of decrease in the hazard for fracture.  
 
3.1.2 Hazard Model for the Aggregate Dataset 
 
The number of patients experiencing a fracture from the aggregate dataset followed a 
binomial distribution with probability of fracture, pfrac,ij  for nij patients at risk for fracture, where  𝑝!"#$,!" =   1 − 𝑒! !!" ! !,!!" !"!  !  [8] 
in the ith treatment arm of the jth trial, Xij represent the model covariates, hij represents the hazard 
	   9	  
equation and t is the duration of observation in trial. 
 
Four different hazard models, which were variations of a Cox regression (eq 7), were evaluated 
on the basis of the LS BMD representation which best predicted the proportion of patients 
experiencing fracture in the aggregate dataset. Each candidate model was also analyzed with and 
without an additional set of covariates, where each covariate represented a additional effect 
specific to each class of therapy in the dataset (𝐸!"#$,!  ).  
 ℎ(𝑡)   = ℎ!  𝑒[!!!! !!!!! ] 
 
where each xi is a covariate and h0 is the baseline hazard 
 
 
 
[9] 
 
Covariates consistent across all the model candidates included post-menopausal age, method of 
vertebral fracture identification (IradFracture = 1 if measured radiologically, and 0 if identified as 
clinical fractures), and body mass index (BMI).  
The four candidate model structures for the BMD covariate(s) were as follows:  
1.) Time-
dependent 𝐶𝑂𝑉!"# =   𝛽!"#,!   log   𝐵𝑀𝐷!" 𝑡𝐵𝑀𝐷    
 
 
 
 
[10] 
2.) Time-
dependent + 
change from 
baseline BMD 
 
𝐶𝑂𝑉!"# =   𝛽!"#,! log 𝐵𝑀𝐷  !" 𝑡𝐵𝑀𝐷+   𝛽!"#  !"#,!𝐵𝑀𝐷!"#$%  !"#,!" 𝑡  
 [11] 
3.) Baseline  + 
change from 
baseline BMD 
 
𝐶𝑂𝑉!"# =   𝛽!"#  !"#$,! log 𝐵𝑀𝐷!,!"𝐵𝑀𝐷!+   𝛽!"#  !"#,!𝐵𝑀𝐷!"#$%  !"#,!" 𝑡  
 [12] 
4.) Time-
dependent + 
baseline BMD 
𝐶𝑂𝑉!"# =   𝛽!"#,! log 𝐵𝑀𝐷  !" 𝑡𝐵𝑀𝐷+      𝛽!"#  !"#$,! log 𝐵𝑀𝐷!,!"𝐵𝑀𝐷!  
 [13] 
 for ith arm and jth trial.   
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The hazard model took the form:  ℎ!"   = ℎ!!   exp  (𝐶𝑂𝑉!"# + 𝛽!"#$%&'"()&  (𝑝𝑜𝑠𝑡𝑀𝑒𝑛𝑜𝐴𝑔𝑒  !" 𝑡−   𝑝𝑜𝑠𝑡𝑀𝑒𝑛𝑜𝐴𝑔𝑒  )   +   𝛽!"#$!"%&'!(𝐼!"#$!"%&'!(,!"+   𝛽!"# 𝐵𝑀𝐼!" − 𝐵𝑀𝐼 +    𝐸!"#$,! ) 
 
 
 
 
[14] 
for ith arm, jth trial, and kth drug class (1=placebo, 2=bisphosphonates, 3=PTH/teriparatide, 
4=denosumab, 5=calcitonin, 6=growth secretagogue MK-677, 7=strontium ranelate) 
 
 
3.2 Covariate Structures and Parameter Estimates 
Each model was tested with and without a drug effect and yielded the following results 
for DIC:  
Table 1. Model structures and DIC results 
BMD Covariate Structure DIC 
Time Dependent BMD 2765.227 
Time Dependent BMD + Add’l Drug Effect  2631.669 
Time-dependent + change from baseline BMD 2716.229 
Time-dependent + change from baseline BMD + Add’l Drug Effect 2640.619 
Baseline  + change from baseline BMD  2714.463 
Baseline  + change from baseline BMD + Add’l Drug Effect 2639.259 
Time-dependent + baseline BMD 2731.056 
Time-dependent + baseline BMD + Add’l Drug Effect  2633.337 
 
The model that yielded the lowest DIC score included the time-dependent BMD 
measurement and additional drug effect. The mean parameter estimates for this model are shown 
in Table 2. Figure 1 shows both individual-level and population-level post-predictive checks 
(PPC) of the TTE model, with the NHANES data and predictions stratified by baseline BMD. 
Figure 2 shows PPCs of the aggregate data-driven hazard model at both the individual and 
population levels.  
Table 2. Parameter estimates and 95% CI around the mean 
Parameter Mean 95% CI 𝒉𝟎 (1/years) 0.0583 (0.0447; 0.0749) 𝜷𝑩𝑴𝑫 (1/gm/cm2) 1.33 (-1.78; 4.29) 
	   11	  
𝜷𝒓𝒂𝒅𝑭𝒓𝒂𝒄𝒕𝒖𝒓𝒆 (unitless) -0.204 (-0.386; -0.0275) 𝜷𝒑𝒐𝒔𝒕𝑴𝒆𝒏𝒐𝑨𝒈𝒆  (1/years) 0.0269 (0.0139; 0.0405) 𝜷𝒃𝒊𝒔𝒑𝒉𝒐𝒔𝒑𝒉𝒐𝒏𝒂𝒕𝒆𝒔(unitless) -0.631 (-0.745; -0.513) 𝜷𝑷𝑻𝑯/𝒕𝒆𝒓𝒊𝒑𝒂𝒓𝒂𝒕𝒊𝒅𝒆 
(unitless) 
-0.889 (-1.18; -0.616) 𝜷𝒅𝒆𝒏𝒐𝒔𝒖𝒎𝒂𝒃 (unitless) -0.750 (-1.21; -0.579) 𝜷𝒄𝒂𝒍𝒄𝒊𝒕𝒐𝒏𝒊𝒏 (unitless) -1.68 (-5.0; 0.470) 𝜷𝑴𝑲!𝟔𝟕𝟕 (unitless) -0.689 (-2.68; 0.838) 𝜷𝒔𝒕𝒓𝒐𝒏𝒕𝒊𝒖𝒎  𝒓𝒂𝒏𝒆𝒍𝒂𝒕𝒆 
(unitless) 
-0.289 (-0.886; 0.327) 
Ωh0 0.69 (0.527; 0.898) 
 ΩBMD   6.87 (4.63; 9.95) 
 
 
 
 
Figure 1: Individual (A) and population-level (B) PPCs for the NHANES dataset, stratified by baseline BMD. 
Individual-level predictions estimate fracture probability in the same trial with the same patient covariates. 
Predictions at the population-level reflect probability of fracture in a new trial, but same patient covariates.  
< 0.843 g/cm^2 0.843 − 0.947 g/cm^2
0.947 − 1.05 g/cm^2 > 1.05 g/cm^2
0.80
0.85
0.90
0.95
1.00
0.80
0.85
0.90
0.95
1.00
0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10
Time (years)
Pr
ob
ab
ilit
y o
f n
o 
ve
rte
br
al 
fra
ctu
re
5%ile
95%ile
median
observed
Fracture Risk for Patients Stratifed by Baseline BMD 
 Individual Predictions
< 0.843 g/cm^2 0.843 − 0.947 g/cm^2
0.947 − 1.05 g/cm^2 > 1.05 g/cm^2
0.00
0.25
0.50
0.75
1.00
0.00
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10
Time (years)
Pr
ob
ab
ilit
y o
f n
o 
ve
rte
br
al 
fra
ctu
re
5%ile
95%ile
median
observed
Fracture Risk for Patients Stratifed by Baseline BMD 
 Population PredictionsA B
	   12	  
 
Figure 2: Individual (A) and population (B) -level PPCs for the aggregate dataset, grouped by study arm. The   
indicates the mean percentage of patients with fracture from the clinical data, the red line indicates predicted 
median, and blue lines indicate 90% CI around the prediction. Individual-level predictions estimate fracture 
probability in the same trial with the same patient covariates. Predictions at the population-level reflect 
probability of fracture in a new trial, but same patient covariates. 
 
4. Discussion 
 
 Prior to the development of this hazard model of fracture, there was no published model 
relating changes in LS BMD to probability of fracture in patients with osteoporosis. This work 
leverages a large amount of summary-level metadata, as well as an individual- patient level 
(NHANES) dataset with BMD and fracture in order to provide a framework for linking short-
term changes in BMD to long term fracture outcomes. The model with best performance was the 
simplest model with a single covariate for BMD and a covariate for the additional drug effect.  
 The final model greatly over-predicted the probability of fracture over time in patients in 
the NHANES dataset at the population level (Figure 1B), but estimated individual-level fracture 
rate at a greater level of accuracy (Figure 1). This outcome could indicate high levels of inter-trial 
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variability at the level of the baseline hazard, (h0). It is also important to note that the information 
contained in the NHANES dataset originates from an observational study and is reflective of a 
highly heterogeneous population. Fracture events recorded in this dataset were assessed by 
patient interview and subject to errors in human memory. This is in contrast to the metadata set 
that was made up of mostly prospective trials conducted in-house and subject to a greater level of 
control.  Population-level estimates for the aggregate dataset were also more variable, again for 
the reason that inter-trial variability for the baseline hazard and BMD covariates was high. 
Precision around some of the parameter estimates was poor (C.I. included the null in some cases; 
see Table 2). In the case of the BMD covariate, this is likely due to this measure being highly 
variable across treatment arms and trials. Areal BMD is typically measured with a DEXA 
scanners but there have been documented discrepancies in measurements taken with the different 
types of scanners (Hologic, Lunar, Norland) [48].  
 Hazard models with and without an additional covariate for an independent drug effect 
were compared. It was determined that there is an additional beneficial effect of some classes of 
therapies, which is independent of the contribution of changes in BMD elicited by the therapy, on 
fracture reduction. One reason for this is that different drug mechanisms have differential effects 
on regional areal BMD (aBMD, the type measured here), as well as on bone microarchitecture. 
BMD and bone microarchitecture are loosely associated. For example, changes in 1/3rd radius 
BMD are linked to changes in the cortical bone compartment and distal radius BMD is 
descriptive of changes at intracortical sites[49]. However, development of this model supports the 
widely-held notion that BMD only tells part of the story of the association between bone 
composition, strength and probability of fracture. A study by Sornay-Rendu et al. [50], 
demonstrated that changes in microarchitecture associated with fracture are partially independent 
of changes in aBMD, as measured at the radius and hip. Given the results of this study and the 
findings that the measures of trabecular number, trabecular distribution and separation of 
distribution were the significant measures distinguishing osteoporotic women with and without 
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fracture, one could make the argument that measuring changes in bone microarchitecture would 
be more clinically useful in measuring bone strength and should be more routinely used. However 
in this study, the authors did not consider lumbar spine or femoral neck BMD, two of the 
routinely examined sites in clinical efficacy studies. 
There is much evidence for different classes of therapy having differential effects on 
bone microarchitecture in the published literature. Seeman, et al. [51] published a study looking 
at the differences between denosumab and alendronate effects on bone microarchitecture. The 
authors speculated that treatment-specific changes in total and cortical BMD might point to drug 
mechanisms at the level of the bone multicellular unit (BMU). Because denosumab inhibits 
osteoclast synthesis there is a rapid reduction in newly excavated resorption cavities and 
simultaneous filling of existing cavities, in contrast with alendronate, which does not elicit the 
same CTX response at comparable doses. It has also been suggested that the anti-resporptive 
effect of bisphosphonates is mediated by the distribution of the drug, because the strong affinity 
of bisphosphonates for hydroxyappetite and bone mineral may limit distribution [49].  It is 
possible that osteoclasts may not commence remodeling activity until the entire matrix containing 
the bisphosphonate is resorbed. This process may not be linear or uniform throughout the 
skeleton.  
In contrast to anti-resorptive therapies, teriparatide has been shown to decrease cortical 
thickness in the tibia and radius while increasing cortical porosity and significantly increasing 
trabecular number in the tibia [52]. The authors conjecture that the anabolic mechanism of action 
of PTH is to accelerate intracortical and endosteal remodeling. Zolerdronic acid was used as a 
comparator in this study and did not have an impact on cortical porosity, but did increase cortical 
thickness, consistent with bisphosphonate activity seen in the Seeman, et al. study. Considering 
the variable effects of different agents on microarchitecture, the influence of an independent, 
drug-effect on probability of fracture may stem from differential effects in bone composition that 
are not fully represented by regional areal BMD measures.  
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Future development of the model may include investigation of the relationship between 
BMD and fractures at specific sites. The major limitation to this endeavor is a lack of clinical 
trials reporting site-specific fracture events. Coupling MBMA developed by a comprehensive, 
systematic literature search with individual-level data from the NHANES database allowed for a 
comparison of effects of different drug classes on probability of fracture, and demonstrated the 
influence of patient characteristics on this probability. Still, more clinical data at the level of the 
individual patient is also desired in order to describe effects of patient characteristics on fracture 
risk more precisely.   
  
5. Conclusion  
In the development of a hazard model of fracture, the best predictions came from a model 
that included time-dependent BMD. In addition to these BMD changes elicited by therapy, there 
is a significant contribution of an additional class-specific drug effect that contributes to hazard 
reduction beyond effects on BMD. This additional drug effect likely reflects changes in the bone 
microarchitecture that are not being represented by areal BMD endpoints typically measured in a 
clinical trial. This fracture model is a public and expandable framework for quantifying the extent 
to which patient characteristics and patient response to therapy contribute to fracture reduction. 
As more clinical data become available and therapies with different mechanisms of action are 
developed, the model can be updated. Another feature of this model that distinguishes it from the 
FRAX model is it can be used to make inferences about how variability affects outcome in a 
clinical population. This utility for prediction into a clinical study paradigm is relevant for 
development of new therapies for osteoporosis.  
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Fracture Metadataset 
ID Trial Endpoint 
Total 
Patients (N) 
Study 
Length Treatment(s) 
Covariate 
Information 
Year 
Published Reference 
1 [1]	   % Patients experiencing fracture (uncatagorized) 581 2 years 
placebo 
zolerdronic acid 5 mg/y 
bmi 
caucasian 
years post-
menopause 
clinical fracture 2009 [3] 
2 TOWER 
% Patients experiencing non-vertebral or vertebral 
fracture 542 1.5 years 
placebo 
teriparatide 56.4 mcg/w 
bmi 
previous vertebral 
fracture 
years_post-
menopause 
radiologic fracture 2012 [4] 
4 
 
% Patients experiencing non-vertebral or vertebral 
fracture 323 2.8 years 
teriparatide 20 ug/d 
alendronate 70 mg/w 
bmi 
previous vertebral 
fracture 
previous non-
vertebral fracture 
previous fracture 
years post-
menopause 
smoking 
clinical fracture 2014 [5] 
5 
 
% Patients experiencing vertebral fractures 599 1.5 years 
teriparatide 28.2 ug/w 
teriparatide 1.4 ug/w 
bmi 
asian 
years post-
menopause 
previous vertebral 
fracture 
radiologic fracture 2014 [6] 
6 
 
% Patients experiencing non-vertebral or vertebral 
fracture 253 1 year 
denosumab 60 mg/6mo 
ibandronate 150 mg/mo 
bmi 
caucasian 
years post-
menopause 
previous vertebral 
fracture 
previous non-
vertebral fracture 
previous fracture 
clinical fracture 2013 [7] 
	   ii	  
7 
 
% Patients experiencing vertebral fractures 1254 4 years 
placebo 
strontium ranelate 2g/d 
bmi 
caucasian 
years post-
menopause 
previous vertebral 
fracture 
radiologic fracture 2009 [8] 
8, 9 
VERT North 
America % Patients experiencing vertebral fractures 
base study: 
1329 
extension: 
759 
3 years 
1 year 
extension 
placebo 
risondronate 4 mg/y;  
discontinued during 
extension 
height 
years post-
menopause 
previous vertebral 
fracture 
weight 
radiologic fracture 1999, 2008 [9,10] 
10 EVA 
% Patients experiencing non-vertebral or vertebral 
fracture 1418 0.85 years 
alendronate 10 mg/d 
risendronate 60 mg/d 
bmi 
caucasian 
years post-
menopause 
radiologic fracture 2007 [11] 
11 
 
% Patients experiencing non-vertebral or vertebral 
fracture 
base 
study:618 
extension: 
420 
2 years 
1 year 
extension 
placebo 
minodronate 1 mg/d 
asian 
bmi 
years post-
menopause 
previous vertebral 
fracture 
radiologic fracture 2009, 2012 [12,13] 
12 DIRECT 
% Patients experiencing non-vertebral or vertebral 
fracture 
base study: 
1156 
extension: 
525 
2 years 
1-year 
extension  
placebo 
denosumab 60 mg/6 mo 
alendronate 35 mg/w 
denosumab-only extension 
asian 
bmi 
previous vertebral 
fracture 
radiologic fracture 2014, 2015 [14,15] 
13, 22 
VERT 
International 
% Patients experiencing non-vertebral or vertebral 
fracture 
base study: 
1226 
extension 1: 
260 
extension 2: 
164 
3 years 
 2 2-year 
extensions 
placebo 
risendronate 2.5 mg/d 
risendronate 5 mg/d 
height 
years-post 
menopause 
previous vertebral 
fracture 
radiologic fracture 
2000, 
2003,2004 [16–18] 
14 
 
% Patients experiencing non-vertebral or vertebral 
fracture 355 2 years 
placebo 
risendronate 2.5 mg/d 
risendronate 5 mg/d 
height 
years-post 
menopause 
previous vertebral 
fracture 
smoking 
weight 
clinical fracture 2000 [19] 
15 
 
% Patients experiencing vertebral fracture 296 2 years 
placebo 
risendronate 2.5 mg/d 
risendronate 5 mg/d 
years-post 
menopause 
smoking 
clinical fracture 2005 [20] 
	   iii	  
16, 17 FIT/FLEX 
% Patients experiencing non-vertebral or vertebral 
fracture 
base study: 
3236 
extension: 
1099 
5 years 
5-year 
extension 
placebo 
alendronate 5 mg/d  
bmi 
caucasian 
previous fracture 
previous vertebral 
fracture 
smoking 
clinical fracture 
1996,2004, 
2012 [21–23] 
19, 3 
SOTI  / 
TROPOS Number of vertebral and non-vertebral fractures 
Tropos core 
study: 3646 
sub- study: 
237 
Tropos: 5 
years 
sub-study: 
10 years 
placebo 
strontium ranelate 2g/d 
bmi 
previous vertebral 
fracture 
previous non-
vertebral fracture 
years_post-
menopause 
radiologic fracture 2008, 2012 [24,25] 
20 
Fracture 
Prevention 
Trial 
% Patients experiencing non-vertebral or vertebral 
fracture 1006 1.5 years 
placebo 
 teriparatide 20 or 40 ug/d 
bmi 
years post-
menopause 
previous vertebral 
fracture 
clinical fracture 2009 [26] 
21 
 
% Patients experiencing vertebral fracture 881 3 years 
placebo 
alendronate 5,10, or 20 
mg/d 
bmi 
years post-
menopause 
previous vertebral 
fracture 
radiological fracture 1996 [27] 
23 
 
% Patients experiencing fracture of the spine, femoral 
neck, trochanter  483 2 years 
placebo 
zolerdronic acid 5 mg/y 
asian 
bmi 
years-post 
menopause 
radiologic fracture 2013 [28] 
24 
 
Number of patients experiencing any fracture 412 1 year 
placebo 
zolerdronic acid 5 mg/y 
zolerdronic acid 5 mg/y + 
teriparatide 20 mcg/d 
bmi 
caucasian 
years post-
menopause 
previous vertebral 
fracture 
previous fracture 
clinical fracture 2011 [29] 
25, 31 
FACTS 
International % Patients experiencing fracture (uncatagorized) 
base study: 
936  
extension: 
798 
1 year 
1 year 
extension 
alendronate 70mg/w 
risedronate 35 mg/w 
bmi 
caucasian 
years post-
menopause 
clinical fracture 2006, 2008 [30,31] 
	   iv	  
25 
 
% Patients experiencing fracture (uncatagorized) 78 3 years zolerdronic acid 4mg/y 
caucasian 
height 
weight 
clinical fracture 2007 [32] 
26, 18 
 FREEDOM 
Trial 
% Patients experiencing non-vertebral or vertebral 
fracture 
base study: 
7808 
extension: 
4550 
3 years 
3 year 
extension 
placebo 
 denosumab 60 mg/6mo 
denosumab only during 
extension 
bmi 
years post-
menopause 
previous fracture 
clinical Fracture 2009, 2013 [33,34] 
27 
 
% Patients experiencing non-vertebral or vertebral 
fracture 1637 1.6 years 
placebo 
teriparatide 20 mcg/d 
teriparatide 40 mcg/d 
bmi 
years post-
menopause 
previous fracture 
radiologic Fracture 
caucasian 
smoking 2001 [35] 
28 
 
Total fractures 428 1 year 
placebo 
alendronate 10 mg/d  
caucasian 
years post-
menopause 
clinical fracture 1999 [36] 
29 
 
% Patients experiencing fracture (uncatagorized) 292 1.5 years 
placebo 
alendronate 10 mg/d 
MK-677 25 mg/d 
bmi 
clinical fracture 2001 [37] 
30 
 
% Patients experiencing non-vertebral or vertebral 
fracture 549 1 year 
alendronate 70 mg/w 
risendronate 5 mg/d 
bmi 
caucasian 
years post-
menopause 
previous fracture 
clinical fracture 2003 [38] 
33, 34 
 
% Patients experiencing non-vertebral or vertebral 
fracture 1258 
1 year 
1 year 
extension 
alendronate 10 mg/d, 
35mg/0.5w, or 70 mg/w 
bmi 
years post-
menopause 
clinical fracture 2000, 2002 [39,40] 
34 
 
Number of any kind of fracture 1053 1 year 
alendronate 70 mg/w 
risendronate 35 mg/w 
asian 
black 
bmi 
hispanic 
other race 
years-post 
menopause 
clinical fracture 2005 [41] 
	   v	  
35 STAND % Patients experiencing fracture (uncatagorized) 502 1 year 
alendronate 70 mg/w 
denosumab 60 mg/mo 
bmi 
years post-
menopause 
previous non-
vertebral fracture 
clinical fracture 2010 [42] 
36 
 
Total fractures 
base study: 
597 
extension: 
644 
3 year 
 3 
extension 
periods 
placebo 
 alendronate 5 or 10 mg/d 
bmi 
years post-
menopause 
previous fracture 
radiologic Fracture 2004 [43] 
37 
 
% Patients experiencing fracture (uncatagorized) 286 2 years 
placebo 
alendronate 10 mg/d  
alendronate 20 mg/d 
calcitonin 100IU/d 
bmi 
caucasian 
years post-
menopause 
clinical fracture 
smoking 1995 [44] 
38 
 
% Patients experiencing fracture (uncatagorized) 406 4 years 
placebo 
alendronate 10 mg/d  
bmi 
caucasian 
black 
hispanic 
years post-
menopause 
clinical fracture 2008 [45] 
39 
 
Number. of any clinical fracture 3876 3 year 
placebo 
zolerdronic acid 5 mg/y 
bmi 
years post-
menopause 
clinical fracture 2007 [46] 
 
  
	   vi	  
 
 
 
Supplementary Figure 1: Longitudinal changes in lumbar spine bone mineral density and percentage of patients experiencing fracture from the aggregate dataset by trial. Different 
colors represent trial arms 
Appendix A
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Example	  DAISY	  Input	  for	  a	  full	  TMDD	  with	  subcutaneous	  dose,	  when	  only	  information	  about	  the	  central	  compartment	  (drug	  concentration)	  is	  known.	  	  	  WRITE	  "IDENTIFIABILITY	  of	  TMDD"$	  	  %	  Feb	  25,	  2014	  RJE	  	  %	  B_	  is	  a	  reserved	  name	  used	  to	  indicate	  the	  vector	  (non	  constant)	  input,	  output	  and	  state	  variables.	  %	  (where	  I=u,	  x1/V=y1,C=x1,	  R=x2,	  DR=x3,	  A2=x4)	  	  	   B_:={y1,	  x1,	  x2,	  x3,	  x4}$	  	  	  %	  The	  following	  instruction	  defines	  the	  components	  of	  vector	  B_	  as	  time-­‐depending	  variables:	  	  	   FOR	  EACH	  EL_	  IN	  B_	  DO	  DEPEND	  EL_,T$	  	  %	  Please	  note:	  It	  is	  necessary	  that	  the	  known	  variables	  be	  always	  listed	  before	  the	  unknown	  variables	  and	  in	  the	  following	  order:	  input	  variables,	  output	  variables	  and	  known	  state	  variables.	  	  %	  Please	  note:	  Constant	  inputs	  must	  not	  be	  listed	  in	  vector	  B_,	  but	  directly	  included	  in	  the	  model	  equations.	  	  %	  B1_	  is	  a	  reserved	  name	  used	  to	  indicate	  the	  vector	  of	  unknown	  parameters.	  	  	   B1_:={kdeg,	  kon,	  koff,	  kel,	  k12,	  k21,d,R_0,	  kint}$	  %(R_0=ksyn/kdeg)	  	  %	  NX_	  and	  NY_	  are	  reserved	  to	  indicate	  the	  number	  of	  states	  and	  outputs	  respectively.	  	   NX_:=4$	  	  	  	   NY_:=1$	  	  	  %	  C_	  is	  a	  reserved	  variable	  name	  used	  to	  indicate	  the	  system	  of	  differential	  polynomials	  (both	  rational	  and	  not)	  that	  describe	  the	  model.	  For	  this	  example,	  i.v.	  bolus	  dose	  =	  5	  	  	  C_:={	  	  	   df(x1,	  t)=	  -­‐(kel+k12)*x1-­‐kon*x2*x1+koff*x3+(k21*x4)/(5/d),	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   df(x2,	  t)=	  -­‐kon*x2*x1+koff*x3+(R_0-­‐x2)*kdeg,	   	   	   	   	   	  	   	   	  	  	   df(x3,	  t)=	  kon*x2*x1-­‐(koff+kint)*x3,	  	  	   df(x4,	  t)=	  k12*x1*(5/d)-­‐k21*x4,	  	   118
	   y1=x1	  	  	  	   }$	  	  	  %	  Choose	  an	  integer	  value	  (seed_).	  The	  subroutine	  random	  will	  choose,	  in	  a	  random	  way	  in	  the	  interval	  [1,	  seed_],	  the	  numerical	  values	  corresponding	  to	  each	  component	  (model	  unknown	  parameter)	  of	  vector	  B1_.	  	   SEED_:=100$	  	  %	  Invoke	  the	  procedure	  that	  calculates	  characteristic	  the	  set:	  	  	   DAISY()$	  	  	  %	  This	  is	  the	  end	  of	  the	  input	  file	  in	  the	  case	  when	  initial	  conditions	  need	  not	  to	  be	  considered.	  No	  comment	  lines	  can	  be	  written	  at	  the	  end	  of	  the	  file.	  	  %	  Initial	  conditions:	  if	  the	  user	  knows	  some	  or	  all	  the	  initial	  conditions	  of	  the	  model,	  these	  can	  be	  included	  in	  the	  identifiability	  analysis.	  In	  this	  case,	  the	  (numerical	  or	  symbolic)	  values	  can	  be	  inserted	  at	  the	  end	  of	  the	  input	  file	  with	  instructions	  such	  as	  IC:=	  and	  the	  subroutine	  CONDINIZ	  has	  to	  be	  called.	  The	  complete	  instruction	  is:	  	  	  %	  If	  the	  user	  knows	  only	  some	  of	  the	  initial	  conditions,	  DAISY	  will	  automatically	  provide	  the	  missing	  initial	  conditions	  of	  the	  state	  variables	  xi	  by	  assigning	  them	  the	  unknown	  symbolic	  value	  xi_0.	  	   IC_:={	  x1=d,x2=R_0,	  x3=0,	  x4=0}$	  	  	  	   CONDINIZ()$	  	  	   END$	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Antibody-Drug Conjugate (ADC) TMDD for One ADC Component
dC1
dt
=
ktpAt1 + In(t)
V c
− (kel1 + kpt)C1 − konC1 ·R + koffRC1 + kdec2C2 (1)
dC2
dt
=
ktpAt2
V c
− (kel2 + kpt)C2 − konC2 ·R + koffRC2 − kdec2C2 (2)
dAt1
dt
= kptC1V c− ktpAt1 (3)
dAt2
dt
= kptC2V c− ktpAt2 (4)
dR
dt
= ksyn − kdegR− kon(C1 + C2) ·R + koff (RC1 +RC2) (5)
dRC1
dt
= konC1 ·R− (kint + koff )RC1 (6)
dRC2
dt
= konC2 ·R− (kint + koff )RC2 (7)
dAT
dt
= V c(kdec2C2 + kel2C2 + kintRC2)− kTelAT (8)
C1(0) = 0; C2(0) = 0; At1(0) = 0; At2(0) = 0;
R(0) =
ksyn
kdeg
; RC1(0) = 0; RC2(0) = 0; A
T (0) = 0
(9)
Equations from: L. Gibiansky and E. Gibiansky. Target-mediated drug disposition model and its
approximations for antibody-drug conjugates. J Pharmacokinet Pharmacodyn, 41(1):35-47, Feb 2014.
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setwd("/data/svn-renae/PI/First_Run")
.libPaths("../../script/lib")
library(metrumrg)
library(nlme)
library(ggplot2)
## Read in simulated data #####################################
tab2<-read.table(file="./2.TAB", header=T, as.is=T, skip=1)
head(tab2)
### Wipe out C1 and DV Columns#####
tab2$C<-NA
tab2$CMT<-NA
tab2<-tab2[,c("C","ID",'TIME',"AMT","RATE","EVID","CMT","DOSE","DV")]
tab2$AMT[tab2$AMT==0]<-NA
tab2$DV[tab2$EVID==1]<-NA
tab2$CMT[tab2$EVID==1]<-1
write.table(tab2, file="./bosentan_sim.csv",na='.',sep=",",row.names=FALSE, 
quote=FALSE)
############## Estimate ########################################################
NM72 <- '/opt/NONMEM/nm72/nmqual/autolog.pl'
NONR(
  run = 3,
  command=NM72,
  grid=TRUE,
  diag=TRUE,
  grp= c('DOSE'),
  par.list=c("KEL", "KON", "KOFF", "RMAX", "VCENT", "KTP", "KPT", "KM")
)
tab<-read.table(file="./3.TAB", header=T, as.is=T, skip=1)
p <- ggplot(data=tab, mapping=aes(x=TIME, y=IPRED, group=DOSE))
p + geom_line(aes(x=TIME,y=DV,colour=factor(DOSE)))
p + geom_point(aes(x=TIME,y=IPRED,colour=factor(ID)))+ geom_line(aes(y=IPRED, 
colour=factor(DOSE)), lwd=0.5) + facet_wrap(~ID, scales=c("free"))
############## Full TMDD MODEL 
###################################################
NM72 <- '/opt/NONMEM/nm72/nmqual/autolog.pl'
NONR(
  run = 4,
  command=NM72,
  grid=TRUE,
  diag=TRUE,
  grp= c('DOSE'),
  par.list=c("KEL", "KON", "KOFF", "RMAX", "VCENT", "KTP", "KPT", "KM")
)
tab<-read.table(file="./4.TAB", header=T, as.is=T, skip=1)
p <- ggplot(data=tab, mapping=aes(x=TIME, y=IPRED, group=DOSE))
p + geom_point(aes(x=TIME,y=IPRED,colour=factor(ID)))+ geom_line(aes(y=PRED, 
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colour=factor(DOSE)), lwd=0.5) + scale_y_log10()
+ facet_wrap(~ID, scales=c("free")) + scale_y_log10()
p + scale_y_log10()
#### Get par estimates ############################
rlog(run=c(1:4),append=F,purge=F, file=filename("./",'CombRunLog_est.csv'))
est <- read.table("./CombRunLog_est.csv",sep=",",as.is=TRUE, skip=4)
head(est)
##Clean up the table so that it only includes information you will use for LLP. 
##Delete unnecessary columns
est<-est[,c(6:14,29,60)]
names(est)
[names(est)==c("V6","V7","V8","V9","V10","V11","V12","V13","V14","V29","V60")
]<-
  c("TH1","TH2","TH3","TH4","TH5","TH6","TH7","TH8","TH9","OM5","SG")
head(est)
#The table now consists of only PEs of the fixed and random effects parameters, 
and 
#the RSEs. We want the SEs so we have to calculate the SE from RSE: 
SE=function(RSE, PE){
  (RSE/100)*PE}
est[3,]<-SE(est[2,], est[1,])
head(est)
##The table now consists of point estimates, RSE, and SE values arranged in a 
single column for each parameter.
##We want to create a vector of fixed values for each LL profile: +/-4*SE and 
divide the high and low values by 10
est[4,]<-3*(est[3,])
est[5,]<-est[1,]+est[4,]
est[6,]<-est[1,]-est[4,]
head(est,7)
Finalest<-est
llpth1<-signif(c(seq(from=Finalest[6,"TH1"], to=Finalest[5,"TH1"], 
length.out=10), Finalest[1,"TH1"]),3)
llpth2<-signif(c(seq(from=Finalest[6,"TH2"], to=Finalest[5,"TH2"], 
length.out=10), Finalest[1,"TH2"]),3)
llpth3<-signif(c(seq(from=Finalest[6,"TH3"], to=Finalest[5,"TH3"], 
length.out=10), Finalest[1,"TH3"]), 3)
llpth4<-signif(c(seq(from=Finalest[6,"TH4"], to=Finalest[5,"TH4"], 
length.out=10), Finalest[1,"TH4"]),3)
llpth5<-signif(c(seq(from=Finalest[6,"TH5"], to=Finalest[5,"TH5"], 
length.out=10), Finalest[1,"TH5"]), 3)
llpth6<-signif(c(seq(from=Finalest[6,"TH6"], to=Finalest[5,"TH6"], 
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length.out=10), Finalest[1,"TH6"]),3)
llpth7<-signif(c(seq(from=Finalest[6,"TH7"], to=Finalest[5,"TH7"], 
length.out=10), Finalest[1,"TH7"]),3)
llpth8<-signif(c(seq(from=Finalest[6,"TH8"], to=Finalest[5,"TH8"], 
length.out=10), Finalest[1,"TH8"]), 3)
llpth9<-signif(c(seq(from=Finalest[6,"TH9"], to=Finalest[5,"TH9"], 
length.out=10), Finalest[1,"TH9"]), 3)
llp<-c(llpth1, llpth2, llpth3, llpth4, llpth5, llpth6, llpth7, llpth8, llpth9)
## 10/10/14 Change kel range of values for manuscript #######
llpth1<-signif(c(seq(from=1.03, to=1.059, length.out=10), Finalest[1,"TH1"]),5)
llpth1
llpth2
llpth3
llpth4
llpth5
llpth6
llpth7
llpth8
## New LLPs ##
llpth4[1]<-0.008
llpth4[2]<-0.01
llpth4[3]<-0.04
llpth8[1]<-0.0001
llpth8[2]<-0.0008
llpth8[3]<-0.001
llp<-c(llpth1, llpth2, llpth3, llpth4, llpth5, llpth6, llpth7, llpth8, llpth9)
llp[llp<0] # check that no estimates are less than zero
llp<-signif(llp,3)
#Create control streams for each model run: 8Thetas
#with 10 fixed values per theta=90 control streams to run. 
#create bootstrap control streams
#see help for resample.character
f4<-readLines("4.ctl")
pnm<-readLines("1.pnm")
nms <- 101:111
PE1 <- metaSub(
  f4, 
  names=nms, 
  pattern = list(
    "PROB 4",
    "(0, 0.990)"
  ), 
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  replacement = list(
    "PROB *",
    paste("(",llpth1," FIX",")",sep="")
  ), 
  out = "../First_Run", 
  suffix = ".ctl",
)
nms2 <- 112:122
PE2 <- metaSub(
  f4, 
  names= nms2, 
  pattern = list(
    "PROB 4",
    "(0, 0.633)"
  ), 
  replacement = list(
    "PROB *",
    paste("(",llpth2," FIX",")",sep="")
  ), 
  out = "../First_Run", 
  suffix = ".ctl",
)
nms3 <- 123:133
PE3 <- metaSub(
  f4, 
  names= nms3, 
  pattern = list(
    "PROB 4",
    "(0, 0.344)"
  ), 
  replacement = list(
    "PROB *",
    paste("(",llpth3," FIX",")",";",sep="")
  ), 
  out = "../First_Run", 
  suffix = ".ctl",
)
nms4 <- 134:144
PE4 <- metaSub(
  f4, 
  names= nms4, 
  pattern = list(
    "PROB 4",
    "(0, 7.85)"
  ), 
  replacement = list(
    "PROB *",
    paste("(",llpth4," FIX",")",sep="")
  ), 
  out = "../First_Run", 
  suffix = ".ctl",
)
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nms5 <- 145:155
PE5 <- metaSub(
  f4, 
  names=nms5, 
  pattern = list(
    "PROB 4",
    "(0, 5.37) "
  ), 
  replacement = list(
    "PROB *",
    paste("(",llpth5," FIX",")",sep="")
  ), 
  out = "../First_Run", 
  suffix = ".ctl",
)
nms6 <- 156:166
PE6 <- metaSub(
  f4, 
  names= nms6, 
  pattern = list(
    "PROB 4",
    "(0, 2.31) "
  ), 
  replacement = list(
    "PROB *",
    paste("(",llpth6," FIX",")",sep="")
  ), 
  out = "../First_Run", 
  suffix = ".ctl",
)
nms7 <- 167:177
PE7 <- metaSub(
  f4, 
  names= nms7, 
  pattern = list(
    "PROB 4",
    "(0, 1.49)"
  ), 
  replacement = list(
    "PROB *",
    paste("(",llpth7," FIX",")",sep="")
  ), 
  out = "../First_Run", 
  suffix = ".ctl",
)
nms8 <- 178:188
PE8 <- metaSub(
  f4, 
  names= nms8, 
  pattern = list(
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    "PROB 4",
    "(0, 0.108)"
  ), 
  replacement = list(
    "PROB *",
    paste("(",llpth8," FIX",")",sep="")
  ), 
  out = "../First_Run", 
  suffix = ".ctl",
)
nms9 <- 189:199
PE9 <- metaSub(
  f4, 
  names= nms9, 
  pattern = list(
    "PROB 4",
    "(0, 0.2)"
  ), 
  replacement = list(
    "PROB *",
    paste("(",llpth9," FIX",")",sep="")
  ), 
  out = "../First_Run", 
  suffix = ".ctl",
)
NOD <- metaSub(
  pnm, 
  names=nms, 
  out = "../First_Run", 
  suffix = ".pnm"
)
runs<-c(98:99)
NONR(
  run = 97,
  command=NM72,
  grid=TRUE,
  diag=TRUE,
  pe= "orte 8",
  mode= "para"
)
NONR(
  run = 97,
  command=NM72,
  grid=TRUE,
  diag=TRUE
)
rlog(run=c(101:200),append=F,purge=F,file=filename("./",'CombRunLog_est2.csv'))
126
Page 7 of 9
estdata3.R 11/5/15, 11:48 AM
##because thetas 4,5,7 were fixed values, there was no runlog for these runs and 
were
##not included in the combined runlog
dropNA<-function(x){
  bad<-is.na(x)
  good<-x[!bad]
}
LLPbos<-read.table("CombRunLog_est2.csv", sep=",", quote="", as.is=TRUE, 
fill=TRUE)
nrow(LLPbos)
head(LLPbos)
#select only the lines with objective function values for runs:
OFVRes<-LLPbos[,c(2,3,5)] #results from all runs
OFVRes<-OFVRes[OFVRes$V2!="RSE",]
OFVRes$V5<-as.numeric(OFVRes$V5)
OFVRes$V2<-NULL
PEdata<-function(ThFIX,OFVs, ...){
  data.frame(ThFIX, OFVs, ...)}
llp<-c(llp,0.445)
PEdat<-PEdata(llp, OFVRes)
head(PEdat)
tail(PEdat)
# For all runs, create a column in the dataset labeling each theta:
Theta<-c(rep(1,11), rep(2,11), rep(3,11), rep(4,11), rep(5,11), rep(6,11), rep(7,
11), rep(8,11), rep(9,11),3)
length(Theta)
#create the dataset that includes the OFVs, theta labels, and the Fixed parameter 
values
llpdat<-PEdata(llp, OFVRes, Theta)
head(llpdat)
row.names(llpdat)<-NULL
llpdat$V2<-NULL
# To order the Thetas sequentially and name fixed effect parameters: 
llpdat<-llpdat[order(llpdat$Theta, llpdat$ThFIX),]
llpdat$THETA<-factor(paste("Theta", llpdat$Theta))
# Remove runs that didn't run or compile correctly
colnames(llpdat)<-c("ThFIX","ERR","OFVRes",'Theta',"THETA")
llpdat$ERR<-as.factor(llpdat$ERR)
llpdat$ERR<-map(llpdat$ERR,c(".","0","134","136","137","error"),c(NA,0,1,2,3,NA))
llpdat2<-llpdat[!is.na(llpdat$ERR),]  ### These didn't run
llpdat3<-llpdat2[llpdat2$ERR<2,] ### These didn't compile correctly
llpdat3<-llpdat3[llpdat3$ThFIX!=1.04000,]
llpdat3$THETA<-map(llpdat3$Theta, c(1:9), 
                  c("Kel", "Kon", "Koff", 
"Ksyn","Vcent","Kpt","Ktp","Kdeg","Kint"))
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add<-data.frame(
  ThFIX = c(0.99,1.010), ERR = c(0,0), OFVRes = c(6131.279,5953.5988), Theta = c
(1,1), THETA = c("Kel","Kel"))
llpdat3<-rbind(llpdat3, add)
llpdat3<-llpdat3[order(llpdat3$Theta, llpdat3$ThFIX),]
llpdat3$flg<-with(llpdat3,ifelse(ThFIX %in% c(1.03320,1.03640),1,0))
#1.03640,1.04290,1.05260, 
llpdat3<-llpdat3[llpdat3$flg==0,]
# Then rerun the plot script with index.cond according to desired arrangement
##Now we need plot reference lines for the MOFV and +3.84MOFV, which corresponds 
to the 95% CI. 
my.LLPplots<-function(x,y, point.color="blue"){
  panel.xyplot(x,y,col=point.color, pch=19, cex=0.4, type="b")
  ymin<-min(y)
  panel.abline(h=ymin)
  panel.abline(h=ymin+3.84, lty=2, col="red")
}
##Need to set Y scale to read easier: USE prepanel=function(x, 
y, ...)list(xlim=range(x), ylim=c(min(y)-1, min(y)+4.84))
axisLP<-function(side, ...){
  if(side=="bottom"){
    xlim<-current.panel.limits()$xlim
    xmin<-xlim[[1]]
    xmax<-xlim[[2]]
    Major<-pretty(signif(seq(xmin, xmax, length.out=5), 2))
    Minor<-((Major[-1]+Major[-length(Major)])/2)
    labl<-as.character(Major)
    panel.axis(side="bottom", at= Minor, outside=TRUE, labels=FALSE, ticks=TRUE, 
tck=0.6, line.col="black")
    panel.axis(side="bottom", at= Major, outside=TRUE, labels=labl, ticks=TRUE, 
tck=1.2, line.col="black")
  }
  else axis.default(side, ...)}
library(lattice)
tiff(
  file="Fig4b2.tiff",
)
xyplot(
  OFVRes~ThFIX|THETA,
  llpdat3,
  layout=c(3,3),
  as.table=TRUE, 
  prepanel=function(x, y, ...)list(xlim=range(x), ylim=c(min(y)-1, min(y)+4.84)),
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  panel=my.LLPplots,
  scales=list(relation="free", cex=0.65),
  axis=axisLP,
  between=list(x=0, y=2),
  xlab='Fixed Parameter Value',
  ylab='Min OFV'
)
dev.off()
rlog(run=c(101:199),
     project="./",
     append=FALSE,
     extra=c("^worke")
)
##panel.axis(side="bottom", at=Major, half=FALSE, outside=TRUE, labels=labl, 
ticks=TRUE, tck=1, line.col="orange")
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$PROB 97 BOSENTAN ESTIMATION FROM SIMULATED DATASET WITH FULL TMDD
$INPUT C ID TIME AMT RATE EVID CMT DOSE DV
$DATA ../bosentan_sim.csv IGNORE=C
$SUB ADVAN6 TRANS1 TOL=6
$MODEL NPAR=9 NCOMP=4 COMP=(CENTRAL) COMP=(PERIPH) COMP=(RESPONSE) COMP=(EFFECT)
$PK
KEL=THETA(1)*EXP(ETA(1))
KON=THETA(2)*EXP(ETA(2))
KOFF=THETA(3)*EXP(ETA(3))
KSYN=THETA(4)*EXP(ETA(4))
VCENT = THETA(5)*EXP(ETA(5))
KPT=THETA(6)*EXP(ETA(6))
KTP=THETA(7)*EXP(ETA(7))
KDEG=THETA(8)*EXP(ETA(8))
KINT=THETA(9)*EXP(ETA(9))
S1=VCENT/1000 ; Unit adjustment
;S3=V3
A_0(3)=KSYN/KDEG
$DES
C1=A(1)/VCENT
C2=A(2)
C3=A(3)
C4=A(4)
DADT(1)=-(KEL+KPT)*C1+KTP*(A(2)/VCENT)-KON*A(3)*C1+KOFF*A(4)
DADT(2)=KPT*C1*VCENT-KTP*A(2)
DADT(3)=KSYN-KON*A(3)*C1+KOFF*A(4)-KDEG*A(3)
DADT(4)=KON*A(3)*C1-(KOFF+KINT)*A(4)
;A_0 (3)=KSYN/KDEG
$ERROR
;Y = F+ERR(1)
Y = F*(1+ERR(1))
IPRED=F
$THETA
(1.063 FIX)   ;  THETA(1)  KEL
(0, 0.633)   ;  THETA(2)  KON
(0, 0.344)  ;  THETA(3)  KOFF
(0, 7.85)   ;  THETA(4)  KSYN
(0, 5.37)    ;  THETA(5)  VCENT
(0, 2.31)    ;  THETA(6)  KPT
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(0, 1.49)     ; THETA (7) KTP
(0, 0.108) ; THETA (8) KDEG
(0, 0.2) ; THETA (9) KINT
$OMEGA
0 FIX
0 FIX
0 FIX 
0 FIX 
0.02
0 FIX
0 FIX 
0 FIX
0 FIX
$SIGMA
0.05
$ESTIMATION MAXEVAL=9999 METHOD=1 PRINT = 5 MSF=./97.MSF NOABORT
;$COVARIANCE
$TABLE NOPRINT ONEHEADER FILE=../97.TAB
ID TIME AMT EVID CMT DOSE IPRED
$TABLE NOPRINT ONEHEADER FILE=../97par.TAB
ID DV KEL KON KOFF VCENT KTP KPT KSYN KDEG KINT
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Figure A.1: Sensitivity analysis for parameters describing combination treatment. Parameters were varied between the ranges 0.8+/- esti-
mated parameter value and plotted against the clinical data (red) +/- 95%CI
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Model Code
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// FINAL MODEL CODE  
 
$GLOBAL 
#define max(a,b) ((a) > (b) ? (a) : (b)) 
#define F11 T85 
#define PicOCkin Pic0 
 
#define SETINIT if(NEWIND <=1) 
 
 
// Definitions: Initialize Compartments 
   
#define Q0 Q_0 
#define RNK0 RNK_0 
#define L0 L_0 
#define ROB10 ROB1_0 
#define Qbone0 Qbone_0 
#define O0 O_0 
#define RX20 RX2_0 
#define CREB0 CREB_0 
#define M0 M_0 
#define TGFBact0 TGFBact_0   
#define TGFB0 TGFB_0 
#define PREPTH0 PREPTH_0 
#define PTH0 PTH_0 
#define OBfast0 OBfast_0 
#define OC0 OC_0 
#define P0 P_0 
#define T0 T_0 
#define BMDfn0 BMDfn_0 
#define BMDls0 BMDls_0 
#define BMDlsDEN0 BMDlsDEN_0 
#define EST0 EST_0 
#define GFR0 GFR_0 
#define OBslow0 OBslow_0 
#define OCY0 OCY_0 
#define TOL0 TOL_0 
 
#define PKCP (PKCENT/PKVC) 
#define DENCP (DENCENT/DENVC) 
 
#define CaConc0 (P0/V1) 
#define PTHconc0 (PTH0/V1) 
#define OB (OBfast*trans + OBslow) 
 
#define PTHconc (PTH/V1) 
#define CaConc (P/V1) 
#define C1 (P/V1) 
#define C2 (ECCPhos/V1) 
#define C8 (B/V1) 
#define D  ROB1 
#define Osteoclast OC 
#define OB0 (OBfast0 + OBslow0) 
#define Osteoblast (OBfast*trans + OBslow) 
#define Calcitriol0 (B_0/V1) 134
 
#define BMDlsSCLER0 BMDlsSCLER_0 
#define BMDfnSCLER0 BMDfnSCLER_0 
#define BMDthSCLER0 BMDthSCLER_0 
 
#define BMDlsTERI0 BMDlsTERI_0 
#define BMDfnTERI0 BMDfnTERI_0 
#define BMDthTERI0 BMDthTERI_0 
 
#define BMDlsDEN0 BMDlsDEN_0 
#define BMDfnDEN0 BMDfnDEN_0 
#define BMDthDEN0 BMDthDEN_0 
 
 
  // denosumab concentration (mol)  
#define DENMOL (DENCENT/DENVC/150000)*1000*1000 
 
 // sclerostin (nmol/L) and sclerostin ab concentration (nmol)  
#define SOSTCP (SOSTCENT/SOSTVC) 
 
// Parameter Declaration 
    
 double E0PicOBkb; 
 double EmaxPicOBkb;  
 double EC50PicOBparenKb ; 
 double EC50PicOBkb ; 
 double PicOBkb; 
 double E0RUNX2kbEff;   
 double PicOBkbEff ; 
 double kbprime ; 
 double kbslow ; 
 double kbfast ; 
 double RUNkbMax; 
 double INparen ; 
 double RUNkb50; 
 double RUNX2kbPrimeEff ; 
 double KIN_P;  
 double SCLEREFF; 
 double BSAP; 
 double E0PicROB; 
 double EC50PicROBparen; 
 double EC50PicROB;  
 double Dr; 
 double PicROB; 
 double ROBin;  
 double bigDb; 
 double koutOCY; 
 double kin_TOL; 
 double PhosEffect; 
 double J48; 
 double J27; 
 double RUNX2; 
 double KPT; 
 double kin_T; 
 double kin_BMDdel; 135
 double kin_BMDdelTERI;  
 double kin_BMDdelTERIth;  
 double SCLER_TOL; 
 double SC50; 
 double SCLEREFF_TOL; 
 double EC50SCLER; 
 double fracOBEffect; 
 double Hazard; 
 double Survival; 
 double lsBMD; 
 double SclerBMDpred; 
 double DenoBMDpred; 
 double TeriBMDpred; 
 double ComboBMDpred; 
 double damp; 
 double drug; 
 
// PARAMETER VALUES  
 
$PARAM 
  OBtot0 = 0.00501324  // initial OB compartment concentration 
  k1 = 0.00000624  // binding affinity RANKL-OPG 
  k2 = 0.112013 // dissassociation rate RANKL 
  k3 = 0.00000624 // binding affinity RANK-RANKL 
  k4 = 0.112013 // dissassociation rate RANK 
  V1= 14 // volume of distribution: CA compartment (L) 
  FracJ14 = 0.107763 // extracellular CA flux 
  J14OCmax = 0.543488 // de-mineralization of CA 
  J14OCgam = 1.6971 // de-mineralization of CA 
  FracJ15 = 0.114376 // extracellular CA flux 
  kinRNKgam = 0.151825 //TGF-B on RANKL effect 
  koutRNK = 0.00323667 // RANK degradation 
  MOCratioGam = 0.603754 // RANK-RANKL complex effect on OB 
  Da = 0.7/24 // OC formation rate 
  OBtgfGAM = 0.0111319 // OB influence on latent TGF-b 
  koutTGF0 = 0.0000298449 // degradation rate TGF-b 
  koutTGFGam = 0.919131 // TGF-b scaling effect on degredation 
  OCtgfGAM = 0.593891 // scaling effect on latent TGF-b 
  EmaxPicROB = 3.9745 // emax effect of TGF on responding OB 
  PicROBgam = 1.80968 // gamma term on TGF on responding OB 
  FracPicROB =  0.883824 // fraction of responding osteoblast 
precursors contributing to mature osteoblasts 
  PicOBgam = 0.122313 // gamma on active TGF-beta 
  FracPicOB = 0.000244818 // fraction of osteoblast precursors 
contributing to mature osteoblasts 
  EmaxPicOB = 0.251636 // emax on OB compartment 
  E0Meff = 0.388267 // RANK-RANKL Complex and Latent TGF-Beta effect 
  EmaxMeffOC = 3.15667 // Max effect of  RANK-RANKL Complex on 
osteoclasts 
  kinOCgam = 8.53065 // gamma on RANK-RANKL complex 
  EmaxPicOC = 1.9746 // Max effect of active TGF-Beta, osteoclasts 
  FracPicOC = 0.878215 // Fraction of osteoclast precursors 
contributing to differentiation 
  PicOCgam = 1.0168 // Active TGF-Beta effect on osteoclasts 
  E0RANKL = 3.80338 // SS initial condition for RANKL 136
  EmaxL = 0.469779 // max effect of RANKL on osteoclasts 
  T16 = 1.06147 // PTH-sensitive calcium reabsorption in kidney 
  T64 = 0.05 //1-alpha hydroxylase degredation rate 
  T65 = 6.3 // extracellular phosphate concentration input rate 
  T67 = 1.54865 // alpha hydroxylase effect on PTH excretion 
  AlphOHgam =  0.111241 // 1-alpha hydroxylase effect on PTH 
  k14a =  0.0000244437 // rate of non-immediately exchangeable calcium-
immediately exchangely bone calcium 
  HApMRT = 3.60609 //endogenous hydroxy-apatite formation 
  koutL = 0.00293273 // degradation rate of RANKL 
  TotOsteoEffectGam = 0.173833 // Fractionated effect on RANKL 
  TESTPOWER = 1 // not used currently - can be used to increase the 
effect of PTH 
  opgPTH50 = 3.85 // EC50 term of PTH effect on OPG 
  IO = 0 // additional OPG substrate 
  RX2Kout0 = 0.693 // RunX2 effect on extracellular PTH 
  E0rx2Kout = 0.125 // RunX2 to extracellular PTH 
  EmaxPTHRX2x = 5 // Max effect of PTH on calcium flux from plasma into 
bone 
  E0crebKin = 0.5 // Creb formation rate 
  EmaxPTHcreb = 3.39745 // max effect of PTH on creb 
  crebKout = 0.00279513 // creb degratation rate 
  bcl2Kout = 0.693 // degradation rate of Bcl-2 
  ScaEffGam = 0.9 // effect of calcium ratio on calcium excretion via 
kidney 
  PhosEff0 = 1.52493 // baseline extracellular phosphate effect on 1-
alpha hydroxylase 
  PhosEff50 = 1.3021 // EC50 term for phosphate effect on 1-alpha 
hydroxylase 
  PhosEffGam = 8.25229 // gamma term for phosphate effect on 1-alpha 
hydroxylase 
  PO4inhPTHgam = 0 // effect of phosphate on PTH 
  T69 = 0.10 // degradation rate of circulating calcitriol 
  Reabs50 = 1.57322 // EC50 term for PTH-sensitive calcium reabsorption 
in kidney 
  T7 = 2 //  effect of circulating calcitriol to extracellular calcium 
  T9 = 90 // effect of circulating calcitriol to extracellular calcium 
and excretion 
  T70 = 0.01 // effect on PTH leaving PTH gland pool 
  T71 = 0.03 // effect of PTH gland on calcium reabsorbtion 
  T33 = 0.003 // effect of circulating calcitriol on calcitriol-
dependent calcium absorption into gut 
  T34 = 0.037 // effect of circulating calcitriol on calcitriol-
dependent calcium absorption out of gut 
  T35 = 90 // EC50 term for circulating calcitriol on calcitriol-
dependent calcium absorption 
  CaPOgam = 1 // gamma term on effect for circulating calcitriol on 
calcitriol-dependent calcium absorption 
  T46 = 1.142 // rate of phosphate renal excretion 
  T52 =  0.365 // rate of oral phosphate absorbtion 
  OralPhos = 10.5/24 // rate of oral phosphate absorbtion into gut 
  F12 = 0.7  // availability of oral phosphate 
  T49 = 51.8 // rate of extracellular phosphate to intracellular 
phosphate 
  T55 = 0.019268 // intracellular phosphate to extracellular phosphate 137
  PicOBgamkb = 2.92375 //  TGF-beta effects on Osteoblast and clast 
differentiation 
  MultPicOBkb = 3.11842 // fraction of ROB contributing to TGF-beta 
effect on OB differentation 
  FracPic0kb = 0.764028 // fraction of osteoblast precursors that 
contribute to differentiation in TGF beta 
  E0RUNX2kbEffFACT = 1.01 // osteoblast apoptosis as affected by PTH 
  RUNkbGAM = 3.81644 // gamma term on RUNX2 effect of osteoblast 
apoptosis 
  RUNkbMaxFact = 0.638114 // emax term of RUNX2 effect of osteoblast 
apoptosis 
  RUNX20 = 10 // RUNX2 baseline effect on EC50 for RUNX2 
  Frackb = 0.313186 // degradation rate of fast/slow osteoblasts 
  T81 = 0.75 // effect of calcitriol-dependent calcium absorption on 
oral calcium. 
  T87 = 0.0495 // rate of calcium movement to/from gut 
  T28 = 0.9 // EC50 term for calcium movement to/from gut 
  OralCa = 24.055/24 // calcium intake via gut per day 
  T310 = 0.105929 // fraction of oral calcium being absorbed 
  T77 = 0.909359 //effect on extent of absorption of orally-
administered calcium dose 
  T80 = 4 // gamma term for calcitriol-dependent calcium absorption 
  CtriolPTgam = 12.5033 // gamma term on calcitriol for PT gland 
capacity 
  CtriolMax = 4.1029 // max effect of calcitriol for PT gland capacity 
  CtriolMin = 0.9 // min effect of calcitriol for PT gland capacity 
  PTout = 0.0001604 // flux out of PT gland 
  kout = 100/14 // degredation rate of PTH 
  T58 = 6249.09 // max PTH-related calcium flux 
  T59 = 11.7387 // gamma term for PTH-related calcium flux 
  T61 = 96.25 // min PTH-related calcium flux 
  IPTHint = 0 // intravenous PTH 
  IPTHinf = 0 // infused PTH 
  Pic0 = 0.228142 //  baseline of osteoblast precursors 
  EmaxLpth = 1.30721 // Emax PTH effect on RANKL 
  kO = 15.8885 // formation rate OPG 
  kb = 0.000605516 // conversion rate of preosteoblasts to osteoblasts 
  LsurvOCgam =3.09023 // effect of RANKL on osteoclasts 
  FracOBfast = 0.797629 //fraction of osteoblast pool that are quickly 
differentiated 
 
  // Teriparatide PK parameters 
  TERIKA = 10.4, TERIVC = 94.4, TERIVD  = 7, TERICL = 62.2, TERIF = 
0.95 
 
  //Generic PK parameters 
  PKKA = 0, PKVC = 10, PKQ1 = 0, PKQ2 = 0 
  PKVP1 = 1, PKVP2 = 1, PKCL = 0, PKVMAX=0, PKKM=1 
 
  kdenosl = 1.98411e-06 // denosumab effect on RANKL 
  E2scalePicB1 = 0.0000116832 //effect of estrogen on osteoblast 
apoptosis 
  FracOBE = 20 // max of OB contribution to effect on RANKL 
   
  // Denosumab PK parameters from Peterson, et al.The AAPS Journal, 138
24(6 Abstract W4340), 2004 // 
  DENVMAX = 3110, DENKM = 188, DENVC = 2340 
  DENVP = 1324  // = Q/K(12,11) 
  DENCL = 2.75 
  DENQ = 18.67 // = K(12,11) * VC 
  DENKA = 0.00592, DENF = 0.729 
   
  ESTON = 0 // estrogen effect (switch) 
  koutEST=0.05776227 // degredation rate of estrogen 
  menoDUR=as.hour(as.year(1.66)) // duration of menopause 
  ageGAM = -2.3 // age effect on estrogen effect 
  age50 = 0.64 // EC50 of age effect on estrogen 
  ageENTER = as.hour(as.year(41)) // Ave age at meno onset 
  ageDONE = as.hour(as.year(51)) // Ave age at meno end 
  tgfbGAM = 0.0374 // TGF-b effect on estrogen 
  tgfbactGAM = 0.045273 // active TGF-b effect on estrogen 
  robGAM = 0.16 // estrogen effect on responding osteoblasts 
  maxTmESTkid = 0.923737 // maximum fractional calcium reabsorption in 
the kidney 
  GFRtau=10  // years over which GFR declines 
  GFRdelta=0  // change in GFR 
 
  // Sclerostin PK Parameters // 
  SOSTVMAX = 5.87/24, SOSTKM = 0.453, SOSTVC = 2.9, SOSTVP = 3.29 
  SOSTCL = 0.254/24, SOSTQ = 0.467/24, SOSTKA = 0.187/24, SCLERF=0.904 
   
  // Sclerostin PD Parameters // 
  SOSTKIN=3.725/24, SOSTKOUT= 25/24, SOSTK0 = 0.197/24 
 
  // Sclerostin effects // 
  FracOCY = 0.5 // Fraction of OB becoming OCY 
  EMAXSCLER = 4.670795836 
  gammaDr = 0.044584465 // sclerostin effect on ROB 
  gammaOCY = 0.276280938 // sclerostin effect on OCY apoptosis 
  gammaOPG = 1.597073748 // sclerostin effect on OPG (via Wnt 
signaling) 
  SCLEROBgam =  0.162250232 // sclerostin effect 
  SMAX = 8.690800116 // max sclerostin effect 
  kout_T = 0.006073441 // translation compartment rate constant (for 
sclerostin effect on OB) 
  kout_TOL = 0.001901105 // tolerance compartment rate constant (for 
sclerostin effect on RANKL) 
 
  TYPE = 2 // Allows for simultaneous fit of P1NP and CTx 
 
  // Denosumab BMD Parameters 
 
  koutBMDls = 0.000397 
  koutBMDlsDEN = 7.374996e-05 
  koutBMDfnDEN = 0.0001186424 
  koutBMDthDEN = 0.0001080459 
  gamOB = 0.0793 
  gamOCls = 0.14 
  gamOClsDEN = 7.912201e-02 
  gamOCfnDEN = 0.0514712439 139
  gamOCthDEN = 0.0552337198 
 
  // Sclerostin BMD Parameters 
 
  koutBMDSCLER = 0.000145 
  gamOBSCLERls =  0.75766752 
  gamOCSCLER = 0.06530286 
  gamOBSCLERth = 0.22459622 
  gamOBSCLERfn = 0.13145334 
  gamOBSCLER = 0.099 
  kout_BMDdel = 0.00245716 
 
  // Teriparatide BMD Parameters 
 
  kout_BMDdelTERI = 0.001 
  koutBMDlsTERI =  0.00055370 
  koutBMDthTERI =  0.0001394248 
  koutBMDfnTERI =  0.000066284 
  gamOCfnTERI =   0.21199 
  gamOClsTERI = 0.016916 
  gamOCthTERI = 0.13118 
  gamOBTERIfn =  0.495529 
  gamOBTERIls =  0.271226 
  gamOBTERIth =  0.29803 
 
 // Combination (teriparatide and denosumab) Arm BMD Parameters 
 
  koutBMDlsCOMBO = 0.0001368262 
  koutBMDthCOMBO = 0.0001048986 
  koutBMDfnCOMBO = 0.0001275736 
 
  gamOClsDEN_TERI = 0.1015274694 
  gamOCthDEN_TERI = 0.0704668698 
  gamOCfnDEN_TERI = 0.0671132952 
 
 // Placeholder for Hazard Model Covariates (these are supplied by the 
dataset) // 
  baseHazard = 0.058265425 
  HazBMDCov = 1.3259 
  HazpostMenoAgeCov = 0.02690102025 
  HazradFracCov = -0.20419 
  HazBMICov = -0.021603069564 
  agepostmeno= 20 
  radFracInc= 0 
  BmdbaseRef = 0.783 
  postMenoAgeRef = 20 
  ageLastMenPeriodRef = 51.7 
  bmiRef = 27.1 
  lsBMDbase = 0.8 
 
  // addtional drug effect // 
  betaDrug_DENO=-1.73 
  betaDrug_TERI=-0.898 
  betaDrug_COMBO=-1.213  //combo ave deno&bisphos = avoid using this 
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 // Used to determine which BMD data to table out // 
 
Scler_BMD_type=0,Deno_BMD_type=0,Teri_BMD_type=0,DEN_TERI_COMBO=0,Combo
_BMD_type=0, SCLER_DEN_SEQ=0 
 
 
////////////////////////////////// 
 
 
// Link compartment number to subcu compartment name 
$CMTN  
SOSTSC, DENSC, TERISC 
 
// INITIAL CONDITIONS  
 
$INIT 
 
    PTH = 53.90     // (pmol) 
    S = 0.5         // PTH gland pool     
    PTmax = 1.00    // PT gland max capacity 
    B = 1260.0      // Circulating calicitriol (pmol) 
    SC = 0.0        // Subcu PTH compartment (pmol) 
    P = 32.90       // Extracellular calcium (mmol) 
    ECCPhos = 16.8  // Extracellular phosphate (mmol) 
    T = 1.58471     // Oral calcium (mmol) 
    R = 0.50        // Calcitriol dependent ca absorption 
    HAp = 1.00      // Hydroxyapetite conc 
    PhosGut = 0.839  // Oral phosphate (mmol) 
    IntraPO = 3226.0 // Intracellular phosphate (mmol) 
    OC = 0.00115398  // Osteoclast population  
    ROB1 = 0.00104122 // Responding osteoblasts 
    L = 0.4         // RANKL concentration 
    RNK= 10.0       // RANK concentration   
    O = 4.0         // OPG 
    Q = 100.0       // Immediate-exchangeable bone calcium (mmol) 
    Qbone = 24900.0 // Non-immediate exchangeable bone calcium (mmol) 
    RX2 = 10.0      // RunX2 
    CREB = 10.0     // Creb 
    BCL2 = 100.0    // Bcl-2 
    TERISC = 0, TERICENT=0   // Teriparatide PK 
    PKGUT=0, PKCENT=0, PKPER1 = 0, PKPER2 = 0  // Generic PK 
    DENCENT=0, DENPER = 0,  DENSC=0 //Denosumab PK  
    UCA=0           // Urine Calcium (pmol) 
    VALUE1=0        // Indicator 1 
    VALUE2=0        // Indicator 2 
    VALUE3=0        // Indicator 3 
    TGFB=0          // Latent TGF beta 
    TGFBact=0       // Active TGF beta 
    OBfast=0        // Fast differentiating osteoblasts 
    OBslow=0        // Slow differentiating Osteoblasts 
    M=0             // RANK-RANKL complex 
    N=0             // OPG-RANKL complex 
    AOH=126         // 1-alpha hydroxylase (pmol)         
    EST  = 1        // estrogen 
    BMDls = 1       // lumbar spine BMD for combination therapy 141
    BMDfn = 1       // femoral neck BMD 
    GFR = 100/16.667  // GFR 
    SOSTSC = 0, SOSTCENT=0, SOSTPER=0 //Sclerostin Ab PK 
    SCLER = 0.149         // Sclerostin compartment  (nmol/L) 
    OCY = 0.0709 //0.0117          // Osteocytes 
    trans = 1 // translation compartment 
     
    BMDlsSCLER = 1       // Sclerostin lumbar spine BMD 
    BMDfnSCLER = 1       // Sclerostin femoral neck spine BMD 
    BMDthSCLER = 1       // Sclerostin total hip BMD 
     
    BMDlsDEN = 1     // Denosumab lumbar spine BMD 
    BMDfnDEN = 1    // Denosumab femoral neck spine BMD 
    BMDthDEN = 1    // Denosumab total hip BMD 
     
    delBMDls = 1 // delay compartment for lumbar spine BMD 
    delBMDth = 1 // delay compartment for total hip BMD 
    delBMDfn = 1 // delay compartment for femoral neck BMD 
      
    BMDlsTERI = 1       // TERI lumbar spine BMD // 
    BMDfnTERI = 1       // TERI femoral neck spine BMD // 
    BMDthTERI = 1       // TERI lumbar spine BMD 
    delBMDlsTERI = 1 // delay compartment for lumbar spine BMD with 
TERI 
    delBMDfnTERI = 1 // delay compartment for femoral neck BMD with 
TERI 
    delBMDthTERI = 1 // delay compartment for total hip BMD with TERI 
 
    BMDlsCOMBO = 1 // DEN/TERI combo lumbar spine BMD // 
    BMDthCOMBO = 1 // DEN/TERI combo total hip BMD // 
    BMDfnCOMBO = 1 // DEN/TERI combo femoral neck BMD // 
 
    TOL = 1 
    cumHazard = 0 
 
  
// INITIALIZING COMPARTMENTS and DEFINING BIOAVAILABILITIES  
 
$MAIN 
  TGFB_0 = Pic0*1000; 
  TGFBact_0 = Pic0; 
  OBfast_0 = OBtot0*FracOBfast; 
  OBslow_0 = OBtot0*(1-FracOBfast); 
  M_0 = k3*RNK_0*L_0/k4; 
  N_0 = k1*O_0*L_0/k2; 
  AOH_0 = B_0/10; 
 _F(_N_SOSTSC)=SCLERF; 
 _F(_N_TERISC)=TERIF; 
 _F(_N_DENSC)=DENF; 
 
 
// ALGEBRAIC RELATIONSHIPS and DIFFERENTIAL EQUATIONS  
 
$ODE 
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  // parameters derived from SS initial conditions  
  double T13 = (CaDay/24)/Q0; 
 
  double T15 = CaDay/(CaConc0*V1*24); 
 
  double J14OC50= exp(log((J14OCmax*pow(OC0,J14OCgam)/T13) - 
pow(OC0,J14OCgam))/J14OCgam); 
 
  double OCeqn = 
(J14OCmax*pow(Osteoclast,J14OCgam))/(pow(Osteoclast,J14OCgam) + 
pow(J14OC50,J14OCgam)); 
 
  double kinRNK = (koutRNK*RNK0 + k3*RNK0*L0 - k4*M0) / 
pow(TGFBact0,kinRNKgam) ; 
 
  double MOCratio = M/Osteoclast; 
 
  double MOCratio0 = M0/OC0; 
 
  double MOCratioEff = pow((MOCratio/MOCratio0), MOCratioGam); 
 
  double J14OCdepend = OCeqn*Q0*FracJ14*MOCratioEff; 
 
  double J14 = T13*Q0*(1-FracJ14) + J14OCdepend; 
 
 
  // CALCIUM FLUX from PLASMA into BONE 
  double J15 = (T15*P*(1-FracJ15) + T15*P*FracJ15*HAp); 
 
 
  //  CREB-RELATED EQUATIONS 
 
  double EC50PTHcreb = ((EmaxPTHcreb*PTHconc0)/(1-E0crebKin)) -  
PTHconc0; 
 
  double crebKin0= crebKout*CREB0; 
 
  double crebKin = crebKin0* (E0crebKin + 
EmaxPTHcreb*PTHconc/(PTHconc+EC50PTHcreb)); 
 
  double bcl2Kin = RX2*CREB*bcl2Kout; 
 
 
  // CALCITRIOL-DEPENDENT CALCIUM ABSORPTION EQUATIONS  
 
  double T36 = T33 + (T34-T33)*(pow(C8,CaPOgam)/(pow(T35,CaPOgam)+ 
pow(C8,CaPOgam))); 
 
  double T37 = T34 - (T34-T33)*(pow(C8,CaPOgam)/(pow(T35,CaPOgam)+ 
pow(C8,CaPOgam))); 
 
 // CALCIUM - FILTRATION- RELATED EQUATIONS 
 
  double CaFilt = 0.6*0.5*GFR*CaConc; 
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  // Maximum calcium reabsorption in the kidney - PTH sensitive 
  double mtmEST = (1-maxTmESTkid)/(1-0.1);  //(1-maxEST)/(1-minEST) 
  double tmEST = 1 - mtmEST + mtmEST*EST; 
 
  double ReabsMax = tmEST * (0.3*GFR*CaConc0 - 0.149997)*(Reabs50 + 
CaConc0) / CaConc0; 
 
  // Effect of PTH on calcium reabsorption  
  double T17 = PTHconc0*T16 - PTHconc0; 
 
  double ReabsPTHeff = (T16*PTHconc)/(PTHconc + T17); 
 
  // PTH-sensitive calcium reabsorption in kidney  
 
  double CaReabsActive =  (ReabsMax*C1/(Reabs50 + C1))*ReabsPTHeff; 
 
  double T20 = CaFilt - CaReabsActive; 
 
  double T10 = T7*C8/(C8+T9); 
 
  // Temporary calcium excretion rate  
  double J27a = (2-T10)*T20; 
 
  // J27 will be the flux of calcium out of the plasma via the kidney  
  if (J27a<0)  J27 = 0 ; else  J27 = J27a; 
 
  double ScaEff = pow( (CaConc0/CaConc), ScaEffGam); 
 
  double T72 = 90 * ScaEff; 
 
  double T73 = T71 * (C8 - T72); 
 
  double T74 = (exp(T73) - exp(-T73)) / (exp(T73) + exp(-T73)); 
 
  double T75 = T70 * (0.85 * (1 + T74) + 0.15) ; 
 
  double T76 = T70 * (0.85 * (1 - T74) + 0.15); 
 
 
 
//  PHOSPHATE-RELATED EQUATIONS  
 
double PO4inhPTH = pow((C2/1.2),PO4inhPTHgam); // C2 is extracellular 
phosphate concentration 
 
double PhosEffTop = (PhosEff0 - 1)*( pow(1.2, PhosEffGam) + 
pow(PhosEff50, PhosEffGam)); 
 
double PhosEffBot =PhosEff0 * pow(1.2, PhosEffGam); 
 
double PhosEffMax =  PhosEffTop / PhosEffBot; 
 
double PhosEff = PhosEff0 - (PhosEffMax*PhosEff0 * pow(C2, PhosEffGam) 
/(pow(C2, PhosEffGam)  + pow(PhosEff50, PhosEffGam))); 
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if (C2 > 1.2) PhosEffect = PhosEff ; else PhosEffect = 1; 
 
double T68 = T66*pow(PTHconc, AlphOHgam)/(pow(T67, 
AlphOHgam)*PO4inhPTH+pow(PTHconc, AlphOHgam)) ; 
 
double SE = T65*T68*PhosEffect; 
 
 // ORAL ABSORBTION 
  double J53 = T52*PhosGut; 
 
  double J54 = T49*C2; 
 
  double J56 = T55*IntraPO; 
 
 // EXTRACELLULAR PHOSPHATE EQUATION (MMOL) 
 // J14 = calcium flux from bone into plasma 
 // J15 = calcium flux from plasma into bone 
 // J27 = calcium flux from plasma to urine 
 // J40 = calcium flux from gut to plasma 
  dxdt_ECCPhos = J41  - J42 - J48 + J53 - J54 + J56; 
 
 // PHOSPHATE EQUATIONS (DIETARY, INTRACELLULAR) 
 
  dxdt_PhosGut = OralPhos *F12 - J53; 
 
  dxdt_IntraPO = J54 - J56; 
 
 // PHOSPHATE RENAL EXCRETION 
  double T47 = T46*0.88*GFR; 
 
  double J48a = 0.88*GFR*C2 - T47; 
 
  if (J48a < 0) J48 = 0 ; else J48 = J48a; 
 
 
 // TGF-B - RELATED EFFECTS on OSTEO -BLASTS and -CLASTS  
 
bigDb = (kb*OB0*Pic0/ROB10); 
 
double kinTGF = koutTGF0*TGFB0; 
 
double koutTGF = koutTGF0*(pow((TGFB/TGFB0),koutTGFGam)); 
 
double koutTGFact = koutTGF0*1000; 
 
double koutTGFeqn = koutTGF*TGFB*(pow((Osteoclast/OC0), OCtgfGAM)); 
 
E0PicROB = (FracPicROB*Pic0); 
 
EC50PicROBparen = (EmaxPicROB*pow(TGFBact0,PicROBgam) / (Pic0 - 
E0PicROB)) - pow(TGFBact0,PicROBgam); 
 
EC50PicROB = (exp(log(EC50PicROBparen)/PicROBgam)); 
 
Dr = (kb*OB0/Pic0) ; 145
 
PicROB = (E0PicROB + 
EmaxPicROB*pow(TGFBact,PicROBgam)/(pow(TGFBact,PicROBgam) + 
pow(EC50PicROB,PicROBgam))); 
 
ROBin = (Dr*PicROB); 
 
double E0PicOB = FracPicOB*Pic0; 
 
double EC50PicOBparen = (EmaxPicOB*pow(TGFBact0,PicOBgam)/(Pic0 - 
E0PicOB)) - pow(TGFBact0,PicOBgam); 
 
double EC50PicOB = exp(log(EC50PicOBparen)/PicOBgam); 
 
double PicOB = E0PicOB + EmaxPicOB*pow(TGFBact,PicOBgam) / 
(pow(TGFBact,PicOBgam) + pow(EC50PicOB,PicOBgam)); 
 
KPT = (bigDb/PicOB); 
 
double EC50MeffOC = exp(log(pow(M0, kinOCgam)*EmaxMeffOC/(1-E0Meff) - 
pow(M0, kinOCgam))/kinOCgam); 
 
double MeffOC = E0Meff + (EmaxMeffOC * pow(M, kinOCgam)/(pow(M, 
kinOCgam) + pow(EC50MeffOC,kinOCgam))); 
 
double kinOC2 = Da*PicOCkin*MeffOC*OC0; 
 
double E0PicOC = FracPicOC*Pic0; 
 
double EC50PicOCparen = (EmaxPicOC*pow(TGFBact0, PicOCgam)/(Pic0 - 
E0PicOC)) - pow(TGFBact0, PicOCgam); 
 
double EC50PicOC = exp(log(EC50PicOCparen)/PicOCgam); 
 
double PicOC = E0PicOC + ((EmaxPicOC*pow(TGFBact, 
PicOCgam))/(pow(TGFBact, PicOCgam) + pow(EC50PicOC, PicOCgam))); 
 
double PiL0 = (k3/k4)*L0; 
 
double PiL = M/10; 
 
double EC50survInPar = (E0RANKL - EmaxL)*(pow(PiL0, 
LsurvOCgam)/(E0RANKL - 1)) - pow(PiL0, LsurvOCgam); 
 
double EC50surv = exp(log(EC50survInPar)/LsurvOCgam); 
 
double LsurvOC = E0RANKL - (E0RANKL - EmaxL)*(pow(PiL, 
LsurvOCgam)/(pow(PiL, LsurvOCgam) + pow(EC50surv, LsurvOCgam))); 
 
double KLSoc = Da*PicOC*LsurvOC; 
 
double T66 = (pow(T67, AlphOHgam) + pow(PTHconc0, AlphOHgam) 
)/pow(PTHconc0, AlphOHgam) ; 
 
double k15a = k14a*Qbone0/Q0 ; 146
 
double J14a = k14a*Qbone; 
 
double J15a = k15a*Q ; 
 
E0PicOBkb = MultPicOBkb*Pic0; 
 
EmaxPicOBkb = FracPic0kb*Pic0; 
 
EC50PicOBparenKb = ((E0PicOBkb - EmaxPicOBkb)*pow(TGFBact0,PicOBgamkb)) 
/ (E0PicOBkb - Pic0)  - pow(TGFBact0,PicOBgamkb); 
 
EC50PicOBkb = exp(log(EC50PicOBparenKb)/PicOBgamkb); 
 
PicOBkb = E0PicOBkb - (E0PicOBkb  - 
EmaxPicOBkb)*pow(TGFBact,PicOBgamkb) / (pow(TGFBact,PicOBgamkb) + 
pow(EC50PicOBkb,PicOBgamkb)); 
 
 
// D = ROB1; RESPONDING OSTEOBLASTS  
dxdt_ROB1 = ROBin * pow(1/EST,robGAM) - 
pow((SCLEREFF),gammaDr)*KPT*ROB1 ; 
 
//LATENT AND ACTIVE TGFB POOLS  
 
dxdt_TGFB = kinTGF*(pow((Osteoblast/OB0),OBtgfGAM)) * 
pow(1/EST,tgfbGAM) - koutTGFeqn * pow(EST,tgfbactGAM); 
 
dxdt_TGFBact = koutTGFeqn * pow(EST,tgfbactGAM) - koutTGFact*TGFBact; 
 
 // ESTROGEN-RELATED EFFECTs on OSTEOBLAST APOPTOSIS  
  
 E0RUNX2kbEff =(E0RUNX2kbEffFACT*kb); 
   
 PicOBkbEff = (PicOBkb/Pic0)*(1/(pow(EST,E2scalePicB1))) ; 
  
 kbprime =  (E0RUNX2kbEff*PicOBkbEff - RUNX2kbPrimeEff); 
 kbslow = (kbprime*Frackb); 
 kbfast = ((kb*OB0 + kbslow*OBfast0 - kbslow*OB0) / OBfast0 ); 
 
 // PTH EFFECTS on OSTEOBLAST APOPTOSIS (CONTINUOUS vs. INTERMITTENT 
DOSING) 
 
  if (BCL2 > 105)  RUNX2 = BCL2 - 90 ; else  RUNX2 = 10; 
 
  RUNkbMax = E0RUNX2kbEff*RUNkbMaxFact; 
 
  INparen = (RUNkbMax * pow(RUNX20,RUNkbGAM)) / (E0RUNX2kbEff - kb) - 
pow(RUNX20,RUNkbGAM); 
 
  RUNkb50 = exp(log(INparen)/RUNkbGAM); 
 
  RUNX2kbPrimeEff = RUNkbMax*pow(RUNX2,RUNkbGAM) / (pow(RUNX2,RUNkbGAM) 
+ pow(RUNkb50,RUNkbGAM)); 
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  // EQUATIONS RELATED TO CALCIUM FLUX TO/FROM GUT  
 
  double T29 = (T28*T0 - T310*T0)/T310; 
 
  double T31 = T28*T/(T+T29); 
 
  // R is calcitriol-dependent gut Ca2+ absorption  
  double T83 = R/0.5; 
 
  // J40 = calcium flux from gut to plasma  
  double J40 = T31*T*T83/(T + T81) + T87*T; 
 
  // T85 relates to extent of absorption of orally-administered dose  
 
  double T85Rpart = pow(R, T80)/(pow(R,T80) + pow(T81,T80)); 
  double T85 = T77*T85Rpart; 
 
  // CALCITRIOL-RELATED EQUATIONS  
 
  double INparenCtriol =((CtriolMax - CtriolMin) * pow(Calcitriol0, 
CtriolPTgam)) / (CtriolMax - 1)- pow(Calcitriol0,CtriolPTgam); 
 
  double Ctriol50 = exp(log(INparenCtriol) / CtriolPTgam) ; 
 
  double CtriolPTeff = CtriolMax - (CtriolMax - CtriolMin) * pow(C8, 
CtriolPTgam) / (pow(C8, CtriolPTgam) + pow(Ctriol50, CtriolPTgam)); 
 
  double PTin = PTout * CtriolPTeff; 
 
  double FCTD = (S / 0.5) * PTmax; 
 
  dxdt_B = AOH - T69 * B; 
 
  //  PTH-RELATED CALCIUM FLUX  
 
 double INparenCa =(T58 - T61) * pow(CaConc0, T59) / (T58 - 385) - 
pow(CaConc0, T59); 
 double T60 = exp(log(INparenCa) / T59) ; 
 double T63 =  T58 - (T58 - T61) * pow((CaConc), T59) / (pow((CaConc), 
T59) + pow(T60, T59)); 
 
 // PTH-RELATED EQUATIONS  
 // production rate from precursor 
  double EPTH = T63*FCTD; 
 
 // Infused and subcutaneously administered PTH 
 double IPTH= 0.693*SC + IPTHinf; 
 
 // Total PTH input rate 
 double SPTH = EPTH + IPTH; 
 
 dxdt_PTH = SPTH - kout*PTH + TERIPKIN; 
 
 // PT GLAND max capacity 148
 dxdt_PTmax = PTin - PTout * PTmax; 
 
 // PTH GLAND pool 
 
 dxdt_S = (1 - S) * T76 - (S* T75); 
 
 // Subcutaneous PTH administration 
 
 dxdt_SC = IPTHint - 0.693*SC; 
 
 
 // 1- ALPHA HYDROXYLASE 
//////////////////////////////////////////////// 
 
 dxdt_AOH = SE - T64*AOH ; 
 
 // CALCIUM 
///////////////////////////////////////////////////////////// 
 
 dxdt_P = J14 - J15- J27 + J40; 
 
 // ORAL CALCIUM (MMOL) 
 // J40 --> flux from gut to plasma 
 dxdt_T = OralCa*T85 - J40; 
 
 // Calcitriol-dependent Ca2+ absorption 
 dxdt_R = T36*(1- R) - T37*R; 
 
//  BONE CALCIUM 
// Immediately-exchangable 
dxdt_Q = J15 - J14 + J14a - J15a; 
 
// Non-immediately-exchangable 
dxdt_Qbone = J15a - J14a; 
 
// HYDROXYAPATITE  
 
double kLShap = 1/HApMRT; 
 
double kHApIn = kLShap/OB0; 
 
// CALCIUM in HYDROXYAPATITE 
double J41 = 0.464*J14; 
double J42 = 0.464*J15; 
 
dxdt_HAp = kHApIn*Osteoblast - kLShap*HAp; 
 
// ESTROGEN-RELATED EQUATIONS  
 
 double AGE = ageENTER + T_0; 
 
 double kinEST=0 ; 
 
 double ageONSET = ageDONE-menoDUR; 
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 if(AGE < ageONSET) kinEST = koutEST * pow((AGE/ageENTER),ageGAM); 
 
 if(AGE >= ageONSET) kinEST = koutEST * pow((AGE/ageENTER),ageGAM) * (1 
- age50 * (pow((AGE-ageONSET),2)/(pow((menoDUR/2),2) + pow((AGE-
ageONSET),2)))); 
 
  dxdt_EST = (kinEST - koutEST * EST)*ESTON; 
 
 
 // OSTEOBLASTS:fast and slow removal rates  
 
 double Frackb2 = kbfast/kbprime; 
 
 dxdt_OBfast = (bigDb/PicOB)*D*FracOBfast*Frackb2  - kbfast*OBfast; 
 
 dxdt_OBslow = (bigDb/PicOB)*D*(1-FracOBfast)*Frackb - kbslow*OBslow; 
 
 
 // OC: ACTIVE OSTEOCLASTS 
 dxdt_OC = kinOC2 - KLSoc*OC; 
 
 
// SCLEROSTIN-RELATED EFFECTS; PROPAGATES THROUGH OSTEOCYTE APOPTOSIS  
// translation compartment 
 
kin_T = kout_T; 
 
EC50SCLER =  (exp(log(EMAXSCLER-1)/SCLEROBgam)); 
 
SC50 = (SMAX - 1); 
 
dxdt_trans = 
kin_T*(EMAXSCLER*pow(SCLEREFF,SCLEROBgam)/(pow(EC50SCLER,SCLEROBgam)+po
w(SCLEREFF,SCLEROBgam))) - kout_T*trans; 
 
SCLEREFF = (SCLER/SCLER_0); 
 
SCLER_TOL = (SMAX*SCLEREFF/(SC50 + SCLEREFF)); 
 
kin_TOL = kout_TOL; 
 
dxdt_TOL = kin_TOL*(SCLER_TOL) - kout_TOL*TOL; 
 
 // OSTEOCYTES  
 
 koutOCY = (OB0*FracOCY)*(pow((SCLEREFF),gammaOCY)); 
 
 dxdt_OCY = OB*FracOCY*OCY0 - koutOCY*OCY; 
 
// RANKL-OPG AXIS  
 
double kinLbase = koutL*L0; 
 
fracOBEffect = FracOBE/TOL; 
 150
double OsteoEffect = pow((Osteoblast/OB0), 
(TotOsteoEffectGam/fracOBEffect)) ; 
 
double OsteoCYEffect = pow((OCY/OCY0), (TotOsteoEffectGam*(1-
(1/fracOBEffect)))) ; 
 
double PTH50 = EmaxLpth*PTHconc0 - PTHconc0 ; 
 
double LpthEff = EmaxLpth*(PTHconc) / 
((PTH50*pow((OsteoCYEffect*OsteoEffect),TESTPOWER)) + (PTHconc)) ; 
 
double kinL = kinLbase*(OsteoCYEffect)*(OsteoEffect)*LpthEff; 
 
double pObase = kO*O0; 
 
double pO = 
pObase*(D/ROB10)*((PTHconc+(opgPTH50*(D/ROB10)))/(2*PTHconc))+ IO; 
 
double RX2Kin = RX2Kout0*RX20; 
 
double EC50PTHRX2x = ((EmaxPTHRX2x*PTHconc0)/(RX2Kout0 - E0rx2Kout)) - 
PTHconc0; 
 
double RX2Kout = E0rx2Kout + EmaxPTHRX2x*PTHconc/(PTHconc+EC50PTHRX2x); 
 
// L: RANK-L 
dxdt_L = kinL- koutL*L - k1*O*L + k2*N - k3*RNK*L + k4*M -  
kdenosl*DENMOL*L; 
 
// RNK: RANK 
dxdt_RNK = kinRNK*pow(TGFBact,kinRNKgam) - koutRNK*RNK - k3*RNK*L  + 
k4*M; 
 
// M: RANK - RANK-L complex 
dxdt_M = k3*RNK*L - k4*M; 
 
// N:  - RANK-L - OPG complex 
dxdt_N = k1*O*L - k2*N; 
 
// O: OPG 
dxdt_O = pO*pow((SCLEREFF),gammaOPG) - k1*O*L + k2*N - kO*O; 
 
 
// DIFFERENTIAL EFFECTS of PTH ADMINISTRATION  
dxdt_RX2 = RX2Kin - RX2Kout*RX2 ; 
 
dxdt_CREB = crebKin - crebKout*CREB; 
 
dxdt_BCL2 = bcl2Kout*CREB*RX2 - bcl2Kout*BCL2; 
 
 
// FILTRATION RATE EQUATIONS 
double GFRend = GFR0 - GFRdelta/16.667; 
 
double GFRtau_ = GFRtau*8766; 151
 
double kGFR = -log(GFRend/GFR0)/GFRtau_; 
 
dxdt_GFR = -kGFR*GFR; 
 
// URINE CALCIUM EQUATION 
dxdt_UCA = J27; 
 
 
// PK EQUATIONS  
 
// GENERAL PK COMPARTMENTS 
double PKCLNL = PKVMAX/(PKKM+PKCP); 
 
dxdt_PKGUT = -PKKA*PKGUT; 
 
dxdt_PKCENT = PKKA*PKGUT + PKQ1*PKPER1/PKVP1 + PKQ2*PKPER2/PKVP2 - 
(PKQ1+PKQ2+PKCL+PKCLNL)*PKCENT/PKVC; 
 
dxdt_PKPER1 = PKQ1*PKCENT/PKVC - PKQ1*PKPER1/PKVP1; 
 
dxdt_PKPER2 = PKQ2*PKCENT/PKVC - PKQ2*PKPER2/PKVP2; 
 
// DENOSUMAB PK 
 
double  DENCLNL =  (DENVMAX/(DENKM+DENCP)); 
 
dxdt_DENSC =  -DENKA*DENSC; 
 
dxdt_DENCENT = DENKA*DENSC + DENQ*DENPER/DENVP - 
(DENQ+DENCL+DENCLNL)*DENCENT/DENVC; 
 
dxdt_DENPER = DENQ*DENCENT/DENVC - DENQ*DENPER/DENVP; 
 
// TERIPARATIDE PK 
 
double TERIPKIN = TERISC*TERICL/TERIVC; 
 
dxdt_TERISC = -TERIPKIN; 
 
dxdt_TERICENT  = TERIPKIN - TERICENT*TERIKA; 
 
 
// SCLEROSTIN AB PK AND SCLEROSTIN 
 
double SOSTCLNL = SOSTVMAX/(SOSTKM+SOSTCP); 
 
dxdt_SOSTSC = -SOSTKA*SOSTSC; 
 
dxdt_SOSTCENT = SOSTKA*SOSTSC - SOSTCLNL*SOSTCENT-(SOSTCL*(SOSTCP))-
(SOSTQ*(SOSTCP)) + (SOSTQ*(SOSTPER/SOSTVP)); 
 
dxdt_SOSTPER = (SOSTQ*(SOSTCENT/SOSTVC))-(SOSTQ*SOSTPER/SOSTVP); 
 
dxdt_SCLER = SOSTKIN-SOSTKOUT*SCLER-(SOSTK0- 152
SOSTKOUT)*SCLER*(SOSTCENT/SOSTVC)/(SOSTKM+(SOSTCENT/SOSTVC)); 
 
 
 // BONE MINERAL DENSITY (BMD) EQUATIONS  
 // Lumbar spine - generic (pbo) 
 
 double kinBMDls =  koutBMDls*BMDls0; 
 
 dxdt_BMDls = kinBMDls * pow(OB/OB0,gamOB) - koutBMDls * 
pow(OC/OC0,gamOCls) * BMDls; 
 
 //Lumbar spine with DENOSUMAB 
 
 double kinBMDlsDEN =  koutBMDlsDEN*BMDlsDEN0; 
 
 dxdt_BMDlsDEN = kinBMDlsDEN * pow(OB/OB0,gamOB) - koutBMDlsDEN * 
pow(OC/OC0,gamOClsDEN) * BMDlsDEN; 
     
 //Femoral neck with DENOSUMAB 
   
 double kinBMDfnDEN =  koutBMDfnDEN*BMDfnDEN0; 
 
 dxdt_BMDfnDEN = kinBMDfnDEN * pow(OB/OB0,gamOB) - koutBMDfnDEN * 
pow(OC/OC0,gamOCfnDEN) * BMDfnDEN; 
 
//Total hip with DENOSUMAB 
   
 double kinBMDthDEN =  koutBMDthDEN*BMDthDEN0; 
 
 dxdt_BMDthDEN = kinBMDthDEN * pow(OB/OB0,gamOB) - koutBMDthDEN * 
pow(OC/OC0,gamOCthDEN) * BMDthDEN; 
  
 //Lumbar spine for SCLEROSTIN 
     
 double kinBMDlsSCLER =  koutBMDSCLER*BMDlsSCLER0; 
      
 kin_BMDdel = kout_BMDdel; 
      
 dxdt_delBMDls = kin_BMDdel * pow(OB/OB0,gamOBSCLERls) - 
kout_BMDdel*delBMDls; 
 
 dxdt_BMDlsSCLER = kinBMDlsSCLER * delBMDls - koutBMDSCLER * 
pow(OC/OC0,gamOCSCLER) * BMDlsSCLER; 
     
 //Femoral neck for SCLEROSTIN 
     
 double kinBMDfnSCLER =  koutBMDSCLER*BMDfnSCLER0; 
 
 dxdt_delBMDfn = kin_BMDdel* pow(OB/OB0,gamOBSCLERfn) - 
kout_BMDdel*delBMDfn; 
      
 dxdt_BMDfnSCLER = kinBMDfnSCLER * delBMDfn  - pow(OC/OC0,gamOCSCLER) * 
koutBMDSCLER * BMDfnSCLER; 
      
 //Total hip for SCLEROSTIN 153
     
 double kinBMDthSCLER =  koutBMDSCLER*BMDthSCLER0; 
    
 dxdt_delBMDth = kin_BMDdel * pow(OB/OB0,gamOBSCLERth) - 
kout_BMDdel*delBMDth; 
      
 dxdt_BMDthSCLER = kinBMDthSCLER * delBMDth - koutBMDSCLER * 
pow(OC/OC0,gamOCSCLER) * BMDthSCLER; 
 
 //Lumbar spine for TERIPARATIDE 
 
  double kinBMDlsTERI =  koutBMDlsTERI*BMDlsTERI0; 
 
 kin_BMDdelTERI = kout_BMDdelTERI; 
 
 dxdt_delBMDlsTERI = kin_BMDdelTERI * pow(OB/OB0,gamOBTERIls) - 
kout_BMDdelTERI*delBMDlsTERI; 
 
 dxdt_BMDlsTERI = kinBMDlsTERI * delBMDlsTERI - koutBMDlsTERI * 
pow(OC/OC0,gamOClsTERI) * BMDlsTERI; 
 
//Femoral neck for TERIPARATIDE 
 
  double kinBMDfnTERI =  koutBMDfnTERI*BMDfnTERI0; 
    
  kin_BMDdelTERI = kout_BMDdelTERI; 
    
  dxdt_delBMDfnTERI = kin_BMDdelTERI* pow(OB/OB0,gamOBTERIfn) - 
kout_BMDdelTERI*delBMDfnTERI; 
 
  dxdt_BMDfnTERI = kinBMDfnTERI * delBMDfnTERI  - 
pow(OC/OC0,gamOCfnTERI) * koutBMDfnTERI * BMDfnTERI; 
 
//Total hip for TERIPARATIDE 
 
  double kinBMDthTERI =  koutBMDthTERI*BMDthTERI0; 
 
  dxdt_delBMDthTERI = kin_BMDdelTERI* pow(OB/OB0,gamOBTERIth) - 
kout_BMDdelTERI*delBMDthTERI; 
 
  dxdt_BMDthTERI = kinBMDthTERI * delBMDthTERI  - 
pow(OC/OC0,gamOCthTERI) * koutBMDthTERI * BMDthTERI; 
 
 
// BMD with combination therapy  
 
// DEN/TERI COMBO 
 double kinBMDlsCOMBO = koutBMDlsCOMBO; 
 
dxdt_BMDlsCOMBO = 0; 
if(DEN_TERI_COMBO==1) dxdt_BMDlsCOMBO = kinBMDlsCOMBO * 
pow(OB/OB0,gamOB) - koutBMDlsCOMBO* 
pow(OC/OC0,gamOClsDEN_TERI)*BMDlsCOMBO; 
 
double kinBMDthCOMBO = koutBMDthCOMBO; 154
dxdt_BMDthCOMBO = 0; 
if(DEN_TERI_COMBO==1) dxdt_BMDthCOMBO = kinBMDthCOMBO * 
pow(OB/OB0,gamOB) - koutBMDthCOMBO* 
pow(OC/OC0,gamOCthDEN_TERI)*BMDthCOMBO; 
 
double kinBMDfnCOMBO = koutBMDfnCOMBO; 
dxdt_BMDfnCOMBO = 0; 
if(DEN_TERI_COMBO==1) dxdt_BMDfnCOMBO = kinBMDfnCOMBO * 
pow(OB/OB0,gamOB) - koutBMDfnCOMBO* 
pow(OC/OC0,gamOCfnDEN_TERI)*BMDfnCOMBO; 
 
// FRACTURE PROBABILITY  
// Reference values:  
// BMDhat = 0.8 g/cm^2 
// postMenoAgehat = 20 y 
// BMIhat = 27.1 kg/m^2 
//req dataset items = agepostmeno (at baseline), radFracInc, BMI, 
lsBMDbase 
// code in switches: 
// DEN_TERI_COMBO = 0 : no drug 
// DEN_TERI_COMBO = 1 : combinination TERI/DEN 
// DEN_TERI_COMBO = 2 : TERI only 
// DEN_TERI_COMBO = 3 : DEN only 
// DEN_TERI_COMBO = 4 : SCLER only 
 
double PBO_BMD = 1; 
double betaDrug = 0; 
if (DEN_TERI_COMBO==0) {  
    PBO_BMD = BMDls;  
}    
 
double COMBO_BMD = 1; 
if (DEN_TERI_COMBO==1) {  
    COMBO_BMD = BMDlsCOMBO;  
  betaDrug = betaDrug_COMBO; 
} 
 
double TERI_BMD = 1; 
double TERI_BMDth = 1; 
double TERI_BMDfn = 1; 
if (DEN_TERI_COMBO==2) {  
    TERI_BMD = BMDlsTERI;  
  betaDrug = betaDrug_TERI; 
  TERI_BMDth = BMDthTERI; 
  TERI_BMDfn = BMDfnTERI; 
}      
 
double DEN_BMD = 1;  
double DEN_BMDth = 1;  
double DEN_BMDfn = 1;  
if (DEN_TERI_COMBO==3) {  
    DEN_BMD = BMDlsDEN;  
  betaDrug = betaDrug_DENO; 
  DEN_BMDth=BMDthDEN; 
  DEN_BMDfn=BMDfnDEN; 155
}  
 
double SCLER_BMD = 1;  
double SCLER_BMDth = 1;  
double SCLER_BMDfn = 1;  
 
if (DEN_TERI_COMBO==4) {  
    SCLER_BMD = BMDlsSCLER; 
  SCLER_BMDth=BMDthSCLER; 
  SCLER_BMDfn=BMDfnSCLER; 
}  
 
if(SCLER_DEN_SEQ==1){ 
  SCLER_BMD = BMDlsSCLER;  
  SCLER_BMDth=BMDthSCLER; 
  SCLER_BMDfn=BMDfnSCLER; 
  DEN_BMD = BMDlsDEN; 
  DEN_BMDth=BMDthDEN; 
  DEN_BMDfn=BMDfnDEN; 
} 
     
double lsBMDtot = (PBO_BMD + COMBO_BMD + TERI_BMD + DEN_BMD + 
SCLER_BMD)-4; 
 
double thBMDtot = (1 + TERI_BMDth + DEN_BMDth + SCLER_BMDth)-3; 
     
double fnBMDtot = (1 +  TERI_BMDfn + DEN_BMDfn + SCLER_BMDfn)-3; 
     
 
// HAZARD MODEL EQUATIONS  
     
drug = betaDrug; 
     
lsBMD = lsBMDtot*lsBMDbase; //nominal BMD 
 
double lsBMDCFB = (lsBMDtot*lsBMDbase) - lsBMDbase; //CFB BMD 
     
double postMenoAge = agepostmeno + T_0/365.25/24; 
     
Hazard = baseHazard*exp(HazBMDCov*log(lsBMD/lsBMDbase) + 
       HazpostMenoAgeCov*(postMenoAge-postMenoAgeRef )+  
       HazradFracCov*radFracInc+HazBMICov*(BMI-bmiRef) + betaDrug); 
 
dxdt_cumHazard = Hazard / 365.25/24; 
 
Survival = exp(-cumHazard); 
 
 
// TELLS CODE WHICH DATA TO PRINT  
 
$TABLE 
table(DENMOL) = (DENCENT/DENVC/150000)*1000*1000; 
table(OB) = (OBfast*trans + OBslow); 
table(BSAPsim) = (OB/OB0*100); 
table(P1NPsim) = ((2050 * pow((BSAP), 1.8) / ((pow(467, 1.8) + 156
pow((BSAP),1.8))))-20.4181); 
table(SCLEREFF) = ((SCLER/SCLER_0)); 
table(CTXsim) = (OC/OC0*100); 
table(OsteoEffect) = pow((Osteoblast/OB0), 
(TotOsteoEffectGam/fracOBEffect)); 
table(fracOBEffect) = (FracOBE/TOL); 
  
table(lsBMDsimSCLER) = (BMDlsSCLER*100); 
table(lsBMDsimTERI) = (BMDlsTERI*100); 
table(lsBMDsimDEN) = (BMDlsDEN*100); 
table(thBMDsimSCLER) = (BMDthSCLER*100); 
table(thBMDsimTERI) = (BMDthTERI*100); 
table(thBMDsimDEN) = (BMDthDEN*100); 
table(fnBMDsimSCLER) = (BMDfnSCLER*100); 
table(fnBMDsimTERI) = (BMDfnTERI*100); 
table(fnBMDsimDEN) = (BMDfnDEN*100); 
table(BMDls)=(BMDls*100); 
table(lsBMDsimCOMBO) = (BMDlsCOMBO*100); 
table(thBMDsimCOMBO) = (BMDthCOMBO*100); 
table(fnBMDsimCOMBO) = (BMDfnCOMBO*100); 
 
table(Hazard) = (cumHazard*1); 
table(Survival) = (Survival*1); 
 
 
// ALLOW FITTING TO MULTIPLE ENDPOINTS IN A SINGLE DATASET  
DV = ((2050 * pow((BSAP), 1.8) / ((pow(467, 1.8) + pow((BSAP),1.8))))-
20.4181); 
if(TYPE==1) DV = (OC/OC0*100); 
table(DV) = DV; 
 
if(Scler_BMD_type==0) SclerBMDpred = (BMDlsSCLER*100);  
if(Scler_BMD_type==1) SclerBMDpred = (BMDthSCLER*100); 
if(Scler_BMD_type==2) SclerBMDpred = (BMDfnSCLER*100); 
table(SclerBMDpred) = SclerBMDpred; 
 
if(Deno_BMD_type==0) DenoBMDpred = (BMDlsDEN*100);  
if(Deno_BMD_type==1) DenoBMDpred = (BMDthDEN*100); 
if(Deno_BMD_type==2) DenoBMDpred = (BMDfnDEN*100); 
table(DenoBMDpred) = DenoBMDpred; 
 
if(Teri_BMD_type==0) TeriBMDpred = (BMDlsTERI*100);  
if(Teri_BMD_type==1) TeriBMDpred = (BMDthTERI*100); 
if(Teri_BMD_type==2) TeriBMDpred = (BMDfnTERI*100); 
 
if(Combo_BMD_type==0) ComboBMDpred = (BMDlsCOMBO*100);  
if(Combo_BMD_type==1) ComboBMDpred = (BMDthCOMBO*100); 
if(Combo_BMD_type==2) ComboBMDpred = (BMDfnCOMBO*100); 
table(ComboBMDpred) = ComboBMDpred; 
 
// TABLE SEVERAL ENDPOINTS TOGETHER 
 
// report("EVID/TIME/SOSTCENT", OCY, TIME, SOSTCENT); 	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